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The objective of this study was to develop a polymeric drug delivery system for an 
alternative formulation as well as for oral delivery of paclitaxel, which is used in our 
research as a prototype anticancer drug due to its excellent efficiency against a wide 
spectrum of cancers and its great commercial success as the best seller among 
antineoplastic agents, In our nanoparticle formulation, vitamin E TPGS (TPGS) is 
used as a necessary auxiliary in nanoparticle formulation as well as a “mask” for the 
nanoparticles to cross the GI barrier for oral chemotherapy. Paclitaxel-loaded, TPGS-
emulsified poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles were prepared by a 
modified solvent extraction/evaporation single emulsion technique. Nanoparticle of 
various recipes were characterized by various state-of-the-art techniques such as laser 
light scattering for particle size and size distribution, scanning electron microscopy 
(SEM) for surface morphology, X-ray photoelectron spectroscopy (XPS) for surface 
chemistry, and high performance liquid chromatography (HPLC) for in vitro drug 
release kinetics. Caco-2 cells were employed as an established in vitro model of the 
GI barrier. Human colon adenocarcinoma cells (HT-29 cells) were used to evaluate 
the cytotoxicity of the drug formulated in the nanoparticles, which was measured in a 
close comparison with its current clinical dosage form Taxol®. In vivo 
pharmacokinetics was also determined and compared with Taxol®.  
The formulated nanoparticles were found in quite uniform size of ~240 nm diameter. 
The in vitro drug release profile exhibited a biphasic pattern with an initial burst 
followed by a sustained release. Uptake of fluorescent nanoparticles by Caco-2 cells 
was evidenced by confocal microscopy, which was found strongly dependent on the 
size and surface coating of the nanoparticles. In vitro HT-29 cell viability experiment 
 VII
demonstrated that the drug formulated in the nanoparticles theoretically could be 
46.18, 41.64, 19.65, 10.47 times more effective than that in Cremophor EL 
formulation (Taxol®) after 24, 48, 72, 96 hours treatment, respectively at 0.25 μg/ml 
paclitaxel concentration. In vivo PK measurement also showed advantages of the 
nanoparticle formulation versus Taxol®. Vitamin E TPGS emulsified PLGA 
nanoparticle formulation of paclitaxel has advantages versus Taxol and may provide 
an ideal solution for the problems caused by Cremophor EL. The technology may also 
apply to other anticancer drugs. 
 
 VIII






In order to improve the patient compliance and drug performance, pharmaceutical 
formulation researchers have been driven to design controlled release devices to deliver 
small molecule drugs, peptides and proteins, genes, and vaccines. Since a new 
formulation may extend the patent expire time of the specific drugs, the pharmaceutical 
companies are cooperating with research institutes to make the controlled release 
formulation available on the market. 
The controlled drug delivery systems draw increased attention due to its enhanced 
efficacy of existing potent drugs at lesser expenses and fewer dosing schedule. Controlled 
delivery system maintains the drug level in the blood between the maximum and 
minimum therapeutic levels at a minimum dosage for an extended period of time (Karsa, 
1996; Dunn, 1991). Conventional delivery system provides fluctuated drug level in the 
blood, either exceeding the maximum or falling below the minimum therapeutic level, 
resulting in toxic side effects or inefficacy. 
Most anticancer drugs have limitations in clinical administration due to their poor 
solubility and other unfavorable properties. Paclitaxel is chosen as model drug for this 
study since it has shown promising antineoplastic activity for a wide spectrum of cancers, 
particularly against drug-refractory ovarian (Runowicz et al., 1993) and breast cancer 
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(Holmes et al., 1991). Currently, only available dosage form is Taxol® for intravenous 
(i.v.) injection, which is cumbersome for the patients and limits the use of frequent 
dosing schedule for a prolonged systemic exposure to the drug. Due to its high 
hydrophobicity, adjuvant as Cremophor EL (CrEL) has to be used, which is responsible 
for serious side effects (Lehoczky, 2001). Thus, the development of successful paclitaxel 
delivery system devoid of CrEL is essential for a better clinical administration with less 
side effects.  
Although phase I study showed that co-administration of paclitaxel with P-gp inhibitors 
such as cyclosporine A increased oral bioavailability and it may be a medical solution for 
oral chemotherapy (Malingre et al., 2000b; Britten et al., 2000), cyclosporine A itself is 
an immunosuppressive agent and may cause severe nephropathies. Other types of P-gp 
inhibitors are also costly and need premedications to reduce side effects (Asperen et al., 
1997; Malingrè et al., 2001a). Thus, this approach is not successful at the moment. 
Biodegradable and bioadhesive nanoparticulate carriers could be an ideal solution for 
intravenous or oral delivery of paclitaxel as well as of other anticancer drugs. 
Biodegradable and biocompatible polymer prevents adverse effects and accumulation of 
polymer in the body over long-term application. Bioadhesive nanoparticulate based drug 
delivery system has been shown to increase oral bioavailability of drugs due to the 
increased residence time of the nanoparticulates within the gastrointestinal (GI) tract and 
increased contact time with the intestinal epithelium and hence increased uptake. 
Moreover, appropriate coating of nanoparticles may provide engineering make-ups to 
escape from the recognition of P-gp and improve interaction with the endothelial cells.  
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1.2 Objective of study 
The aim of this study is to develop a new product of biodegradable polymeric 
nanoparticles for clinical administration of paclitaxel with less side effects, and with 
further modification, to promote oral chemotherapy. This system may also be applied to 
other anti-cancer drugs. Several additives including natural additives are applied not only 
to improve the adhesion and interaction of the nanoparticles with intestinal cells but also 
to act as emulsifier and solubilizer in the preparation process. The effects of various 
emulsifiers are investigated for the fabrication of biodegradable nanoparticles in an effort 
to achieve desirable properties for effective sustained release of drug with maximum drug 
efficacy. The physicochemical properties of nanoparticles are characterized by various 
state-of-the-art techniques. The in vitro release of the drug-loaded particles is also 
examined to study in greater detail of the release kinetics of the drug used and is modified 
by optimizing the preparation parameters. Evaluation of the effectiveness of the 
formulated nanoparticles delivery system in the in vitro cell line experiments and in vivo 
animal tests are performed to closely study the interaction between cells and polymeric 
particles, the particle uptake and to evaluate the efficacy and feasibility of the formulated 
delivery system.   
 
1.3 Significance of Study 
New dosage forms under development in this study may reduce side effects caused by 
both the anticancer drug and the adjuvant to provide possible improved efficacy. 
Intravenous administration of paclitaxel using biodegradable nanoparticulate system will 
1) eliminate possible irritant reactions, 2) reduce systemic side effects, and 3) provide 
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sustained release. Potential administration of biodegradable nanoparticulate system via 
oral route will: 1) obviate the difficulties of the i.v. access, 2) improve quality of life of 
patients, 3) reduce side effects, 4) increase efficacy at lower dosage for longer time 
saving scarce drug, and 5) offer convenience to the patients eliminating the needs for 
hospitalization, physicians and nursing assistance and infusion equipment. This system, 
applying novel functional surfactants, has a potential to overcome the multi-drug 
resistance (MDR) of paclitaxel, which has been another serious problem in the clinical 
administration of paclitaxel. This novel oral formulation of paclitaxel may be developed 
into a completely new form of cancer chemotherapy. 
 
1.4.  Thesis Organization  
This thesis comprises of 6 chapters. Chapter 1 presents a brief introduction, objective and 
significance of study. Chapter 2 provides a background understanding of cancer and its 
treatment, novel anticancer drug paclitaxel and its chemotherapy, and how biodegradable 
polymeric nanoparticles can be employed as drug delivery systems. Chapter 3 discusses 
the formulation and characterization of PLGA nanoparticles for oral paclitaxel 
administration. Effects of particle size and surface coating on cellular uptake of 
polymeric nanoparticles for oral delivery of anticancer drugs were investigated and 
detailed in Chapter 4. PLGA nanoparticles formulation for paclitaxel delivery was 
evaluated and discussed in Chapter 5 with extensive in vitro and in vivo studies for its 
drug release profile, cellular uptake, cytotoxicity and pharmacokinetics. Chapter 6 
summarizes the findings of this study and gives recommendations for future work. List of 
publications stem out from this study and achievements are given in Appendix A and 
Appendix B, respectively.  





2.1. Cancer and Cancer Treatment 
2.1.1. What is cancer? 
Cancer is a group of diseases characterized by the uncontrolled growth of abnormal 
cells that disrupt body tissue, metabolism, etc. and tend to spread locally and to 
distant parts of the body. Humans are made up of cells and the normal cells divide and 
grow at a controlled rate. Cancer initiates as a change in the gene of a single normal 
cell in any part of the body. Once this change takes place, the set of instructions in the 
gene is changed and the cell becomes abnormal which no longer acts like it normally 
does. Cancer is actually due to the accumulation of many such errors. Life-threatening 
cancer develops gradually as a result of a complex mix of factors such as complex 
interactions of viruses, a person’s genetic make-up, their immune response and their 
exposure to other risk factors which may favor the cancer. The notion of cancer as a 
serious, life-threatening disease must be very ancient; and probably for a long time 
different cultures have speculated that both external and internal factors play a role in 
the cause of cancer. 
Cancer is the second leading cause of death in the United States closely following the 
heart diseases. The statistics report from National Cancer Institute (2002) stated that 
men have a little less than 1 in 2 lifetime risk of developing cancer while women have 
a little more than 1 in 3, in the US. That implies 30% of all Americans will develop 
some kind of cancer in their lifetimes. Cancers of the prostate and breast will be the 
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most frequently diagnosed cancers in men and women, respectively, followed by lung 
and colorectal cancers both in men and in women (cancer statistic, 2004). In Sweden, 
the incidence is approximately the same in the US, more than one fifth of all deaths is 
due to cancer. In Singapore, cancer is the leading cause of death (27% of total deaths) 
which means about one in four deaths is from cancer (Hock, 2002). Breast cancer is 
the leading cancer in Singaporean women, accounting for 20% of the cases (Chia, 
1996).   
The occurrence of cancer leads to pain, suffering and psychological harm to the 
patients and their families, but it is also an economic issue. In the United States, 
approximately 16 million new cancer cases have been diagnosed since 1990 and the 
overall costs for cancer in 2001 were estimated at $156.7 billion. It is estimated that 
1.37 million new cases of cancer will be diagnosed in 2004 and one in every four 
deaths will be caused by cancer (American Cancer Society, 2002). More than 10 
million people are diagnosed with cancer every year. It is estimated that there will be 
15 million new cases every year by 2020. Cancer causes 6 million deaths every year 
or 12% of deaths worldwide (http://www.who.int/cancer/en/).  
Although our current understanding of what causes cancer is not complete, we now 
know enough to prevent at least one-third of all cancers. Cancer is largely 
preventable: by stopping smoking, providing healthy food and avoiding the exposure 
to carcinogens. Information is also available that would permit the early detection and 
effective treatment of a further one-third of cases. The chance of cure increases 
substantially if cancer is detected early. Cancer control is a public health approach 
aimed at reducing causes and consequences of cancer by translating our knowledge 
into practice. 
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2.1.2. How to treat cancer? 
Cancer treatment is a multidisciplinary therapy consisting of surgery, radiotherapy, 
chemotherapy and immunotherapy (Jönsson and Karlsson, 1990). The treatment 
sometimes has a curative intent, sometimes a palliative intent.  
One typical therapeutic approach to solid tumor is surgical removal followed by 
irradiation and/or systemic chemotherapy to kill malignant cells which may have 
survived the surgery, and prevent metastasis and re-growth of the tumor. Surgery may 
leave unavoidable residual cancer cells and have undesirable side effect of changing 
the growth rate of the remaining cancer cells by triggering a faster metastatic process. 
Thus, multimodal therapy that comprises radiotherapy, chemotherapy, 
immunotherapy, and other forms of treatments follows the surgery to provide a better 
chance to kill the metastatic cancer cells or at least to keep them in the remission 
state.  
The choice of treatment depends on the type and location of the cancer, whether the 
disease has spread, the patient's age and general health, and other factors (NCI, 2000). 
In many cases, especially for early stage cancer, undetectable cancer, metastatic 
cancer, or non-solid-tumor cancer (e.g. leukemia), chemotherapy has been proved to 
be necessary and effective treatment. Over the last decade, the situations have 
imposed the clinicians and researchers to aware the increasing demand of patients’ 
quality of life in cancer treatments (Gotay et al., 1992). The ultimate goal of treatment 
is to increase life span and/or improve the quality of life for the patients. 
Although great effort has been made in cancer research, no substantial progress can be 
observed in the past fifty years in fighting against cancer. The death rate in the USA 
was 193.9 per 100,000 in 1950 and remained as high as 194.0 per 100,000 in 2001 
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(Cancer Statistic, 2004). It is clear that the progress in cancer treatment has been slow 
and inefficient. Significant increments in cure rate are unlikely to be achieved unless 
more profound knowledge of cancer pathophysiology can be pursued, new anti-cancer 
agents discovered, novel biomedical technologies developed. It is a multidisciplinary 
challenge needing more and closer collaboration between clinicians, medical and 
biomedical scientists and biomedical engineers to eventually find a satisfactory 
solution. 
 
2.1.3. Chemotherapy and anti-cancer drugs 
Chemotherapy for cancer is treatment of cancer using therapeutical agents that have 
direct tumor-killing properties. Drugs that are specifically designated as part of 
hormone therapy and immunotherapy are sometimes included. Chemotherapy is most 
effective against cancers that divide rapidly and have a good blood supply. Aims of 
chemotherapy treatments are to cure; to maintain long term remission (free of 
disease); to increase the effectiveness of surgery or radiotherapy; to help control pain 
or other symptoms. 
Drugs that are effective in treating cancer interfere with the activity of cancer cells, 
either by going in directly to sabotage a specific phase of cell development or by 
sending confusing messages that cause the cells to destroy themselves. Not all drugs 
are effective against all cancers, and the different groups of drugs act in different way.  
Chemotherapy drug doses and schedules are developed so that the drugs enter the 
body, kill the rapidly dividing cancer cells, and are expelled before they can damage 
most healthy cells, which divide more slowly. But the normal cells that make up the 
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mucous lining of the intestinal tract, the hair producing cells, and the bone-marrow 
cells are also rapidly-dividing cells, hence these, too, are affected by the chemicals, 
causing the three most common side effects: nausea and vomiting, hair loss, and 
bone-marrow depression. Different drugs may cause different side effects and/or 
people may react differently to the same drug – some people have no side effects; 
some people have all of them; and most people fall somewhere in between.  
 
2.2. Paclitaxel and chemotherapy 
Chemotherapy is an effective treatment for cancer and other serious diseases such as 
cardiovascular restenosis and AIDS. Among the available drugs for chemotherapy, 
paclitaxel (Taxol®) is one of the best anti-cancer drugs and also reported to possess 
radio-sensitizer properties. 
 
2.2.1. Paclitaxel: promising anti-cancer drug 
Paclitaxel (5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-
diacetate-2-benzoate-13-ester with (2R, 3S)-N-benzoyl-3-phenylisoseine),  is a white 
to off-white crystalline powder with empirical formula of C47H51NO14 and a 
molecular weight of 853.9. It is highly lipophilic, insoluble in water, and melts at 
around 216-217°C. It is a complex, oxygen-rich diterpenoid (Rowinsky and 
Donehower, 1995; Rowinsky et al., 1992) and its chemical structure has been 
elucidated by chemists as in Fig. 2.1. It consists of some benzene rings and other 
hydrophobic structures, which lead to its high water insolubility of paclitaxel. 











Figure 2. 1. Chemical structure of paclitaxel. 
 
Paclitaxel was originally isolated from the bark of the Pacific yew tree (Taxus 
brevifolia). Its anti-tumor activity was first detected in 1967 when the US National 
Cancer Institute (NCI) was carrying out tests to screen for the possible presence of 
cytotoxic agents from natural products. The growing demand of paclitaxel, limitations 
of resources and environmental concerns led to the production of a semi-synthetic 
form of paclitaxel derived from the needles and twigs of the Himalayan yew tree 
(Taxus bacatta), which is a renewable resource. The FDA (Food and Drug 
Administration) approved the semi-synthetic form of paclitaxel in the spring of 1995.  
Phase I and II clinical studies have demonstrated the significant activity of paclitaxel 
against a variety of solid tumors (Rowinsky et al., 1990; Holmes et al., 1991; 
Runowicz et al., 1993; Spencer and Faulds, 1994; Rowinsky and Donehower, 1995) 
including breast cancer, advanced ovarian carcinoma, lung cancer, head and neck 
carcinoma, colon cancer, multiple myeloma, melanoma, AIDS-related Kaposi’s 
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sarcoma and acute leukemias. In 1992, it was approved by the US Food and Drug 
Administration (FDA) for ovarian cancer, later in 1994, for advanced breast cancer 
and then for early stage breast cancer in October 1999. 
Reports have shown brain tumors are sensitive to the paclitaxel in vitro (Cahan et al., 
1994) and it can also act as a radio-sensitizer for glioma cells in vitro (Tishler et al., 
1992). Recent studies using paclitaxel as the radio-sensitizer have shown that 
exposure to very low concentrations (10 ¯ 100nM) elicits potent clinical anti-
neoplastic activity against a variety of advanced solid human tumors (Bissett and 
Kaye, 1993).  
Paclitaxel has a low therapeutic index, and the therapeutic response is always 
associated with toxic side-effects (Terwogt et al., 1997). The major side effects 
include: depression of bone marrow, reduction of blood cell production, reversible 
hair loss, gastrointestinal problems, nerve damage, and so on (Kohler and Goldspiel, 
1994). However, the excellent therapeutic efficacy outweighs the risks associated with 
paclitaxel. 
 
2.2.2. Anticancer mechanism of paclitaxel 
Paclitaxel, a prototype for a new class of anticancer drugs, has a unique way of 
preventing the growth and separation of cancer cells: it promotes microtubules 
assembly (Park, 1997). Microtubules, made up of numerous tubulins, are a necessary 
and essential component in cells which carry out many important cellular functions, 
such as nutrition ingestion, sensory transduction, cell movement, cell shape control 
and spindle formation during cell division. In normal cell growth, microtubules are 
formed when a cell starts dividing. Once the cell stops dividing, the microtubules are 
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broken down or destroyed. Paclitaxel stops the microtubules from breaking down, but 
it promotes and stabilizes microtubule assembly by non-covalent interaction with 
tubulin, thereby blocking cell replication in the late G2 mitotic phase of the cell cycle 
(Kumar, 1981; Manfredi and Horwitz, 1984; Horwitz, 1994). Cancer cells become so 
clogged with microtubules that they cannot grow and divide and thus lead to cell 
death (NCI, 2001; Guchelaar et al., 1994; Lopes et al., 1993; Brown et al., 1991; 
Rowinsky et al., 1990; Donehower et al., 1978). This mechanism of inhibition is 
unique from that of other mitotic inhibitors such as vinca alkaloids, which inhibit 
microtubule assembly (Ettinger et al., 1995). 
 
2.2.3. Clinical administrations of paclitaxel 
Since paclitaxel is highly hydrophobic (water solubility ≤ 0.5mg/L) (Liggins et al., 
1997; Straubinger and Sharma, 1995) and not absorbed from the GI tract due to multi-
drug resistant (MDR) transporter, it is mainly given by intravenous (i.v.) 
administration. Due to its poor solubility in conventional aqueous vehicles, the only 
available dosage form of paclitaxel, Taxol®, is formulated in a mixture of Cremophor 
EL (polyoxyethylated 35 castor oil) and dehydrated alcohol (1:1, v/v) as a 
concentrated solution containing 6 mg paclitaxel per ml. Cremophor is an excipient in 
many drug formulations used to overcome poor water solubility. However, it is 
associated with leaching of plastic from standard IV tubing, hypersensitivity 
reactions, complement activation, axonal swelling, and demyelination and may 
interact with paclitaxel to cause myelosuppression; it may also contribute to reduced 
cell penetration by encapsulating the drug. 
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2.2.3.1. Intravenous (i.v.) administration of paclitaxel 
Taxol® must be further diluted 5 to 20-folds with 0.9% sodium chloride injection or 
other aqueous i.v. solutions before i.v. administration (Goldspiel, 1994). The 
drawback of this formulation is its short term stability upon dilution; it was found 
physically stable for only 3 h when diluted to drug concentrations ≤ 0.6mg/ml (Boyle 
and Goldspiel, 1998).  Taxol® is generally given at a dose of 135 or 175 mg/m2 as a 3 
or 24 h infusion, every 3 weeks (Kramer and Heuser, 1995; Seidman et al., 1995). 
Premedication with corticosteroids (e.g. dexamethasone), diphenhydramine and 
antihistamine (both H1 and H2-receptor antagonist, e.g. cimetidine, ranitidine) is used 
to increase safety and reduce intensity and the incidence of serious hypersensitivity 
reactions associated with Cremophor-based paclitaxel administration (Weiss et al., 
1990; Goldspiel, 1994; Lam et al., 1997). 
It is now well established that the CrEL plays a major role in the hypersensitivity 
reactions (Miller and Sledge, 1999; Schiller, 1998; Spencer and Faulds, 1994; Jordan 
et al., 1993; Horwitz et al., 1986; Schiff et al., 1979). The less known side effects of 
CrEL are neurotoxicity, nephrotoxicity and cardiotoxicity (Zuylen, et al., 2001; 
Lehoczky et al., 2001). Although some studies suggested that CrEL and Tween 80 
may enhance taxane cytotoxicity (Nygren et al., 1995) and might have a cytotoxic 
effect of their own (Fjällskog et al., 1993), this could not be confirmed by others 
(Terzis et al., 1997).  
It was also reported that CrEL has influence on the functions of endothelial and 
vascular muscle, leading to vasodilation, laboured breathing, lethargy, hypotension 
and toxicity to myocardium. Formulation of paclitaxel, with Cremophor and ethanol, 
precipitates upon dilution with infusion fluid and also during storage for extended 
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time periods (Lewis, 1990). Hence, an in-line filter is recommended for the 
intravenous line and it is suggested that drug is administered promptly after dilution. 
Paclitaxel formulation in ethanol:CrEL mixture also shows an incompatibility with 
the components of the infusion sets. It was reported (Venkataraman et al., 1986; 
Pfeifer and Hale, 1993; Rowinsky et al., 1993; Fjallskog et al., 1993; Dorr, 1994; 
Goldspiel, 1994; Allwood and Martin, 1996; Song et al., 1996; Xu et al., 1998) that 
both ethanol and Cremophor leach diethylhexylpthalate (DHEP) from the 
polyvinylchloride (PVC) containers and intravenous infusion line. The manufacturers 
of paclitaxel thus recommended the use of glass, polypropylene or polyolefin 
containers for its storage. These recommendations however, pose a number of 
practical problems since the availability of these types of containers is severely 
limited and as such the medical staff may be unfamiliar in its handling.  
Hence, it becomes necessary to come up with alternative dosage forms that are 
capable of overcoming the problems of CrEl. 
 
2.2.3.2. Oral administration of paclitaxel  
Oral route is the easiest and the most convenient way of drug administration, 
especially when repeated or routine dosing is required (Florence and Jani, 1993). Oral 
administration of paclitaxel is to be preferred as it may circumvent the use of CrEL 
and it offers convenience to the patients and improves the quality of life of the 
patients. It facilitates more chronic treatment regimens and promotes long exposure to 
the drug, which may have pharmacodynamic advantages and can thus improve the 
efficacy.  
Chapter 2: Literature Review 
 15
Unfortunately, oral paclitaxel is poorly bioavailable due to rapid elimination from the 
body by the first pass effect of cytochrome P450 (CYP) dependent metabolic process; 
and its high affinity for the plasma membrane multidrug transporter P-glycoprotein 
(P-gp) which is abundantly present in the GI tract (Dintaman and Silverman, 1999; 
Panchagnula, 1998; Seidman et al., 1995; Lopes et al., 1993; Rowinsky et al., 1990; 
Link et al., 1995; Donehower et al., 1987).  
 
2.2.4. Limitations of clinical paclitaxel formulations 
The main limitation for clinical application of paclitaxel is its low solubility in water 
and most of the pharmaceutical solvents. The reported water solubility of paclitaxel 
varies from ~7 μM (~6 mg/L) to 35 μM (~30 mg/L), depending on the determination 
method employed (Tarr and Yalkowsky, 1987; Swindell et al., 1991). Its solubility 
cannot be improved by the manipulation in pH because its molecules lack functional 
groups that are ionizable within the pharmaceutically useful pH range. The common 
approaches to enhance solubility such as the addition of charged complexing agents, 
the production of alternate salt forms, etc. are not applicable in the case of paclitaxel 
(Straubinger, 1995).    
The major obstacle in formulating successful oral paclitaxel dosage form is P-gp in 
the mucosa of the small and large intestine which limits the oral uptake of paclitaxel 
and mediates direct excretion of the drug in the intestinal lumen (Adams et al., 1993). 
This P-gp limitation was confirmed by some studies. The systemic exposure of oral 
paclitaxel was found 6-folds higher in mdr1a knockout mice model (lacking 
functional P-gp in the gut) than in wild-type mice (Asperen et al., 1996). High 
systemic availability could be achieved in wild-type mice when paclitaxel was 
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administered per-oral in combination with SDZ PSC 833 or with CsA, both are 
efficacious P-gp inhibitors (Asperen et al., 1997). However, these P-gp inhibitors may 
also suppress immune system and propose side effects over long-term application. 
Moreover, the cost of these inhibitors is another hindrance for successful development 
of oral dosage form of paclitaxel. 
Another setback is the requirement of relatively large doses of paclitaxel for a 
complete block of cell proliferation. Paclitaxel concentration required to completely 
inhibit cell growth is in excess of 10, 000 folds of that required to inhibit tumor cell 
growth by 50% (IC50) which is in nanomolar range (Spencer and Fraulds, 1994). 
The most serious clinical problem of the current paclitaxel formulation is 
hypersensitivity reactions due to its toxic adjuvant, CrEl and ethanol mixture. These 
problems were observed during clinical trials and were found to be critical point in 
development of paclitaxel. Paclitaxel was approved for phase II trials in April 1985, 
only after including premedication with antihistamines in the regimen along with 24 h 
continuous infusion to reduce peak concentration of both Cremophor and taxol. 
 
2.2.5. Alternative formulations of paclitaxel for potential clinical applications 
Paclitaxel has been recognized as the most potent anticancer agent for the past few 
decades. However, its use as an anti-cancer drug is compromised by its intrinsically 
poor water solubility. The effective chemotherapy using paclitaxel is relying on the 
development of new delivery systems which attracted a substantial number of studies 
investigated to deliver paclitaxel by new formulations.  
The primary goal of formulation development for paclitaxel is to eliminate the 
Cremophor vehicle by reformulation of the drug in a better-tolerated vehicle which 
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has the possibility of improving the efficacy of paclitaxel based anticancer therapy. A 
great deal of effort is being directed towards the development of aqueous based 
formulations for paclitaxel, including soluble semi-synthetic paclitaxel derivatives 
that do not require solubilization by Cremophor and that decrease the systemic 
clearance of the drug (Singla et al., 2002). 
Some of these efforts to achieve a safer and better-tolerated formulation include water 
soluble prodrugs (Greenwald et al., 1996; Pendri et al., 1998), enzyme activatable 
prodrugs used in conjugation with antibodies (Rodrigues et al., 1995), albumin 
conjugates (Dosio et al., 1997), complexes with cyclodextrins (Sharma et al., 1995; 
Dordunoo and Burt, 1996) and conjugates (Li et al., 1998), parenteral emulsions (Tarr 
et al., 1987; Simamora et al., 1998; Kan et al., 1999), nanocapsules (Bartoli et al., 
1990), liposomes (Sharma et al., 1996a), mixed micelles (Chai et al., 1994), and 
micro- and nanoparticles of biodegradable polymers as controlled drug delivery 
systems. 
Among these, some dosage forms have been able to dissolve substantial amounts of 
paclitaxel and successfully improved the effects of anti-tumor activity in animal 
models. Water miscible co-solvents are used as the method of formulating intravenous 
non-water-soluble drugs. Paclitaxel, inherently possessing limited aqueous solubility 
can be rendered water soluble by using principle of co-solvency (Tarr and 
Yalkowsky, 1987; Bissery et al., 1991), commonly used solvents being polysorbate 
80, ethanol etc. However, the precipitation of the drug on dilution with the aqueous 
media is an important factor to be considered. 
 
In order to improve solubility while preserving the activity, a number of water soluble 
paclitaxel prodrugs and derivatives have been synthesized that contain hydrophilic or 
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charged functionalities attached to the specific sites on the paclitaxel molecule 
(Hayashi et al., 2003). Sugars can be used as a hydrophilic appendage to tether them 
to the C-10 hydroxyl group in a taxoid through an ester linkage, since the taxoid is 
susceptible to Lewis acids often utilized in the conventional glycosylation protocols.  
Prodrug synthesis has also been extensively studied to increase the aqueous solubility 
of paclitaxel (Burt et al., 1995).  The preferred position for the preparation of prodrug 
of paclitaxel is 2’ position since many 2’-acyl-paclitaxel derivatives hydrolyze fairly 
rapidly back to paclitaxel in blood compartments (Mellado et al., 1984). Since the 
configuration of C-7 hydroxyl group does not seem to be a factor in determining 
cytotoxicity, C-7 prodrug ester has also been synthesized (Deutsch et al., 1989). In 
vitro, these prodrugs have been shown to possess cytotoxic activity against tumor cell 
lines comparable to those of paclitaxel. In addition, human plasma catalyzes the 
release of active paclitaxel. A prodrug strategy employing PEG as a solubilising agent 
has been successfully demonstrated in case of paclitaxel (Greenwald et al., 1994, 
1996). 
New paclitaxel amino acid derivatives were synthesized which have a glutaryl group 
substituted at the 2' position followed by the reaction of a peptide link between the 
carboxyl and the amino terminal group of the amino acid (Paradis and Page, 1998). 
The derivatives were cytotoxic in vitro against many sensitive cell lines. They also 
increased G2+M phase arrest. These derivatives were stable for over a year and 
showed a better solubility in water than the parent compound. However, no derivative 
has progressed to clinical evaluation because of problems such as chemical instability 
and the loss of pharmacological activity.  
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Several approaches were investigated to improve oral bioavailability of paclitaxel. 
These include the association of the drug complex to natural or modified 
cyclodextrins and to colloidal drug carrier systems, particularly polymeric 
nanoparticles (Boudad et al., 2001) which have proved to be an effective controlled 
drug delivery system. 
However, problems have still been encountered with these alternative methods, such 
as in vivo stability of liposomes and dosage limiting toxicity of the dosage forms used 
(Tarr et al., 1987; Sharma et al., 1995). The possible leakage of the drug from the 
liposomes formulation constrained the successful development of formulation using 
liposome which is a promising drug carrier. The mixed micelles formulation and 
parenteral emulsions have the similar safety problems to be resolved. New 
formulations with more consistent release properties are necessary to be developed for 
successful delivery of paclitaxel to human body. 
Polymer micelles are convenient passive  targeting carrier systems of anticancer drugs 
since they are structurally strong and unlike liposomes are not captured by the 
reticuloendothelial cell system (RES) because of their particle size (20–100 nm) 
(Yokoyama et al., 1990; Kataoka et al., 1993). Polymeric micellar paclitaxel 
formulation using non-toxic, biodegradable polymers have also been developed 
(Ramaswamy et al., 1997; Miwa et al., 1998). Using panel of cell cultured lines; it 
was found that the cytotoxic activity of paclitaxel was retained when formulated as 
mixed-micellar solution. In addition, for the same solubilization potential, the mixed-
micellar vehicle appeared to be less toxic than the standard non-aqueous vehicle of 
paclitaxel containing Cremophor EL (Chai et al., 1994). Micelle encapsulated 
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paclitaxel is thereby water soluble and in addition devoid of common side effects 
associated with Cremophor vehicle. 
None of the methods seemed to be effective enough to replace CrEL based vehicle 
although the different approaches investigated so far have shown a lot of promise for 
paclitaxel delivery. The final product for human use is still far away. For that reason, 
a great deal of effort has been given to develop more tolerable vehicles that improve 
the efficacy of paclitaxel in clinical chemotherapy. 
Of these alternatives solutions, nanoparticles and microparticles attained much 
importance, mainly due to their tendency to be able to accumulate in inflamed areas 
of the body (Diepold et al., 1989; Illum et al., 1989; Alpar et al., 1989). Moreover, 
they possess better stability in biological fluids and during storage.  
Clinical trials showed satisfactory results (Ichihara et al., 1989, Wang et al., 1993) and 
thus, the use of nanoparticles or microparticles of biodegradable polymers for 
chemoembolization has been pursued in efforts to achieve the desired result of 
enhancing the therapeutic efficacy of anticancer agents while minimizing its systemic 
order effects.  
The current approaches are mainly focused on developing formulations that are 
devoid of CrEL, the possibilities of preparation on a large scale and stability for 
longer periods of time (Panchagnula, 1998; Feng et al., 2000; Feng and Huang, 2001; 
Mu and Feng, 2001; Wang et al., 2002). Various anticancer drugs such as cisplatin, 
interferon β, etc. can be encapsulated together to achieve synergistic effects (Zand et 
al., 2001). 
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2.2.6. Our engineering approach for potential alternative clinical paclitaxel 
formulation 
There has been intensive investigation directed to oral delivery of paclitaxel, which is 
expected to provide a long-time exposure at an appropriate therapeutic level of drug 
and to greatly improve the quality of life of the patients. However, the obstacle to the 
successful formulation of oral dosage form is its low oral bioavailability due to the 
elimination of a multi-drug efflux pump transporter P-glycoprotein (P-gp) 
(Sparreboom et al., 1997) and the first pass of  cytochrome P450 (CYP 3A) enzymes 
(Cresteil et al., 1994; Harris et al., 1994). P-gp in the mucosa of the small and large 
intestine may limit the oral uptake of paclitaxel and mediate direct excretion of the 
drug in the intestinal lumen (Adams et al., 1993). Medical solution to overcome this 
problem is to apply P450/P-gp inhibitors such as cyclosporin A (Scambia et al., 1995; 
Asperen et al., 1997; Bardelmeijer et al., 2000; Choi et al., 2004). However, the 
inhibitors would also fail the immune system of the patients and thus lead to medical 
complications over long term application. Most of the P450/P-gp inhibitors have their 
own side effects and difficulties in formulation (Bonduelle et al., 1996). Moreover, 
the cost of these inhibitors is another hindrance for successful development of oral 
dosage form of paclitaxel. 
Nanoparticles of biodegradable polymers represent a chemotherapeutic engineering 
solution or cancer nanotechnology solution. Nanoparticles of biodegradable polymers 
for drug formulation and for oral chemotherapy have shown advantages in improving 
the pharmacokinetics and tissue distribution and thus the therapeutic effects of the 
formulated drug (Couvreur et at., 1980; Rolland, 1989). Preliminary results have 
demonstrated that nanoparticles can escape from the vasculature through the leaky 
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endothelial tissue that surrounds the tumor and thus accumulate in solid tumors 
(Leroux et al., 1996; Monsky et al., 1999). It was demonstrated that nanoparticle 
formulation can overcome the multi-drug resistance phenotype mediated by P-
glycoprotein and thus lead to an increase in drug content inside the neoplastic cells 
(Benis et al., 1994; Rowinsky and Donehower, 1995; Seelig, 1998). 
 
2.3. Biodegradable Polymeric Nanoparticles as Controlled Drug Delivery 
Systems 
Polymeric drug delivery systems have been a major focus of pharmaceutical 
companies in recent years (Sandor et al., 2001). The controlled release of 
pharmacologically active agents to the specific site of action at the therapeutically 
optimal rate and dose regimen has been a major goal in designing such delivery 
systems. Liposomes have been used as potential drug carriers instead of conventional 
dosage forms because of their unique advantages such as ability to protect drugs from 
degradation, target the drug to the site of action and reduce the toxicity or side effects 
(Knight, 1981). However, liposomes formulation has some inherent limitations such 
as low encapsulation efficiency, rapid leakage of water-soluble drug in the presence 
of blood components and poor storage stability. Polymeric drug delivery devices offer 
some specific advantages over liposomes. They help to increase the stability of drugs 
/proteins and possess useful controlled release properties.  
The advantages of biodegradable and biocompatible polymeric drug delivery devices 
(Gardner, 1987; Sandor et al., 2001) over traditional dosage forms include: (1) 
improved therapeutic efficacy and reduced toxicity; (2) lower and more efficient 
doses; (3) less frequent dosing; (4) better patient compliance; (5) the ability to 
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stabilize drugs and protect against hydrolytic or enzymatic degradation; (6) the 
elimination of the need for surgical removal of the devices; and (7) the ability to mask 
unpleasant taste or odor (if any).  
The major advantage of polymeric drug delivery system is that the drug in the 
polymer matrix is unaltered, therefore its biological effect, absorption, distribution, 
metabolism, and excretion after being released from the polymer is the same as that of 
the native drug (Dunn, 1991).  Moreover, the release profile can be modulated by 
controlling the proper parameters when the system is prepared.  
Over the past few decades, there has been considerable interest in developing 
biodegradable nanoparticles as effective drug delivery devices, owing to their ability 
to target particular organs/tissues, act as carriers of DNA in gene therapy, and deliver 
proteins, peptides through a peroral route of administration (Lanza et al., 1997; 
Langer, 2000). Nanoparticles (NPs) were first developed around 1970 and initially 
devised as carriers for vaccines and anticancer drugs (Couvreur et al., 1982). The drug 
can be dissolved, entrapped, encapsulated or attached to NP matrix. One of the 
simplest methods to obtain sustained delivery of a biologically active agent is to 
encapsulate or entrap within the polymer. The polymer has to dissolve or disintegrate 
before the drug can be released or else the drug has to dissolve or diffuse from the 
polymer matrix. In either case, the release of drug to the physiological environment is 
extended over a much longer time than if the drug is administered in its native form. 
Furthermore, the strategy of drug targeting was employed to enhance tumor uptake. 
This important research focused on the development of methods to reduce the uptake 
of the nanoparticles by the cells of the reticuloendothelial system (RES) (Couvreur et 
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al., 1986). The use of nanoparticles for ophthalmic and oral delivery was also 
investigated (Labhasetwar et al., 1997). 
Depending on the method of preparation, nanoparticles, nanospheres or nanocapsules 
can be obtained. Nanocapsules are vesicular systems in which the drug is confined to 
a cavity surrounded by a unique polymer membrane, while nanospheres are matrix 
systems in which the drug is physically and uniformly dispersed. Nanoparticles 
generally vary in size from 10 to 1000 nm.  
Nanoparticles present some significant advantages: nanoparticles enable intravenous 
injections and intramuscular and subcutaneous administrations due to the reduction of 
possible irritant reactions involved and are also capable of avoiding uptake by 
microphages (Oppenheim et al., 1982; Aprahamian et al., 1987; Florence, 1997). 
Moreover, due to the small size of these polymeric nanoparticles, the encapsulated 
anticancer drug can escape the elimination by P-gp present in the intestinal cell 
membrane and/or enter between the intestinal cells.  
Nanoparticles have very special properties compared with bulk materials or even 
micron-size particles. Due to its sub-micron nature, it is more efficient in certain 
therapy applications such as intracellular localization of therapeutic agents 
(Labhasetwar et al., 1997). Nanoparticles enable intravenous administration by 
minimizing possible irritant reactions. Nanoparticles could prove to have potential 
applications in oral drug delivery due to their efficient uptake by the gut associated 
lymphatic tissue (GALT), and to improve oral bioavailability of therapeutic agents 
(Desai et al., 1996). Moreover, oral administration of nanoparticles encapsulated 
agent could provide sustained efficacy due to slow breakdown of the polymer over a 
period of time.  
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Oral absorption of polymeric nano- and microparticles by the GI tract has been 
extensively studied for the last two decades. The controlling factors are found to be 
size, nature of the polymer, zeta potential, vehicle, coatings, and presence of nutrients. 
However, the best designed parameters for oral delivery system can not be determined 
yet due to numerous discrepancies lying in the large variety of analytical methods and 
models employed to investigate the particle uptake. 
 
2.3.1. Polymeric delivery system formulation for paclitaxel 
The use of a biodegradable delivery system capable of providing a lower and 
localized dose of paclitaxel to the tumor site attracted intense research on its 
formulation and applications. Several researchers have examined the release of 
paclitaxel and other radiosensitizers from a variety of different carriers (microspheres, 
discs, nanoparticles) using poly (lactide), poly (glycolide) and other co-polymers 
(Doiron et al., 1999). 
The low solubility of paclitaxel may remain as a barrier to design a successful 
formulation with desired sustained release property, even being encapsulated into the 
nanoparticle matrix. Paclitaxel molecules are homogeneously distributed in the solid 
polymer matrix and are not readily dissolved and diffused out of the polymer solid 
phase due to its poor solubility and the very limited amount of water available inside 
the solid phase. Various approaches have been attempted to solve this problem. 
Isopropyl myristate, a fatty acid ester, was added to the solid polymer microparticles 
and the release rate of paclitaxel was increased about 3 times higher than the blank 
samples (Wang et al., 1997). However, the release time span of this formulation was 
too short for a radiotherapy or chemotherapy which usually lasts for about 6-8 weeks. 
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Polymeric paste formulation was investigated using low molecular weight poly (D, L-
lactic acid) (PLA) and polycaprolactone (PCL) as additives to modulate the release 
profile of paclitaxel from the poly (D, L-lactic acid)-block-poly (ethylene glycol)-
block-poly (D, L-lactide) (PDLLA-PEG-PDLLA) copolymer paste (Zhang et al. 
1996). Both the addition of low molecular PLA and the use of copolymer PDLLA-
PEG-PDLLA increased the release rate of the drug comparing with the samples made 
of PCL. However, the copolymer needs to be approved by FDA for the use in human 
body as a biocompatible material and the high temperature used in the experiment 
may cause the degradation or other side reaction of the drug. The effects of various 
water soluble additives such as gelatin, bovine serum albumin, methylcellulose, and 
dextran T500 on the enhanced release of paclitaxel from a polymeric surgical paste 
was studied (Dordunoo et al., 1996). All the additives increased the release rate by a 
possible swelling and solubilizing mechanism.  
Significant amount of works has been done by examining various aspects, such as 
influence of polymer type, concentration, particle formation conditions, and drug type 
on the resultant properties of the controlled release system.  
 
2.3.2. Biodegradable polymers 
Drug delivery systems that control and prolong the action of therapeutic agents have 
grown in importance during the recent years with the development of biodegradable 
polymers. The use of biodegradable polymers eliminates the step of removing the 
system after the drug has been released, which, in some applications, can represent a 
significant advantage over other systems. Much of the effort on encapsulation of drug 
in the pharmaceutical field has concentrated on using biodegradable polymers.  
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Biodegradable polymers are gradually dissolved by hydrolytic or enzymatic cleavage 
of the polymeric structure or by simple dissolution. Generally, there are three defined 
mechanisms of polymer erosion (J Heller, Biomaterials, 1, 51-57). Mechanism I 
concerns polymers that are made water insoluble by their hydrolytically unstable 
cross-links. These polymers, such as cross-linked gelatin, collagen, or poly (vinyl 
alcohol), provide highly hydrophilic matrices. Thus, substances with low molecular 
weight and high water solubility diffuse rapidly through polymeric network 
independently of the rate of erosion of the matrix. These polymers are mainly used for 
the release of sparingly water soluble drugs and for macromolecules such as enzymes 
and antigens.  
Mechanism II includes polymers that are initially water insoluble and are solubilized 
by hydrolysis, ionization, or protonation of a pendent group yet lack backbone 
cleavage. This mechanism has the feature of not causing any significant change in the 
molecular weight of the polymer. These polymers, such as poly (vinyl methyl 
ether/maleic anhydride), cannot therefore be used for implants because of the 
difficulty of their elimination. 
Mechanism III refers to hydrophobic polymers that are converted to small soluble 
molecules by backbone cleavage. As long as these breakdown products are not toxic, 
these polymers, for example, polyanhydrides, polycaprolactones, poly (ortho ester)s, 
poly (lactic acid)s (PLA), poly (glycolic acid)s (PGA), and their copolymers, are 
suitable as implantable carriers for the administration of drugs to any organ. They 
offer a wide range of applications in the ophthalmic field, whether applied on the 
surface of the eye or as intraocular implants. 
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The breakdown of polymers does not necessarily proceed through one mechanism 
only, and erosion occurs by a combination of these mechanisms. 
A broad range of polymers can be used to form micro/nanoparticles but the list of 
polymers approved for use in oral and/or parenteral drug formulation is limited. This 
list includes proteins, polysaccharides, cellulose derivatives, synthetic polyesters 
developed as synthetic suture materials, polyanhydrides, and polyphosphazene.  
Various polymers have been used in drug delivery research as they can effectively 
deliver the drug to a target site and thus increase the therapeutic benefit, while 
minimizing side effects (Kreuter, 1994). The biocompatible polymers such as PLA, 
PLG and PLGA have been used as controlled release formulations in parentral and 
implantation drug delivery applications (Wise et al., 1979). In addition, poly (ε-
caprolactone), PCL, which was first reported by Pitt’s group (1979 and 1980) for the 
controlled release of steroids and narcotic antagonists as well as to deliver ophthalmic 
drugs (Calvo et al., 1996), and poly (alkylcyanoacrylate), PACA, are now being 
developed as NPs.  
Polymers with the greatest relative hydrophobicity, poly (styrene), poly (methyl 
methacrylate) and poly (hydroxybutyrate) were absorbed most readily. The relatively 
less hydrophobic polymers poly (D, L-lactide), poly (L-lactide) and poly (D, L-
lactide-co-glycolide) were absorbed well, but in low numbers. Based on the criteria of 
biocompatibility, biodegradability, adequate absorption by the Peyer’s patches and a 
history of safe use in humans, particles prepared with DL-PLGA were selected as the 
most promising for application as an oral delivery system.  
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2.3.2.1. Poly (lactide-co-glycolide) (PLGA) 
Initially, poly(α-hydroxy acid)s were developed as synthetic, bioresorbable sutures in 
the 1960s. As a result of their good histocompatibility (Kobayashi et al., 1992), this 
family of polyesters now includes the most-investigated biodegradable polymeric 
carriers for drug delivery systems. The principal polymers of this class are homo- and 
co-polymers derived from lactic and glycolic acids: poly-lactide (PLA), poly-
glycolide (PGA), and their co-polymer poly-(lactide-co-glycolide) (PLGA). 
Poly (lactide-co-glycolide) (PLGA) is a type of thermoplastic aliphatic and 
hydrophobic poly (ester). As the name suggests, PLGA is prepared from the co-
polymerization of D, L-lactide with glycolide. The chemical structure of PLGA is 
shown in Fig. 2.2.  
 
                             
Figure 2. 2. Structure of PLGA. The suffixes x and y represent the number of lactic and 
glycolic acid respectively. 
 
Poly(α-hydroxy acids) are generally synthesized by a condensation reaction at high 
temperatures. The ring-opening polymerization of cyclic glycolic and lactic acid 
diesters is an efficient method to produce high-molecular-weight polymers. The 
simple step-growth polymerization method leads only to low-molecular-weight 
polymers with poor mechanical properties (Vert et al., 1984). The presence of an 
asymmetric carbon in lactic acid makes it possible to obtain levorotatory (L), 
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dextrorotatory (D), or racemic (D,L) forms of the corresponding polymer, which can 
have different physicochemical properties. 
PLGA is believed to degrade in vivo by nonspecific hydrolytic scission of the ester 
bonds to yield the monomeric units of lactic acid and glycolic acid (Brandt et al., 
1984) which are eventually excreted from the body. Therefore, it is considered as a 
biodegradable and biologically friendly polymer. Precise specification of PLGA drug 
delivery system can be tailored by selecting the required ratio of LA/GA and 
molecular weight which control the degradation and drug release profiles of a PLGA 
delivery system. 
The physical properties and FDA approval of PLGA make them the most extensively 
studied commercially available biodegradable polymers. These copolymers are 
amorphous and easily dissolve in organic solvents such as dichloromethane and ethyl 
acetate. The degradation rate of PLGA in water is a function of the molecular weight 
and the lactide:glycolide ratio. Higher glycolide content and lower molecular weight 
increase the degradation rate. PLGA degrades by bulk hydrolysis in water (Gopferich, 
1997). The rate of degradation of PLGA controls the release of any encapsulated 
pharmaceutical agent which is released by both diffusion and erosion as the polymer 
hydrolyzes. Thus, depending on the therapy required for a particular drug, the release 
kinetics of that drug from its polymer matrix can be controlled by selecting a PLGA 
with appropriate physical characteristics. 
The properties of PLGA, biodegradability and low toxicity, make it suitable to be 
used in various medical and pharmaceutical applications such as wound closure, 
dental repairs, fracture fixation, ligament reconstruction, vascular grafts, tracheal 
replacement, ventral herniorrhaphy, nerve repair and drug delivery (Wu, 1995). 
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PLGA degrades into lactic and glycolic acids. The lactic acid enters the tricarboxylic 
acid cycle and is subsequently eliminated from the body as carbon dioxide and water. 
Glycolic acid is either excreted unchanged in the kidneys or it enters the tricarboxylic 
acid cycle and is eliminated from the body as carbon dioxide and water (Jain, 2000). 
The greatest advantage in using PLGA in drug delivery lies in the fact that they can be 
degraded into biologically accepted molecules that are metabolized and removed from 
the body via normal metabolic pathways (Peppas, 1997).  
 
2.3.3. Fabrication of nanoparticles for drug delivery system 
Several methods are available in the literature to formulate nanoparticles with drugs 
dispersed uniformly into the polymer matrix or simply adsorbed onto preformed 
particle surface. Some processes involve polymerization reactions while others use 
the preformed polymers. The choice of polymer and method depends on the desired 
properties of the final product (morphology, release profiles, etc.), the properties and 
nature of the polymer and the drug, and the properties of the coating material.  
There are a huge and increasing number of particle preparation processes such as: 
interfacial polymerization, coacervation, complex coacervation, thermal denaturation, 
salting-out, hot melt, solvent evaporation, solvent removal, spray-drying and phase 
separation. It is sometimes difficult to classify the methods because specific 
techniques can be hybrids of two or more methods or can use different mechanisms 
simultaneously.  
Interfacial polymerization involves the condensation of two monomers at the 
interface of the organic and aqueous phases. Monomer polymerization is employed to 
prepare drug-loaded nanoparticles. The drug can be dissolved in the polymerization 
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medium before the addition of the monomer or at the end of the polymerization 
reaction. The formed nanosuspension is then purified by ultracentrifugation or by 
resuspending in an isotonic medium. The size and molecular mass of obtained 
nanoparticles depends on the polymerization variables, such as the type and 
concentration of the surfactant used, the pH of the polymerization medium, the 
concentration of monomer and the stirring speed (Gaspar et al., 1991; Behan et al., 
2001). 
Coacervation or phase separation process uses the common phenomenon of 
polymer-polymer incompatibility to form nanoparticles. The particle wall material 
polymer is dissolved in a solvent and a second polymer (the phase inducer) is 
introduced to form two polymer-rich phases. If drug particles are then introduced, one 
phase, rich in the desired coating polymer, engulfs the drug being encapsulated.  
Coacervation can be induced by a change in temperature or pH of the system; a 
change in electrolyte balance; addition of nonsolvents; addition of other materials 
which are incompatible with the polymer solution. Phase separation is a new method 
in which a one-step precipitation of two polymers or more produces double-walled 
microspheres (Pekarek et al. 1994). Although the range of polymers that can be used 
in this process is essentially infinite in principle, the number of polymers that have 
been used successfully in practice is relatively small.  
The term coacervation used in this context is borrowed from the description of an 
equilibrium state of colloidal systems. In the phase separation process, the term refers 
to a state of partial precipitation of the matrix phase by the coacervation agent. The 
matrix material at this point is still solvent rich, and not completely precipitated, and 
thus maintains a high degree of flow necessary for good film- and particle-forming 
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properties. Several of the coacervation methods are being successfully used to prepare 
a variety of products from peptide microcapsules to encapsulated electrolytes 
(Migliaresi et al., 1987). 
Complex coacervation was used to make the microcapsules in the first successful 
encapsulated product, carbonless copy paper (Kassem and El-Sayed, 1975). This 
process uses the interaction of two oppositely charged polyelectrolytes in water to 
form a polymer-rich coating solution called a coacervate (Chan and Heng, 1998). This 
solution (or coacervate) engulfs the liquid or solid being encapsulated, thereby 
forming an embryo capsule. Cooling the system causes the coacervate (or coating 
solution) to gel via network formation. Gelatin is a primary component of most 
complex coacervation systems.  
The precipitation and/or gelation process precipitates a preformed polymer around 
the core (or a multi- particulate core) to encapsulate the drug in the particles formed. 
The polymer is dissolved in water miscible organic solvent and the drug is dissolved 
or dispersed in the polymer solution which is then poured to water phase in the 
presence or absence of a surfactant. The interfacial turbulence produced by the quick 
diffusion of solvent to the external phase leads to the formation of nanoparticles. One 
example is the precipitation of water-soluble polymers such as gelatin with water-
miscible solvents such as isopropanol. Other examples include the precipitation of 
ethyl cellulose from cyclohexane by cooling, the gelation of sodium alginate with 
aqueous calcium salt solutions (Chan and Heng, 1998), and the thermally induced 
precipitation of proteins to form microspheres.  
Salting-out process involves the addition of salt to an aqueous polymer solution 
ultimately causing the polymer to phase separate from solution (Allémann et al., 
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1992). One potential problem with this process is the possibility of incorporating a 
relatively high concentration of salt in the final product, as these salts may have an 
adverse effect on the drug release behavior. 
The nano or microparticles are usually prepared by the solvent evaporation technique, 
either by freeze dry or spray dry (Burt et al., 1995; Wang et al., 1996; Wang et al., 
1997; Corrigan et al., 1985; Giunchedi et al., 1995). In spray-drying, the evaporation 
of the solvent is achieved in a special, temperature-controlled cyclone.  
The emulsification-solvent-evaporation technique was first described by Beck and 
colleagues for the delivery of contraceptive steroids (Beck et al., 1979). It is the most 
commonly used method for preparation of biodegradable micro- or nano-particles 
encapsulating poorly soluble therapeutic agents. The polymer and drug are dissolved 
in an organic solvent which is volatile and immiscible with water. A dispersed phase 
containing the polymer is emulsified in an immiscible continuous phase containing a 
stabilizing agent. The second phase involves the diffusion of the solvent from the 
emulsion droplet into the continuous phase and its subsequent evaporation. 
Simultaneous inward diffusion of the non-solvent into the droplet causes polymer 
precipitation, microsphere formation, and hardening. Depending on the nature of the 
two phases, the process may be termed oil-in-water (o/w) or water-in-oil (w/o) 
emulsion method.  
The solvent evaporation process requires the use of a surfactant or emulsifier to 
stabilize the dispersed-phase droplets formed during emulsification and inhibit 
coalescence. Surfactants are amphipathic in nature and hence align themselves at the 
droplet surface to promote stability by lowering the free energy at the interface 
between the two phases. Moreover, the creation of a charge or steric barrier at the 
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droplet surface confers resistance to coalescence and flocculation. Surfactants 
employed in the process tend to be hydrophilic in nature and by far poly (vinyl 
alcohol) (PVA) is the most widely used. The amount and type of emulsifier used play 
a significant role in determining morphology, size, encapsulation efficiency, release 
profile and particle uptake. For pharmaceutical applications, emulsifiers must be 
acceptable for therapeutic use (Wade and Weller, 1994). 
Particle size can be adjusted by the source and the energy input such as sonication, 
homogenization, microfluidization, vortexing, etc. for emulsification in the system 
(Desai et al., 1997; Labhasetwar et al., 1997). 
After emulsification, the removal of solvent and the complete particle hardening is 
usually accomplished by gentle agitation of the suspension. After evaporation of the 
solvent, the final stage of the emulsification-solvent- evaporation process is the 
isolation of particles from the dispersed phase containing surfactant. This has 
generally been achieved by centrifugation and filtration, and it is usually followed by 
a further cleaning process in which the particles are washed several times with 
distilled water. The particles are finally dried at ambient conditions or under vacuum, 
or using freeze-drying or fluid-bed drying. 
One disadvantage of using (o/w) emulsification method is poor encapsulation 
efficiency for moderately water-soluble and water-soluble drugs. For the 
encapsulation of hydrophilic drug, a modified method of oil-in-oil is used. In this 
method, an organic liquid such as mineral or castor oil is used as the continuous 
phase. An alternative method involves forming a double emulsion where an aqueous 
drug solution is emulsified in a polymer solution in volatile organic solvent. The 
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resulting emulsion is then emulsified in an aqueous solution giving a double 
emulsion.  
Although the solvent evaporation method is simple, various parameters will influence 
the formation of the particles. These include the polymer composition and molecular 
weight, the nature and solubility of the drug encapsulated, the temperature of the 
emulsion and the properties of the emulsifiers used.  
Solvent extraction is similar in nature to o/w emulsion-solvent evaporation process 
except that following emulsification the preformed particles are poured into a large 
volume of non-solvent to extract the remaining organic solvent, thus causing rapid 
hardening of the particles. 
Solvent removal was developed as a modification of the solvent evaporation 
technique, using organic solvents as the extracting medium (Mathiowitz et al., 1988).  
Spray-drying is a one-step, continuous, particle-drying process that transforms the 
feed material from a fluid state into a dried particulate form by spraying the feed into 
a hot drying medium. The feed material can be in the form of a solution, suspension, 
emulsion, or paste. The resulting product can be powdered, granular, or agglomerated 
particles, depending upon the physical and chemical properties of the feed material, 
the drier design, and its operation. Spray-drying is used in all major industries where 
particle drying is required, ranging from food and pharmaceutical manufacturing to 
chemical industries such as mineral ores and clays (Masters, 1984). Spray-drying has 
proven to be a useful technique in producing controlled release products. The main 
advantage of this process is that it is convenient, fast, and allows the use of mild 
conditions.  
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2.3.4. Characterization of polymeric nanoparticles 
Among the various techniques and instrument available, the characterization of 
particles employed laser light scattering (LLS) for measurement of size and size 
distribution, atomic force microscopy (AFM) and scanning electron microscopy 
(SEM) for morphological studies, X-Ray photoelectron spectroscopy (XPS) for 
surface chemistry, zeta potential for surface charge and stability of nanoparticle 
suspension, and high performance liquid chromatography (HPLC) to study the 
encapsulation efficiency and the in vitro release of the drug. The instruments used and 
the working principles behind the instruments are briefly described in this section.  
 
2.3.4.1. Laser light scattering system (LLS) 
The laser light scattering instrument is used to determine the mean diameter and 
polydispersity of the sample particles. The dried powder samples are suspended in 
filtered deionized water. The scattering of the laser beam focused on this 
solution/suspension containing particles of interest will provide information about 
their molecular structure and motion in the solution.  
Interaction of light (electron-magnetic radiation) with matter results in two processes, 
absorption and scattering. When a beam of light falls upon a matter, the electric field 
associate with the light polarizes the electron cloud of the atoms. Thus a dipole is 
induced in the molecules, which oscillates with the electric field. These oscillating 
electron clouds serve as secondary sources of light and emit light in various directions 
(scattering). The scattered light has almost the same wavelength as the incident light. 
It is the intensity of the scattered light and its angular distribution which gives the 
information regarding the nature of the molecule under study.  
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Various applications of the instrument include characterization of macromolecules 
and their associations, determination of macromolecular size, translation diffusion 
coefficient and the polydispersity of the sample.  
 
2.3.4.2. Scanning Electron Microscopy (SEM) 
The SEM is used to study shape and morphology of the sample particles. The samples 
are coated with platinum or gold before analysis by SEM. An electron beam is 
focused onto the sample surface kept in a vacuum by electron-magnetic lenses and 
scanned over it. The scattered electron from the sample is fed to the detector and then 
to a cathode ray tube through an amplifier, where the images are formed, which gives 
the information on the surface of the sample. The instrumentation comprises of heated 
filament as source of electron beam, condenser lenses, aperture, and evacuated 
chamber for placing the sample, electron detector, amplifier and CTR with image 
forming electronics. 
While conventional light microscope uses a series of glass lens to bend light waves 
and create a magnified image, the scanning electron microscopy (SEM) uses electrons 
instead of light. The SEM is capable of producing very detailed 3-dimensional images 
at much higher magnifications than is possible with a light microscope.  
SEM has been used in the surface studies of materials such as metals, polymers and 
biological materials. Some of the disadvantages of the SEM are complex 
instrumentation and the requirement of high vacuum for optimum performance.  
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2.3.4.3. Atomic force microscopy (AFM) 
The AFM is a form of scanning probe microscopy, which provides the information on 
morphology and properties of surfaces on a nano scale range. AFM can be used to 
study the surface topography, surface hardness and elastic modulus.  
AFM operates by measuring the forces between the sample and the tip. The probe tip 
is brought close enough to the sample surface to detect the repulsive force between 
the atoms of the tip material and sample. The probe tip is mounted at the end of a 
cantilever of a low spring constant and the tip-to-sample spacing is held fixed by 
maintaining a constant and very low force on the cantilever. If the tip is brought close 
to the sample surface, the repulsive force will induce a bending of the cantilever. The 
bending of the cantilever can be detected by a laser beam which is reflected off the 
back of a cantilever. The surface topography of the sample can be tracked by 
monitoring the deflection of the cantilever. The instrumentation for AFM consists of a 
scanner, cantilever, laser source, photodiode detector and microprobe.  
AFM operates at two modes, contact mode that detects the repulsive forces between 
the tip and sample or non-contact mode that detects the van der waals forces that act 
between the tip and sample. The AFM has proved to be a most versatile tool in 
imaging of surfaces and molecules and to measure forces between nanoparticles as a 
function of separation. 
 
2.3.4.4. X-Ray Photo-emission Spectrometry (XPS) 
The XPS is used to analyze the surface chemistry of the particles. When a primary X-
ray beam of precisely known energy impinges on sample atoms, inner shell electrons 
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are ejected and the energy of the ejected electrons is measured. The difference in the 
energy of the impinging X-ray and the ejected electrons gives the binding energy of 
the electron to the atom. The binding energy of the emitted electron depends on the 
energy of the electronic orbit and the element, thus it can be used to identify the 
element involved. The chemical form of the atom affects the binding energy to a 
considerable extent to give rise to some chemical shift, which can be used to identify 
the valence of the atom and its exact chemical form.  
Instrumentation for XPS consists of a radiation source for primary X-rays, 
monochromator, energy analyzer and detected to measure the intensity of the resolved 
electrons. The analysis is carried out in high vacuum. Some of the disadvantages 
associated with the use of XPS are complex instrumentation and the inability of XPS 
to detect impurities at ppm or ppb level. 
 
2.3.4.5. Zeta Potential Analyzer 
Zeta potential is an important indicator of the electronic charge on the surfaces of the 
microscopic material, which can be used to predict and control the stability of colloid 
suspensions or emulsions. The zeta potential of the sample particles suspended in 
filtered deionized water was measured by tracking the charged particles when they 
migrate in a voltage field in a zeta potential analyzer.  
 
2.3.5. In vitro evaluation by cell line models 
Cells taken from animal/human tissue will continue to grow by mitosis if supplied 
with nutrients and growth factors and this cell culture process occurs in vitro as 
opposed to in vivo. Cultures normally contain cells of one type (e.g., fibroblasts). The 
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cells are selected and maintained by sub-culturing or passaging as independent units. 
The cells in the culture may be genetically identical (homogeneous population) or 
may show some genetic variation (heterogeneous population).  
The culture collections provide the cells that have been well characterized in terms of 
growth, origin, and genetic traits. The choice of cell culture depends on the objective 
of the study and the nature of the experiments planned. Most cells in culture grow best 
at 37°C and pH 7.4 which are the normal physiological conditions. 
In vitro models are expected to give better reproducibility and to allow screening of 
higher number of samples compared to in vivo models. There are several advantages 
(Butler, 1996) of using cell line experiments: the consistency and reproducibility; the 
understanding of the behavior of cells in vivo and the effects of a particular compound 
on a specific cell type such as lung cells or intestinal cells; the rapid assessment of the 
potential permeability and metabolism of a drug; the opportunity to elucidate the 
molecular mechanism of drug transport; the opportunity to use human rather than 
animal tissues; and the opportunity to minimize time-consuming, expensive, and 
sometimes controversial animal studies. Cell line experiments are highly preferred 
and appreciated as an initial study to understand and/or predict in vivo conditions. 
In vitro cell culture models allow both quantitation and visualization of particle 
transport and localization on a cellular level using a noninvasive technique. Moreover, 
cell integrity and cytotoxicity can be assessed (Jung et al., 2000) which are especially 
important parameters of intracellular uptake since toxic side effects of the carrier 
system are known to increase epithelial permeability and can lead to 
misinterpretations. Fluorescent particles are the most common tools to assess particle 
uptake both qualitatively and quantitatively. 
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Confocal microscopy and fluorescence microscopy are widely applied for qualitative 
uptake studies. Laser scanning confocal microscopy is an established valuable tool for 
high resolution images and 3-D reconstructions of a variety of biological specimens. 
Desai and colleagues (1997), Suh and co-workers (1998) have extensively used 
confocal microscopy to evidence the fluorescent particle uptake and the extent of 
uptake.  
Human colon adenocarcinoma cell lines, Caco-2 and HT-29, established by Fogh and 
co-workers (1975) have received a great deal of attention in recent years because of 
their ability to express morphologic features of mature enterocytes or goblet cells. P-
gp mediated drug transport in vitro has been successfully studied using Caco-2 cells 
(Artursson et al., 1996; Quaroni and Hochman, 1996). 
Both Caco-2 and HT-29 cells have been widely utilized as in vitro tools for the study 
of intestinal epithelial differentiation, function, and uptake, binding and transport 
phenomena of drugs and nutrients (Audus et al., 1990; Desai et al., 1997; Walle and 
Walle, 1998; McClean et al., 1998; Russell-Jones et al., 1999; Kamm et al., 2000; 
Jung et al., 2000; Ho and Storch, 2001; Yamaguchi et al., 2001). Caco-2 cell line is a 
more relevant in vitro model than HT-29 cell line since Caco-2 cells exhibit 
morphological and functional similarities to intestinal (absorptive) enterocytes, 
possess a higher degree of enterocytic differentiation and spontaneous dome 
formation (Audus et al., 1990; Artursson et al., 2001), perform most of the functions 
associated with intestinal lipid metabolism, transport, and metabolism (Ho and Storch, 
2001). 
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2.3.5.1. Studies of transport processes  
Recent studies in epithelial cell monolayers have developed understandings of the 
functions of a variety of transport mechanisms of endogenous as well as exogenous 
molecules such as drugs. The availability of tissue culture-treated microporous 
membranes facilitates the cell line model to represent a more physiologic environment 
because it allows the exchange of substances across both the apical and the basolateral 
membranes (Audus et al., 1990).  Proper selection of filter material, filter diameter 
and pore size is important depending on the particular application. The integrity of the 
cell monolayer can be determined by measuring transepithelial electrical resistance 
(TEER) using a volt/ohmmeter. 
Only a small quantity (< 1 %) of molecules that survive degradation in the gut is able 
to cross the epithelial cell layer and enter the circulation. The coating of particles with 
targeting agent molecules such as lectins may enhance their binding to intestinal 
epithelial cells (Russell-Jones et al., 1999) to stimulate the enterocytes to endocytose 
the coated particles and transport the particles across the cell and into the circulation, 
thus improving oral bioavailability (Naisbett et al., 1993; Florence et al., 1995; 
Hussain et al., 1997; Russell-Jones et al., 1999). 
Tomato lectin has also been reported to cross the tissue of rat everted intestinal sacs in 
vitro by a mechanism involving adsorptive endocytosis (Naisbett et al., 1993). 
However, Lehr and Lee (1993) did not observe significantly enhanced transport of 
bioadhesive lectins due to adsorptive endo-/transcytosis in comparison with the 
transport of a nonadhesive protein (albumin) by Caco-2 cell line and fluid phase 
transcytosis. 
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In a recent study by Russell-Jones and co-workers (1999) using Caco-2 cells and 
opossum kidney carcinoma cell line (OK cells), a range of targeting molecules, 
including LTB (the binding subunit of E. coli heat labile toxin), ConA (which binds to 
∝-D-mannose) and WGA (wheat germ agglutinin) are reported to be suitable for 
delivery of nanoparticles in a range of sizes from 50 to 500 nm. The level of targeting 
and uptake is directly proportional to the amount of targeting agent attached to the 
particles. However, it should be kept in mind that the targeting effect is greatly 
reduced in the presence of excess free lectin, or specific sugar.     
Preclinical studies have suggested that paclitaxel is not significantly absorbed after 
oral administration due to poor absorption or extensive presystemic hepatic 
metabolism. Walle and Walle (1998) investigated the transepithelial flux of paclitaxel 
using Caco-2 cell line. The flux from the basolateral to the apical side was 4-10 times 
greater than that from the apical to the basolateral side. These data concluded that 
rapid passive diffusion of paclitaxel through the intestinal epithelium is partially 
counteracted by the action of an outwardly directed efflux pump, presumably P-
glycoprotein, P-gp. It was confirmed that the expression of P-gp exists on the apical 
side of the human intestinal cells (Hunter et al., 1993) and that paclitaxel is a substrate 
of this transporter (Gupta, 1995; Horwitz et al., 1986). The ability of verapamil, a 
well-known P-glycoprotein antagonist (Racker et al., 1986), to reduce this active 
transport is additional evidence for the involvement of this mechanism. No 
metabolism of paclitaxel was observed in the Caco-2 cells.  
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2.3.5.2. Cellular uptake of polymeric nanoparticles 
Biodegradable micro- (MP) and nanoparticles (NP) are being widely investigated as 
systems to deliver poorly absorbed drugs including peptides, proteins and vaccines to 
mucosal surfaces (Couvreur and Puisieux, 1993). The specific requirements for the 
system to deliver the drugs effectively are high uptake by malignant cells, low affinity 
to normal tissues and satisfactory intracellular drug release kinetics to achieve 
therapeutic level. 
The polymeric micro- and nanoparticles are of particular interest for oral 
administration as they provide protection of fragile molecules against enzymatic and 
hydrolytic degradation in the gastrointestinal tract (Fattal et al., 2002) and they can 
naturally be taken up by enterocytes (Damge et al., 2000; Florence, 1997) and/or the 
lymphoid tissues in Peyer’s patches (PPs) (Tice, 1990; Jani et al., 1990). Although 
MPs and NPs have been found to be poorly absorbed by the intestine with only a 
small percentage of particles appearing in lymph nodes, blood, liver and spleen 
(Nefzger et al., 1984), drug-loading of particles has been reported to enhance or 
prolong the peroral bioavailability of a number of drugs. Uptake of biodegradable 
NPs and MPs by the gut associated lymphatic tissue after oral administration has 
received a lot of interest because of the possibility of using these carriers to deliver by 
the oral route, antigens or DNA vaccines.  
The uptake is supposed to be dependent on particle’s physicochemical properties such 
as the size, zeta potential and hydrophobicity. Eldridge et al. (1990) have illustrated 
the potential of microspheres as a controlled-release delivery system which targets the 
Peyer’s patches when orally administered. Microspheres made of numerous 
biodegradable and non-biodegradable polymers were seen to be absorbed by the 
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microfold cells of the Peyer’s patches and passed to the underlying leukocytes. Size 
was found to be a determinant controlling absorption. They reported that orally 
administered 1-10 μm microspheres composed of poly (D,L-lactide-co-glycolide) 
(PLGA) were specifically taken up into the Peyer’s patch lymphoid tissue of the gut 
in mice, and those greater than or equal to 5 μm remained for up to 35 days. The 
major determinant in the absorption of microspheres <10 μm is their effective 
hydrophobicity.  
Desai and co-workers (1997) revealed the GI uptake of particles were dependent on 
diameter and concentration of particles, and incubation time and temperature. The 
99.4% (w/w) association of fluorescence with particles confirmed fluorescent 
intensity measured in the cells was mainly due to the uptake of fluorescent particles. 
The small particles of 100 nm had uptake significantly (2.5 fold) greater than larger 
size particles (1 µm) and mostly localized in the endosomes as evident from the 
confocal microscopy studies. They concluded that smaller size particles with 
enhanced intestinal epithelium uptake could be ideal carriers for intestinal 
administration of sustained release vaccines.  
Desai et al. (1997) and McClean et al. (1998) observed a distinct uptake of large 
particles from 1 µm (15%) up to 10 µm (6%) without any loss of monolayer barrier 
function suggesting the mechanism of uptake in Caco-2 cell is size dependent. Kofler 
et al. (1997) also revealed size and surface characteristic-dependent  uptake of 
particles into Peyer’s patches indicating small particle size, rapid antigen release and 
high antigen content provide optimal tools to deliver orally applied antigens.  
Suh and colleagues (1998) have investigated the formulation and the effect of 
paclitaxel-loaded PEO-PLGA nanoparticles (~ 150 nm) on the vascular smooth 
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muscle cells (VSMC). Paclitaxel-loaded particles exhibited comparable anti-
proliferative effect to the free paclitaxel and the cell viability was reversible. The 
sustained drug release profile and cellular internalization suggest that paclitaxel-
loaded nanoparticles may potentially be used as an endocytizable, local sustained 
release drug delivery system. 
The studies have revealed the controlling factors of cellular uptake as size, nature of 
the polymer, zeta potential, coating and presence of nutrients (Delie, 1998). Due to 
numerous discrepancies in the literature, the best design of drug carrier system cannot 
be determined.  
 
2.3.5.3. Mechanisms of uptake of particles in the gastrointestinal tract 
The particle absorption pathway and efficiency in the GI tract highly depend on the 
size of particles administered (Desai et al., 1996) and particles larger than 10 µm were 
not taken up. Investigations of intestinal particle uptake can be performed using 
different models under in vivo (Desai et al., 1996), in situ (Pappo and Ermak, 1989), 
ex vivo (Scherer et al., 1993) or in vitro conditions (Delie, 1998; Desai et al., 1997; 
Norris and Sinko, 1997).  
Consensus has not been reached on the mechanisms of particle uptake by intestinal 
epithelia. Most evidence suggests that the favoured site for uptake is the PP lympho-
epithelial M cell (Lefevre et al., 1985; Eldridge et al., 1990; Jani et al., 1992). 
However, paracellular transport of particles has been favored by others (Volkheimer 
and Schulz, 1968; Aprahamian et al., 1987) while there is also evidence for particle 
endocytosis by intestinal enterocytes (Sanders and Ashworth, 1961; Kreuter et al., 
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1989). It was recently reported that particles in the size range 40 to 120 nm were 
translocated both transcellularly and paracellularly (Mathiowitz et al., 1997). 
 
2.3.5.3.1. Paracellular uptake 
Volkheimer (1977) attributed the passage of particulates through the mucosa of the 
small intestine to persorption which involved “kneading” of the particle between 
intestinal epithelial cells. Significant paracellular transport of macromolecules and 
particles is an unlikely event since the spaces between tight junctions was reported to 
be <10Å. Paracellular permeability for peptides can be enhanced by polymers such as 
chitosan, poly (acrylate), or starch (Jung et al., 2000). However, these hypotheses 
were derived mostly from cell culture models and their relevance for the in vivo 
situation is unclear.  
 
2.3.5.3.2. Endocytotic (Intracellular) uptake 
Sanders and Ashworth (1961) observed 220 nm polystyrene particles in rat intestinal 
epithelial cells one-hour post intra-gastric administration, which suggested possible 
particle absorption by intestinal enterocytes through endocytosis. The particles would 
be then included in cytoplasmic vesicles and discharged in the serosal spaces to gain 
access to the mesenteric lymph or blood. This is supported by Florence and colleagues 
(1995). 
Endocytotic processes are characterized by pinching of membrane vesicles from the 
plasma membrane, followed by an internalization of the engulfed extracellular 
materials (Jung et al., 2000). Of particular interests are transcytotic processes at 
mucosal surfaces by which macromolecules or particles, internalized at the apical 
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plasma membrane of the epithelial cells, are transported to the contralateral plasma 
membrane and released to the basolateral compartment (Fig. 2.3, II-III). Receptor-
mediated endocytosis (RME) requires receptors at the apical cell membrane and 
actively transports particles of sizes up to 500 nm. Adsorptive endocytosis does not 
require receptors but depends on size and surface properties of the adsorbed material 
(Jung et al., 2000). Thus, macromolecules and colloidal carriers (submicron) may 









Figure 2. 3. Schematic drawing of mucus (MU) covered absorptive enterocytes (EC) and 
M cells (MC) in the small intestine. Lymphocytes (LC) and macrophages (MP) from 
underlying lymphoid tissue can pass the basal lamina (BL) and reach the epithelial cell 
layer which is sealed by tight junctions (TJ). Possible translocation routes for NP are (I) 
paracellular uptake, (II) endocytotic uptake by enterocytes and (III) M cells. (From 
Jung et al., 2000). 
 
2.3.5.3.3. Lymphatic uptake 
The absorption of particulates (≤10 µm) predominantly takes place at the intestinal 
lymphatic tissues (i.e. Peyer’s patches) (Hillery et al., 1994, Lefevre et al., 1978). The 
epithelial cell layer overlying the Peyer’s patches contains specialized M cells which 
are believed to be transcytotic (Pappo and Ermak, 1989). Particles in the intestinal 
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lumen localize to M cell apical surfaces and can be internalized by M cells through 
transcytosis. 
 
2.3.5.4. Cytotoxicity study of drug-loaded polymeric nanoparticles 
The therapeutic effects of the drug-loaded polymeric nanoparticles can also be 
demonstrated by determining the viability of the cancer cells under equivalent doses 
over the same period of treatment as with the current clinical formulation. The 
viability of cells after treatment with the drug formulations can be evaluated by the 
MTT assay. This assay is based on the cellular reductive capacity of living cells to 
metabolize the yellow tetrazolium salt, 3-(4, 5-dimethylthizaol-2-yl)-2, 5, 5-diphenyl 
tetrazolium bromide (MTT), to a chromophore, formazan product, whose absorbance can 
be determined by spectrophotometric measurement. The number of viable cells is directly 
related to the measured absorbance which represents the amount of formazan formed by 
living cells.  
The cytotoxic activity of paclitaxel or loaded in PLGA nanoparticles was compared 
with formulation in Cremophor EL by assessing cell viability by the MTT assay using 
NCI-H69 cell line (Fonseca et al., 2002). A much higher cytotoxic effect could be 
observed for nanoparticle formulation after a long incubation time (168 hrs) under the 
same paclitaxel concentration. Another study reported (Suh et al., 1998) that 
paclitaxel incorporated PEO-PLGA nanoparticles of 150nm showed comparable anti-
proliferative effects on vascular smooth muscle cells as free paclitaxel. 
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2.3.6. In vivo evaluation by animal models   
In vivo animal models are applied to investigate the effects and efficacy of specific 
delivery system. In vivo studies give essential information about absorption of 
particles and it is the only means to determine the actual rate of uptake of ingested 
particles. However, inter-species and inter-animal differences will limit extrapolation 
to other models and prevent study comparison. Rate of uptake may also change 
according to the age of the animal. Kofler et al. (1997) revealed size and surface 
characteristic-dependent uptake of microspheres using BALB/c mice; efficient 
microsphere translocation into Peyer’s patches for 0.8 µm microspheres but poor for 2 
µm and surface-modified microspheres. 
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CHAPTER 3 
FORMULATION AND CHARACTERIZATION OF PLGA 




3.1.1. Significance of drug delivery system 
Controlled release of drugs, proteins, and other bioactive agents can be achieved by 
incorporating them in dissolved or dispersed form in polymers (Baker and Lonsdale, 
1974). The controlled drug delivery systems draw increased attention due to its 
enhanced efficacy of existing potent drugs at lesser expenses and fewer dosing 
schedule. Controlled delivery system maintains the drug level in the blood between 
the maximum and minimum therapeutic levels at a minimum dosage for an extended 
period of time (Karsa, 1996; Dunn, 1991). Conventional delivery system provides 
fluctuated drug level in the blood, either exceeding the maximum or falling below the 
minimum therapeutic level, resulting in toxic side effects or inefficacy. Most 
anticancer drugs have limitations in clinical administration due to their poor solubility 
and other unfavorable properties. Thus, biodegradable polymeric controlled delivery 
systems may bring the higher drug efficacy and better applications for the potent anti-
cancer drugs. 
Nanotechnology permits the delivery of drugs that are highly water-insoluble or 
unstable in the biological environment. It is expected that novel drug delivery systems 
can make a significant contribution to global pharmaceutical sales. This is illustrated 
                                                                             Chapter 3: Nanoparticle Formulation 
 53
by the fact that approximately 13% of the current global pharmaceutical market is 
accounted for by sales of products incorporating a drug delivery system. The demand 
for drug delivery systems in the United States alone is expected to grow nearly 9% 
annually to more than US$82 billion by 2007 (Sahoo and Labhasetwar, 2003).  
Many therapeutic agents have not been successful because of their limited ability to 
reach to the target tissue. Although opportunities to develop nanotechnology-based 
efficient drug delivery systems extend into all therapeutic classes of pharmaceuticals, 
the faster growth opportunities are expected in developing delivery systems for 
anticancer agents, hormones and vaccines because of safety and efficacy 
shortcomings in their conventional administration modalities. 
 
3.1.2. Need of efficient drug delivery system for novel anticancer drug, 
paclitaxel 
Paclitaxel, the first of a new class of microtubule stabilizing agents, has been hailed 
by National Cancer Institute (NCI) as the significant advance in chemotherapy of the 
past few decades. Paclitaxel was not a chance discovery but the outcome of the 
investigation over 12,000 natural compounds for anticancer activity (Appendino, 
1993). Paclitaxel is a promising anti-tumor agent with poor water solubility. Hence, 
the current formulation of intravenous (i.v.) administration is in a non-aqueous 
vehicle containing Cremophor EL which may cause various and serious side-effects 
and precipitation on aqueous dilution. The extensive clinical use of this drug is 
somewhat delayed due to the lack of appropriate delivery vehicles.  
Since best medical effects are yet to be achieved, it becomes necessary to come up 
with improved alternate formulations of paclitaxel for a more effective clinical 
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administration that eliminates premedication and the toxicity of the adjuvant CrEL, 
reduces side-effects to the least and also improves drug efficacy. The desired 
formulation should be one that does not consume toxic adjuvant, is capable of 
releasing paclitaxel over an extended period of time and stabilizing the compound 
during long term storage of the formulation but yet economically feasible to be 
produced on a large scale. Various approaches employed to date include cosolvents, 
emulsions, micelles, liposomes, microspheres nanoparticles, cyclodextrins, pastes, 
and implants. 
 
3.1.3. Preparation of nanoparticles by emulsification-solvent evaporation 
method 
Emulsification-solvent evaporation is one of the oldest and most widely used methods 
of particle preparation and the most suitable process for encapsulation of hydrophobic 
drugs. The solubility of the drug and polymer in the organic solvent is a major factor 
in determining the morphology of particles produced by the solvent evaporation 
process and the final state of the polymer itself (crystalline or amorphous). The size of 
the particles achieved substantially depends on the speed and rate of the agitation 
when the oil phase is added to the aqueous phase to form emulsion.  
The solvent evaporation is conceptually simple, but a large number of process 
variables exist which can profoundly affect the nature of the product obtained. Some 
parameters affecting solvent evaporation method are polymer molecular weight and 
concentration, polymer crystallization, type of drug and method of incorporation, 
organic solvent used, type of surfactant in aqueous phase, organic solvent/aqueous 
phase ratio, evaporation temperature and rate of stirring.  
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Semicrystalline polymers often give porous structures with spherulites on the surface 
of the nanoparticles whereas uniform, pore-free nanoparticles are most readily 
obtained with amorphous polymers. One requirement of this process is that the active 
agent (i.e., the drug) partition favorably into the oil phase. This partitioning is favored 
by active agents that are insoluble or sparsely soluble in water. Such agents may be 
insoluble in the organic solvent. In the latter case, the nanoparticles contain a 
dispersion of crystals embedded in a polymer matrix. The crystals should be the same 
ones in the polymer solvent solution, assuming that there is no partial solubilization 
and/or recrystallization. If the active agent dissolves completely in the organic solvent 
phase, it may or may not form crystalline domain in the polymer matrix that makes up 
the nanoparticles. 
Preventing migration of active agent into the aqueous phase from the solvent phase is 
often a problem. Crystalline active agents completely soluble in the solvent phase 
tend to form free crystals in the aqueous phase or on the surface of the microspheres. 
This effect can be minimized by removing the emulsifier from the system before 
solvent evaporation is complete. 
The physicochemical properties of progesterone-loaded poly (L-lactide) microspheres 
prepared by the solvent evaporation method were reported by Izumikawa et al. 
(1991). Solvent removal at atmospheric pressure yielded microspheres of crystalline 
polymer matrices, whereas faster solvent removal under a reduced pressure gave 
microspheres of amorphous polymer matrices. The crystallinity of the polymer 
matrices was closely correlated with the morphology and physical properties of 
microspheres, and affected the drug release rate. The microspheres of crystalline 
polymer matrices had rough surfaces with large surface areas, and exhibited a rapid 
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drug release, whereas the amorphous microspheres provided a slower drug release. 
The results of X-ray diffraction (XRD), differential scanning calorimetry (DSC), and 
Fourier-transform infrared (FTIR) spectroscopy suggested that progesterone formed a 
molecular dispersion in the amorphous polymer matrices. 
 
3.1.3.1. Selection of solvent 
Ethyl acetate and methylene chloride are solvents of first choice due to their relatively 
lower toxicity. Methylene chloride is a preferred solvent due to its high volatility and 
its capacity for dissolving a broad range of polymers. It is used for extraction in the 
food and pharmaceutical industries and also in the extraction of fats and paraffin. 
The use of methylene chloride may impose a problem in obtaining product approval 
by regulatory agencies. As evidenced by Lupron Depo™, the most successful 
microsphere product being used in human, a small amount of methylene chloride 
remaining in a microsphere product is acceptable by the USFDA, but only if the 
product’s therapeutic benefits clearly outweigh a safety concern over the residual 
solvent. Effect of additives or emulsifiers on the drug release kinetics from 
biodegradable matrices is an important determination in designing a drug delivery 
system. 
 
3.1.3.2. Selection of emulsifier 
The emulsifier decreases the extent of droplet coalescence and coagulation and 
stabilizes the emulsion system. The emulsifiers have influential effects on particle size 
and size distribution, morphological properties and release profiles of the 
nanoparticles (Mu and Feng, 2002). In solvent evaporation method, hydrophilic 
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polymeric colloids and anionic or nonionic surfactants such as poly (vinyl alcohol), 
gelatin and sodium dodecyl sulfate are generally applied as emulsifiers. A suitable 
emulsifier or surfactant is required to produce a stable emulsion, a result achieved by 
lowering the surface tension, γ (usually from 40 to 5mN/m-l). Moreover, for 
pharmaceutical applications, emulsifier must be acceptable for therapeutic use (Wade 
and Weller, 1994). 
 
3.1.3.2.1. Poly (vinyl alcohol) (PVA) 
Water soluble synthetic polymer, PVA, has excellent film forming, emulsifying and 
adhesive properties which make it a versatile polymer for many applications. PVA 
(Fig. 3.1) is one of the most frequently used emulsifiers due to its high viscosity and 
strong adsorption around the emulsion drops. However, excess PVA may not easily 
be washed out of the nanoparticles. 
 
                                                                                                       
Figure 3. 1. Structure of poly (vinyl alcohol) 
 
3.1.3.2.2. Poly (acrylic cid) (PAA) 
Another water soluble polymer PAA (Fig. 3.2) has excellent water-holding capability 
and can be used in various applications in diverse fields including commercial and 
medical uses such as super absorbents, textile and drug delivery coatings. The 
bioadhesive properties of PAA which allow them to readily attach and conform to 
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accessible sites of the body found its application in producing bioadhesive polymer 







Figure 3. 2. Structure of PAA 
 
 
3.1.3.2.3. Vitamin E-TPGS (TPGS) 
Vitamin E-TPGS (D-α-topopheryl polyethylene glycol 1000 succinate) is a water-
soluble derivative of natural vitamin E. It is formed by the esterification process 
between vitamin E succinate and polyethylene glycol 1000. It can be seen from the 
chemical structure (Fig. 3.3) that it has amphiphilic properties with the long alkyl tail 
contributing to its lipophilicity and the tocopherol succinate polar group contributing 
to its hydrophilicity. Therefore, it is a good candidate for emulsifying a wide range of 
water-oil immiscible systems. TPGS could be absorbed intact readily in the 
gastrointestinal tracts, and could inhibit P-glycoprotein in the intestine to enhance the 
cytotoxicity of anti-cancer drugs such as paclitaxel (Mu and Feng, 2002). TPGS finds 
its applications in drug delivery systems such as protecting the drug from absorption 











Figure 3. 3. Structure of vitamin E-TPGS 
   
 
3.1.3.2.4. Phospholipid (DPPC) 
Phospholipids have been widely used as natural emulsifiers and other purposes in 
industry although their application as emulsifier in drug delivery formulation has been 
rarely reported. Phospholipids are used as emulsifiers in the products such as animal 
feeds, baking products and mixes, chocolate, cosmetics and soaps, dyes, insecticides, 
paints and plastics. The use of 1,2-dipalmitoylphosphatidylcholine (DPPC, Fig 3.4) as 
an additive in drug delivery formulation was reported to improve the performance of 
the PLGA microspheres in blood flow (Garti, 1999), enhance the pulmonary 
absorption of peptides and proteins (Zhen et al., 1995), reduce phagocytic uptake of 
the microparticles (Evora et al., 1998), and impart better emulsifying effects and 
higher encapsulation of drug in the nanoparticles (Feng and Huang, 2001). 




Figure 3. 4. Structure of DPPC 
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3.1.3.2.5. Monoolein 
Although amphiphilic monoolein (Fig. 3.5) is commonly used as an emulsifying agent 
and as a food additive since the 1950s, its potential applications in the pharmaceutical 
industry has been increasingly discussed recently. Monoolein is a nontoxic, 
biodegradable, and biocompatible material classified as GRAS (generally recognized 
as safe), and it is included in the FDA Inactive Ingredients Guide and in non-
parenteral medicines licensed in the United Kingdom (Ganem-Quintanar et al., 2000). 
Its biodegradability comes from the fact that monoolein is subject to lipolysis due to 
diverse kinds of esterase activity in different tissues (Longer et al., 1996). In 1984, 
monoolein was first proposed as a biocompatible encapsulating and controlled-release 
material. Since then, there have been many diverse applications, and new uses 
proposed. 
 






Figure 3. 5. Structure of monoolein 
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Ganem-Quintanar et al. (1996) classified the applications of monoolein in the 
pharmaceutical field as: (1) emulsifier (nonionic surfactant), (2) solubilizer, (3) 
absorption enhancer, (4) oral drug delivery system, (5) parenteral drug delivery 
system, ( 6 ) vaginal drug delivery system, (7) periodontal drug delivery system, (8) 
colloidal carrier system, (9) storage system for the protection of macromolecules 
susceptible to degradation, (10) bioadhesive, and (11) others, such as a membrane and 
polymorphic lipid model for the determination of lipid bilayer/water partition 
coefficient and electrochemical biosensors. 
 
3.1.3.2.6. Montmorillonite (MMT) 
Increased use of chemically inert clay for cosmetic and medical applications was 
found in the recent years. The two most industrially important clay minerals of 
smectite group are sodium montmorillonite and calcium montmorillonite. 
Montmorillonite (MMT) belongs to the structural family of the 2:1 phyllosilicates. 
MMT is the most commonly used layered silicates and its structure is shown in Fig. 
3.6. Their special characteristics such as leaflet structure, high plastic viscosity, 
antacid and antidiarrhea properties, make them ideal for use as pharmaceutical 
recipients, or as active ingredients, or as colloidal stabilizers in the emulsion.  
Certain pharmaceutical materials including clay exhibit mucoadhesive properties. 
When formulated in certain proportions in aqueous colloidal dispersions with drug 
and in the form of a flowable liquid, these are able to interact with glycoprotein 
transforming into viscous gel to become effective mucoadhesive systems. Therefore, 
MMT is a good candidate to be incorporated in the oral drug delivery systems. 
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Figure 3. 6. Structure of 2:1 Phyllosilicates 
 
 
3.2. Experimental methods 
3.2.1. Materials 
Paclitaxel of purity 99.8% was purchased from Dabur India Ltd. (India). Poly (D, L-
lactic-co-glycolic acid) (PLGA) with L:G molar ratio of 50:50 and MW of 40,000–
75,000, polyvinyl alcohol (PVA) with MW of 30,000–70,000, fluorescence marker 
(coumarin-6), 1,2-dipalmitoylphosphatidylcholine (DPPC), phosphate buffered saline 
(PBS), MEM medium, penicillin-streptomycin solution, Trypsin-EDTA solution, 
Triton® X-100 and Hank’s balanced salt solution (HBSS) were purchased from Sigma 
(St. Louis, MO, USA). Vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate 
(Vitamin E TPGS or simply TPGS) was obtained from Eastman (TN, USA). Distilled 
monooleate was from Grindsted products (Brabrand, Denmark). Montmorillonite K10 
was from Fluka (Buchs, Switzerland). Dichloromethane (DCM, analytical grade) was 
from Merck (Darmstadt, Germany) and acetonitrile (HPLC grade) was from Fisher 
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Scientific (NJ, USA). Fluorescent polystyrene nanoparticles were purchased from 
Duke Scientific (CA, USA).  Fetal bovine serum (FBS) was received from Gibco 
(Life Technologies, AG, Switzerland). Ultrapure water (Millipore, Bedford, MA, 
USA) was used throughout the experiment.  
 
3.2.2. Preparation of nanoparticles  
Nanoparticles, placebo or loaded with paclitaxel or fluorescent marker were prepared 
by a modified solvent extraction/evaporation method (single emulsion). In brief, an 
oil phase solution of dichloromethane (DCM) containing poly (DL-lactide-co-
glycolide) (PLGA, 50:50) was slowly poured into an aqueous solution containing 
emulsifiers such as PVA, vitamin E TPGS, etc. The polymer solution also contained 
paclitaxel or 0.05% (w/v) coumarin-6 as fluorescent marker in preparation of 
fluorescent nanoparticles. This mixture was homogenized for 30 sec by vortexing 
followed by sonication (Microson XL2000, Misonix Inc, NY) set at an energy output 
for 90 sec in pulse mode to produce the oil-in-water (o/w) emulsion. The o/w 
emulsion was stirred over a magnetic stirrer plate overnight at room temperature to 
evaporate dichloromethane and harden the nanoparticles formed. The nanoparticles 
were collected by centrifugation (5810R, Eppendorf, 10,000 rpm, 15min, 18ºC) and 
washed with Millipore water for 3 times to remove excessive emulsifier and 
fluorescent marker. The nanoparticle suspension was then freeze-dried (Christ, Alpha-
2, Martin Christ, Germany) to obtain fine powder of nanoparticles, which was kept in 
a vacuum desiccator. Some emulsifiers were applied to compare the acquired 
physicochemical properties of nanoparticles and choose the most potential 
formulation for delivery of anti-cancer dugs. Formulation optimization was pursued to 
obtain nanoparticles of desired physicochemical properties.  
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3.2.3. Characterization of nanoparticles 
3.2.3.1. Size and size distribution 
Nanoparticle size and size distribution were determined by laser light scattering with 
particle size analyzer (90 Plus, Brookhaven Inst, Huntsville, NY, USA) at a fixed 
angle of 90° at 25°C. In brief, the dried nanoparticles were suspended in filtered 
deionized water and sonicated to prevent particle aggregation and to form uniform 
dispersion of nanoparticles. The size distribution was given by the polydispersity 
index. The lower the value is, the narrower the size distribution or the more uniform 
of the nanoparticle sample. The data reported represent the average of 5 
measurements. 
 
3.2.3.2. Surface Morphology  
Morphology of the formulated nanoparticles was observed by scanning electron 
microscopy (SEM, Jeol JSM 5600LV) at 10-15kV. SEM sample preparation requires 
an ion coating with platinum by a sputter coater (JFC-1300, Jeol, Tokyo) for 40 
seconds in a vacuum at a current intensity of 40 mA after preparing the sample on 
metallic studs with double-sided conductive tape.  
 
3.2.3.3. Surface charge 
Zeta potential is an indicator of surface charge, which determines particle stability in 
dispersion. Zeta potential of nanoparticles was determined by a zeta potential analyzer 
(Zeta Plus, Brookhaven Instruments, Huntsville, NY) by dipping a palladium 
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electrode in the sonicated particle suspension. The mean value of 10 readings was 
reported. 
 
3.2.3.4. Yield of nanoparticles 
The overall yield of particles can be calculated as follows: 
 




obtainedparticlesofamount                        (3.1) 
 
3.2.3.5. Drug loading 
The drug loading or drug content is expressed as:  
 
Drug loading = 100×
particlesofamount
particlesinedencapsulatdrugofamount               (3.2) 
 
3.2.3.6. Encapsulation efficiency 
Encapsulation efficiency is defined as: 
 
Encapsulation efficiency (EE, %) = 100×
addeddrugofamountinitial
particlesinloadeddrug    (3.3) 
 
To determine encapsulation efficiency, 3 mg of particles were dissolved in 1 ml of 
DCM followed by the addition of 3 ml of acetonitrile:water (50:50, v/v) solution to 
extract the drug to be analyzed by high performance liquid chromatography (HPLC). 
DCM was evaporated at room temperature under nitrogen stream until clear solution 
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was obtained. To determine the recovery efficiency of paclitaxel from the extraction 
process, known weights of paclitaxel from 100 to 1000 μg and 3.0 mg of placebo 
particles were subjected to the same extraction procedure.  The recovery was 91.99 % 
which implies that 92 % of paclitaxel was detected and thus all the data obtained were 
corrected before calculating the encapsulation efficiency. 
 
3.2.3.7. X-ray diffraction (XRD) analysis 
X-ray powder diffration analyses were performed on pure paclitaxel, pure emulsifiers 
(PVA, TPGS and DPPC) and paclitaxel-loaded PLGA nanoparticles incorporating 
them, in order to find out whether paclitaxel was present in the nanoparticles in a 
crystalline or an amorphous state. A Shimadzu X-ray Diffractometer (XRD-6000) 
was used and samples were exposed to monochromatic CuKα radiation (40 kV x 30 
mA, λ = 1.5406 Å). The diffraction pattern was determined in the area of 5° <2θ< 45°, 
and the step size was 0.02° and the step time was 0.6 s. 
 
3.2.4. In vitro paclitaxel release studies 
Nanoparticles were dispersed in the simulated physiological fluid, phosphate buffered 
saline (PBS) at pH 7.4.  The buffer solution was kept in an orbital shaker at constant 
gentle shaking of 110 rpm and physiological temperature of 37°C.  At predetermined 
time intervals, the suspensions were centrifuged at 11,000 rpm and 37°C for 18 min.  
The precipitated particles were re-suspended in fresh buffer and placed back in the 
shaker.  The supernatant was kept for HPLC analysis after the drug was extracted 
with DCM followed by mobile phase (acetonitrile:water, 50;50, v/v). For HPLC 
analysis, a reverse phase Inertsil® ODS-3 column (150x4.6 mm i.d., pore size 5 μm, 
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GL Science, Tokyo, Japan) was used and the mobile phase was delivered at a rate of 1 
ml/min by a pump (Perkin Elmer-S200). 50 μl of sample was injected by an auto-
sampler (Perkin Elmer-ISS200) and the column effluent was detected at 227 nm with 
a UV detector.  The calibration curve was prepared for the quantification of drug in 
the particles and it was linear over the range of 50-10,000 ng/ml with a coefficient of 
r2 = 0.9999. 
Due to inefficient extraction process of the highly hydrophobic paclitaxel, the 
extraction factor had to be determined as follows: a known amount of paclitaxel was 
subjected to the extraction procedures in exactly the same manner as mentioned above 
and the actual amount of paclitaxel in the extracted samples was measured. It was 
found that only 43.56 % of the original paclitaxel was detected after the extraction 
process. Therefore, all the data obtained from in vitro release studies should be 
corrected accordingly. 
 
3.2.5. Degradation studies of nanoparticles 
To observe the degradation of particles in vitro and to find a relation between 
degradation of polymer and drug release rate, 3 mg of particles were dispersed in 2 ml 
of PBS buffer and incubated in a shaker bath maintained at 37°C and 110 rpm to 
simulate the physiological conditions. At specified time intervals, particles were 
collected by centrifugation followed by freeze-drying. The change in morphology was 
observed by SEM and the change in molecular weight was determined by gel 
permeation chromatography (GPC) as described below. 
The freeze-dried nanoparticles (0.9–1.2 mg) were dissolved in 1.5 ml of stabilized 
HPLC-grade tetrahydrofuran (THF) and the solutions were filtered through 0.45 µm 
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syringe filters. The filtered solutions of 20 μl were manually injected and analyzed 
using THF as the mobile phase with a flow rate of 1ml/min. HP1100 series HPLC 
system equipped with HP1047A RI detector and Plgel Mixed-C column (Agilent, 
300x7.5mm, 5µm) was employed. The data collection and analysis were done using 
the software provided by the manufacturer. Molecular masses were calculated from a 
calibration curve using a series of polystyrene standards (Polymer Labs, MA) with 
molecular mass range of 1270-5000000.  
 
3.3. Results and Discussion 
3.3.1. Formulation and characterization of nanoparticles 
Nanoparticles with/without paclitaxel were successfully fabricated by oil-in-water 
emulsification/solvent evaporation process using both natural and synthetic 
emulsifiers such as PVA, PAA, TPGS, DPPC, monoolein, and montmorillonite. By 
varying the appropriate preparation parameters, different sizes, stability and 
encapsulation efficiency of particles may be obtained. Most importantly, the release 
profile of this drug delivery system can thus be modified. The particles prepared were 
freeze-dried to enhance stability and storage. The presence of an appropriate amount 
of suitable surfactant can increase the drug’s solubility in the continuous phase and 
thus can affect encapsulation efficiency and release profile (Giunchedi et al., 1998, 
Wang et al., 2001).  
PVA was conventionally used in emulsification method and thus PVA emulsified 
nanoparticles were fabricated as controls. Vitamin E TPGS was chosen as surface 
modification material of nanoparticles and emulsifier since it was claimed to 
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solubilize lipophilic compounds (Wang et al, 2001, 2002; Sokol et al., 1991; 
Boudreaux et al., 1993), and enhance EE of drug (Mu and Feng, 2002). Moreover, 
TPGS could be absorbed intact readily in the GI tract and could inhibit P-gp in the 
intestine to enhance absorption and oral bioavailability (Dintaman and Silverman, 
1999; Sokol et al., 1991; Boudreaux et al., 1993). A natural phospholipid, DPPC, was 
employed because it was suggested to provide better coating and higher EE of drug 
(Feng and Huang, 2001), improve the performance of produced nanoparticles in the 
blood flow (Garti, 1999), enhance the pulmonary absorption of peptides and proteins 
(Zhen et al., 1995), and reduce phagocytic uptake of the nanoparticles (Evora et al., 
1998).  
Particles made of bioadhesive or mucoadhesive materials which can adhere to the 
mucus layer in the intestine have been widely studied to improve particle delivery 
efficiency. Mucoadhesive polymers can be used to formulate particulates which bind 
to intestinal mucus layer and thus slow down the intestinal transit. Therefore, they 
result in a prolonged intestinal residence time for orally administered particles and 
showed increased particle absorption efficiency in the animals studied.  
Bioadhesive properties of PAA had attracted to give it a try in nanoparticle 
formulation for paclitaxel delivery. Amphiphilic monoolein was used because it is 
bioadhesive (Engström et al., 1995), non-toxic, able to incorporate both hydrophilic 
and hydrophobic drugs. Besides, it can act as emulsifier, solubilizer, and absorption 
enhancer. Montmorillonite was applied due to its properties (Tsugita et al., 1983) of 
colloidal stabilizer in oil-in-water emulsions, mucoadhesive material. 
The results showed that TPGS and DPPC were very effective emulsifiers, better 
choices among the emulsifiers tested, at improving the emulsification process for 
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microencapsulation, in agreement with the recognized reported marvelous functions 
of phospholipids and vitamin E TPGS as novel emulsifiers in nanoparticle 
formulation of paclitaxel and other anticancer drugs (Feng and Huang, 2001; Mu and 
Feng, 2002). In addition to the right choice of the emulsifier for particle formulation, 
the amount of emulsifier added plays a fundamental role in determining the 
physicochemical properties of the formulated nanoparticles. Since the role of 
emulsifier is to stay on the interface of the nanoparticles to separate the oil and the 
water phase to stabilize the emulsion; and the smaller particles possess the larger total 
surface area for a given amount of their mass, too little emulsifier would not be 
enough to cover the interface while too much emulsifier would cause aggregation of 
the formed nanoparticles. Moreover, some drug molecules may bind to the excessive 
emulsifier molecules and thus cause the loss of drugs in the washing process. In 
general, small amount of emulsifier would result in large particles while large amount 
of emulsifier would result in reduced drug encapsulation efficiency. Thus, there is an 
optimal amount of the emulsifier which would result in the desired properties of 
nanoparticles. In preparation of nanoparticles by the solvent extraction/evaporation 
method, the concentration needed for the traditional emulsifier PVA was normally at 
least 1% (w/v) (Mu and Feng, 2002; Jefferey et al., 1991) while the required amount 
of TPGS is only 0.015% (w/v) and DPPC is 0.3% (w/v), an amount 67- and 7-times 
less than the PVA but with the same emulsifying effects. This implies that TPGS and 
DPPC have much higher emulsifying efficiency as much lower amount of TPGS and 
DPPC was needed, comparing to PVA, to have the comparable properties of 
nanoparticles. 
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3.3.2. Size and size distribution, yield, encapsulation efficiency and drug loading 
The mean size and size distribution, yield, encapsulation efficiency and drug loading 
of the paclitaxel-loaded particles were summarized in Table 3.1. The narrow size 
distribution with high yield and high encapsulation efficiency is desired to achieve 
more consistent sustained efficacy and an economically feasible system. The low 
yield of particles with monoolein as emulsifier could be due to loss of smaller 
particles in washing process since its high polydispersity indicated wide size 
distribution of particles. In general, the size became bigger as it was expected when 
the drug was encapsulated in the particles.  Paclitaxel encapsulation efficiency was 
higher than 55%, varying according to emulsifier type, except for MMT incorporated 
formulation.  
 













PVA 2% PVA 47.7 294 ± 4.8 0.110 92.8 
PAAL 1% PAA (low Mw) 69.4 830 ± 50 0.152 81.0 
PAAH 1% PAA (high Mw) 39.0 708 ± 13 0.005 72.8 
TPGS 0.03% TPGS 44.9 375 ± 15 0.222 55.7 
DPPC 0.3% DPPC 83.9 263 ± 3.9 0.046 61.8 
Monoolein 1% monoolein 30.0 465 ± 7.0 0.280 61.7 
MMT 1% montmorillonite 66.8 610 ± 13 0.225 13.9 
* Polydispersity = the size distribution width 
It is well known that the size of particles is highly dependent on the preparation 
method and conditions employed. Though it was generally believed that an increase 
in the percentage of the polymer affected the particle size, no significant effect on 
particle size was observed in the polymer concentration range from 1 to 5% (w/w). It 
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might be due to low polymer concentration range investigated. However, it was 
reported to have noticeable effect on size at a much higher polymer percentage of 
25% w/w (Konan et al., 2001). It was postulated that the higher concentration of 
polymer in the preparation might have led to an increased frequency of collisions, 
resulting in fusion of semi-formed particles and producing an overall increase in the 
size of the particles. 
The amount of emulsifier added can influence particle size since it can change the 
viscosity of the continuous phase and hence the formation of particles. If the 
emulsifier is not sufficiently added, the particle cannot be completely coated and 
separated from each other, which leads to aggregation and bigger sized particles. On 
the other hand, if the emulsifier is added in excess, the suspension is not well 
separated due to excess emulsifier in the solution, which again leads to the formation 
of bigger sized particles and a sheet of spread particles. Moreover, drug will interact 
with excess emulsifier and encapsulation efficiency will be decreased. Thus, it should 
be optimized to get well-separated and coated particles for better delivery of drug. 
From Table 3.2, it can be seen that 0.5% and 2% (w/v) PVA did not make much 
difference in size of the particles although the yield of the nanoparticles was a bit 
higher at 2%. When it was increased to 5% (w/v) PVA, the size of the particles 
became almost 3 times bigger than at 2% PVA. Thus, 2% was selected as the optimal 
amount of PVA that should be used in the formulation. 
 
Table 3. 2. Effect of emulsifier amount on characteristics of PLGA 50:50 nanoparticles 
Emulsifier (w/v) Size ± SD (nm) Polydispersity Yield (%) 
0.5% PVA 219.4 ± 10.5 0.144 65.8 
2% PVA 212.5 ± 7.5 0.098 72.8 
5% PVA 702.0 ± 56.6 0.425 70.2 
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When the volume of aqueous phase was increased, the mixing efficiency is decreased 
due to high volume of mixture, or high loading to the sonicator. The reduction in 
mixing efficiency probably produced an increase in the size of the emulsion droplets 
formed during the process, which would result in the formation of larger particles. 
It was found, as expected, that the higher the sonication strength, the smaller the 
particles obtained. When the sonication was done at an output of 12W, the size of 
particles was about half of that of particles prepared at 6W while keeping all the other 
parameters the same. However, the mixing time did not give noticeable difference in 
size of particles when it was increased from 1 minute to 5 minutes. The nanoparticle 
preparation process parameters stated in Table 3.1 were chosen, from the formulation 
optimization, for further studies by characterization and in vitro evaluation of 
nanoparticles. 
The results regarding the particle size, obtained from the two different techniques 
(90Plus and SEM), sometimes show large differences. Typically, the 90Plus particle 
sizer demonstrated mean volume diameters much higher than those given by SEM 
analyses (number size average). The difference in size determining technique and the 
effect of freeze-drying could also be responsible for this inconsistency. With this 
point in mind, the particle size was determined before the freeze-drying and it was 
found to be in agreement with the SEM analysis. Thus, it was assumed there might be 
some aggregations in the suspension caused by either freeze-drying or inadequate 
dispersion.  
Numerous studies have shown the cryoprotective effect of excipients such as sugars to 
prevent particle aggregation during the freeze-drying process (Mehnert and Mader, 
2001; Konan et al., 2001; Chasteigner et al., 1996). The effectiveness of 
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cryoprotective additive D-Trehalose (Sigma, St. Louis, MO) against the adverse 
effects of freeze-drying on the particle redispersibility was evaluated by varying the 
concentration and the addition step in the process since trehalose was claimed to be 
the best cryoprotectant (Mehnert and Mader, 2001; Konan et al., 2001). When D-
Trehalose was included in the preparation process rather than in the suspension prior 
to freeze-drying, it was observed to produce well-separated and non-aggregated 
particles. The size determination showed the close results before and after freeze-
drying.  It seemed to be one option to prevent particle aggregation and different size 
analyzing results for future preparation procedures.  
 
3.3.3. Morphology of nanoparticles 
Scanning electron microscopy (SEM) and atomic force microscopy (AFM) have been 
used to characterize the surface morphology of paclitaxel loaded PLGA nanoparticles 
fabricated with various emulsifiers. Figure 3.7 shows the SEM images of paclitaxel 
loaded PLGA nanoparticles formulated with (a) PVA, (b) vitamin E TPGS, (c) 
monoolein, (d) montmorillonite, (e) DPPC, and (f) PAA (low Mw) as emulsifier (Bar 
= 1μm). Under SEM examination, nanoparticles of all formulations exhibited 
spherical morphology and smooth surfaces, confirming results obtained by 90Plus 
size analysis. No significant difference in morphology can be observed between each 
sample. However, nanoparticles incorporated with monoolein and MMT showed a 
wider size distribution, and furthermore, particles did not properly form up to the 
preferred physicochemical properties. Therefore, nanoparticles incorporating PVA, 
TPGS and DPPC were selected for further detailed characterization and evaluation of 
their efficacy. 
































Figure 3. 7. SEM images of paclitaxel-loaded PLGA particles with emulsifier: A) PVA; 
B) vitamin E TPGS; C) monoolein; D) montmorillonite; E) DPPC; F) PAA (low Mw). 
 
AFM technique has been widely applied to produce surface-dependent information in 
three dimensions on the nanometer scale. It is capable of resolving surface details 
down to the atomic level and can give morphological images in high resolution (Mu 
A B 
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and Feng, 2002). Thus, AFM is ideally suited for characterization of nanoparticles. By 
applying AFM technique, the true structure of nanoparticles can be revealed with very 
high resolution since the image is obtained by direct contact or tapping of the AFM 
tip on or over the particles surface.  
 
Figure 3. 8. AFM overview image of a layer of paclitaxel-loaded PLGA nanoparticles 
prepared with PVA as emulsifier. 
 
There was no observed aggregation or adhesion of the nanoparticles (Fig. 3.8). AFM 
gives direct 3-D measurements of the surface structure of the samples. Further, using 
materials sensing modes such as lateral force and phase contrast, it is possible to 
differentiate the types of materials at a sample surface. Figure 3.9(a) shows the 3D 
image of a single paclitaxel loaded, PVA emulsified PLGA nanoparticle. Figure 
3.9(b) shows closely observed surface morphology in a zoom-in image while Figure 
3.9(c) shows the cross-section analysis of a single nanoparticle. 
 



























Figure 3. 9. AFM images: (A) 3D image; (B) close-up image; (C) cross-section and 

















Figure 3. 10. AFM 3D images of paclitaxel loaded PLGA nanoparticles incorporating    
(a) TPGS; (b) DPPC. 
 
AFM images of the nanoparticles fabricated with TPGS or DPPC were seemed to 
have a similar feature (Fig. 3.10) and smooth surface. AFM offers the capability of 
3D visualization and both qualitative and quantitative information on many physical 
properties including size, morphology, surface texture and roughness. AFM 
investigation clearly substantiates the existence of complex topography of the 
nanoparticle surface, which contains micro-caves and pores (Fig. 3.11) rather than 
simply being smooth as shown in the conventional SEM images. Such a porous 
structure of the nanoparticle surface could explain a diffusion mechanism of the drug 
from the nanoparticles. This can be explained by the denser packing of TPGS or 

























Figure 3. 11.  AFM image clearly visualizing the complex topography of paclitaxel-
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3.3.4. Zeta potential analysis 
Zeta potential can be quantified by tracking the charged particles when they migrate 
in a voltage field, as is done in a zeta potential analyzer. Since the particles in contact 
with a liquid acquire an electronic charge on their surface, zeta potential is a useful 
indicator of this surface charge property and can be employed as an index to the 
stability of the nanoparticles. 
In most circumstances, the higher the absolute value of the zeta potential of the 
particles, the larger the amount of charge on their surface resulting in the stronger 
repellent interaction among the particles to overcome the natural tendency to 
aggregate and hence higher stability of the particles is achieved. Therefore, higher 
value of zeta potential implies more stable suspension and lower value points out the 
colloid instability. In the area of drug delivery studies, zeta potential analysis is often 
employed to investigate various systems such as nano- and microparticles, liposomes, 
micelles, etc. 
The zeta potential values of the drug-loaded nanoparticles prepared with various 
emulsifiers/surface modifiers are shown in Figure 3.12. The negative zeta potential 
value implies negative charge on the surface and may be attributed to the presence of 
ionized carboxyl groups on the particles surface (Stolnik et al., 1995). The particle 
suspension is said to be stable if the zeta potential value is higher than 18. As the 
concentration of PVA changed, the zeta potential also changed and it was found to 
have the highest value at high PVA concentration of 8% (data not shown). However, 
the size of the particles and the effectiveness of the removal of excessive PVA from 
the suspensions also need to be taken into considerations. The stability and the size 
have to be compromised to achieve a better formulation for enhanced uptake and 
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bioavailability. The zeta potential was found to be strongly influenced by the 

































3.3.5. X-ray diffraction study 
To determine whether paclitaxel was incorporated in the nanoparticles in its 
crystalline or amorphous form, an XRD study was conducted. Figure 3.13 shows the 
XRD patterns of free paclitaxel, pure TPGS and TPGS-incorporated PLGA 
nanoparticles with and without paclitaxel encapsulated. It appeared that paclitaxel was 
semi-amorphous and that PLGA (data not shown) and TPGS were amorphous which 
explained why the blank PLGA nanoparticles expressed the amorphous state. The 
XRD pattern of paclitaxel-loaded TPGS-incorporated PLGA nanoparticles clearly 
demonstrates that they consisted of a mixture of PLGA, TPGS and paclitaxel since the 
graphs of the blank nanoparticles and paclitaxel can be superimposed to form the 
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graph of the drug-loaded nanoparticles. In addition, these XRD patterns lead to the 
conclusion that the drug is present in the nanoparticles in an amorphous state since no 


























Figure 3. 13.  XRD analyses of paclitaxel, TPGS, blank PLGA nanoparticles and 
paclitaxel-loaded PLGA nanoparticles with TPGS coating. 
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If the drug dissolves completely in the organic solvent phase, it may or may not form 
crystalline domain in the polymer matrix that makes up the nanoparticles. 
Microspheres with low active agent payloads (e.g., <20 wt %) have no crystalline 
domain as determined by differential thermal analysis. At higher payloads, 
crystallinity may appear. The drug loading in this work was 5% and the XRD patterns 
of drug-loaded PLGA nanoparticles, regardless of the incorporating material (PVA, 
TPGS or DPPC), expressed that the drug was present in an amorphous state in all 
those potential formulations (Fig. 3.14). 
 
























Figure 3. 14.  XRD pattern of paclitaxel-loaded PLGA nanoparticles incorporating 
PVA, TPGS and DPPC. 
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3.3.6. In vitro paclitaxel release studies 
The effect of emulsifiers on the in vitro release profiles of paclitaxel was presented in 
Fig. 3.15. There are three primary mechanisms of the drug release from PLGA 
microparticles: swelling, diffusion and degradation (Schwendeman et al., 1996). The 
mechanism of paclitaxel release from the formulated nanoparticles was found to be 
dominated by diffusion through tortuous paths in the polymer matrix. Since the 
degradation time of polymer is about 1-2 months, the release by polymer matrix 
erosion was not significant in this release period. 
The nanoparticles formulated with TPGS, DPPC and MMT exhibited almost the same 
release pattern with higher initial burst and the accumulated amount of paclitaxel 
released in 31 days was about 70-75 %. High initial burst was attributed to the 
immediate dissolution and release of paclitaxel adhered on the surface and located 
near the surface of the nanoparticles. The nanoparticles incorporating PAA (both low 
and high Mw) and PVA possessed almost identical release pattern, especially for the 
first 15days, and their cumulative release of paclitaxel was 29-34% after 31 days. The 
faster drug release of the former group maybe due to the facilitation of the drug 
solubility by the additives (i.e. TPGS, DPPC and MMT) and hence more drug 
diffusion leading to the higher and faster drug release from the nanoparticles. 
Monoolein emulsified nanoparticles released about 46% of paclitaxel in 31 days.  
The release profile can be optimized since the amount of emulsifier used in the 
preparation process plays a significant role in controlling the drug release profile 
(Feng and Huang, 2001; Mu and Feng, 2001). In general, similar release patterns, 
though the released amount varied according to the emulsifier used, were observed for 
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the nanoparticles prepared with different emulsifiers, providing slower and steady 



































Figure 3. 15. Effect of emulsifier/additive on in vitro release of paclitaxel from 
nanoparticles. 
 
3.3.7. In vitro degradation studies 
It is important to understand the degradation profiles of the particles in order to 
develop successful drug delivery system providing suitable release profile. As can be 
seen from Fig. 3.16, erosion of the PLGA particles occurred only after the second 









Figure 3. 16. Degradation profile of paclitaxel-loaded PLGA particles with: A) PVA; B) 
montmorillonite; C) vitamin E TPGS; D) DPPC after 2 weeks under the simulated 
physiological conditions. 
 
For the amorphous PLGA particles, degradation in PBS solution was believed to 
occur in two stages. The first stage, water diffusion into the amorphous regions with 
random hydrolytic scission of ester bonds, occurred in the first two weeks of the 
study. The second stage started when most of the amorphous regions are degraded 
from the third week onwards, after which the hydrolytic attack progresses from the 
edge towards the centre of crystallites. Figure 3.17 shows the SEM images of 
degradation of nanoparticles over 4 and 8 weeks. At 4 weeks, the degradation has 
proceeded but the original morphology was still discernible. The continuing 
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degradation induced agglomeration of individual particles. At 8 weeks, the formulated 
nanoparticles became highly porous and have lost their original surface features and 
thus, they lost their mechanical integrity, as shown in Fig. 3.18. The nanoparticles 
now appeared to have started coalesce, appearing as an amorphous mass and their 








Figure 3. 17. Degradation profile of paclitaxel-loaded PLGA particles with monoolein as 







Figure 3.18. SEM images of paclitaxel-loaded PLGA particles incorporating A) TPGS 
and B) DPPC after 8 weeks in simulated physiological conditions at 37°C. 
 
A B
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The effect of the degradation on the loss of molecular weight determined by GPC was 
shown in Fig. 3.19. These results indicated that the emulsifier has certain effect on 
degradation of nanoparticles and hence their molecular weight loss. Furthermore, it 
provided the quantitative evidence of the degradation behaviors observed in the 



























Figure 3. 19. Degradation profile of paclitaxel-loaded particles. 
 
In the first stage of degradation of the semi-crystalline PLGA polymer, water uptake 
was basically governed empirically by the intrinsic hydrophilicity of the repeat units 
and by end-group effects. Since the end groups of PLGA are alkoxylic and carboxylic 
whose number is increased as molecular weight falls due to degradation, the 
essentially hydrophobic polymer becomes more hydrophilic. Water uptake was 
determined by two events. The first was simple diffusional ingress into the dry 
interior of the particles and in the absence of degradation this would occur to a level 
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that would be characteristic of the equilibrium swelling of this kind of material. 
However, these polymers are hydrolytically unstable and following, or even during 
this initial diffusional phase, the polymer can degrade and take up more water. In the 
second stage of degradation, water uptake was then through the highly porous surface 
of the particles as the amorphous regions were degraded. By then, a loss of 
nanoparticles integrity was inevitable due to the breakdown of the polymer matrix, 
which was reflected by the increased porosity on the surface. From the results 
presented here, it can be predicted that the morphology of the polymeric matrix 
should greatly influence the drug release profiles, because for both diffusion and 
degradation controlled mechanisms, the matrix morphology is a key factor. 
 
3.4. Conclusion 
Biodegradable polymeric nanoparticles were successfully prepared by oil-in-water 
emulsification/solvent evaporation process using both chemical and natural 
emulsifiers. A combination of the optimized parameters gives rise to a small, 
reproducible particle size with narrow size distribution and high encapsulation 
efficiency.  
 
Comparing to chemical emulsifiers, natural surfactants such as polysaccharides, 
phospholipids, cholesterol and vitamin are preferred since they may have better 
performance in preparation and application of polymeric nanoparticles for clinical 
administration. Moreover, the natural emulsifiers DPPC and TPGS have much higher 
emulsifying efficiency comparing to the chemical emulsifier PVA. This implies that 
much lower amount of DPPC (about 1/33 of PVA) or TPGS (about 1/67 of PVA) is 
needed for the same formulation procedures. This is quite possible since TPGS and 
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DPPC have greater tendency to migrate to the surface of nanoparticles which has been 
supported by the XPS analysis of the surface chemistry (Feng et al., 2004). 
Furthermore, XRD analyses revealed that the drug was present in these nanoparticles 
in an amorphous state. The drug release profile and the degradation pattern are 
comparable for these TPGS and DPPC-incorporated nanoparticle formulations. 
Therefore, nanoparticle formulations incorporating TPGS and DPPC were selected as 
the most suitable formulations for further evaluations. 
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CHAPTER 4 
EFFECTS OF PARTICLE SIZE AND SURFACE COATING ON 
CELLULAR UPTAKE OF POLYMERIC NANOPARTICLES FOR 
ORAL DELIVERY OF ANTICANCER DRUGS 
 
4.1. Introduction 
Oral delivery of anticancer drugs is a challenge, which has advantages over the 
current regime of chemotherapy by injection or infusion. Oral chemotherapy can 
provide a long-time, continuous exposure of the cancer cells to the anticancer drugs of 
a relatively lower thus safer concentration and thus give little chance for the tumor 
blood vassals to grow, resulting in much better efficacy and fewer side effects than 
the current intermittent chemotherapy could do. Oral chemotherapy is convenient and 
thus preferred by the patients, which can greatly improve the quality of life of the 
patients. This is especially important for the patients with advanced or metastatic 
cancer. Oral chemotherapy can eventually promote a new concept of chemotherapy: 
“chemotherapy at home” (Feng and Chien, 2003; Feng et al., 2004; Bottomley, 2002; 
Ajani and Takiuchi, 1999; Demario and Ratain, 1999). Unfortunately, most anticancer 
drugs are not bioavailable due to their pure solubility, stability and permeability, i.e. 
orally administrated anticancer drugs have little chance to get into the blood system 
and thus reach the tumor site. The reason has been under intensive investigation and it 
has been found that the orally administrated anticancer drugs would be eliminated by 
the first metabolic process with cytochrome P450 and by the efflux pump of P-
glycoproteins (P-gp) (Malingré et al., 2001; Sparreboom et al., 1997). Medical 
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solutions, which are currently being developed in pharmaceutical companies, usually 
propose to apply P450/P-gp suppressors such as cyclosporin A to make oral 
chemotherapy feasible. However, the P450/P-gp suppressors would fail the immune 
system of the patients and thus may cause complex medication to the patients. Also, 
most P450/P-gp suppressors may have side effects and/or difficulties in formulation 
of their own (Malingré et al., 2001; Van Zuylen et al., 2000; Terwogt et al., 1998; 
Bonduelle et al., 1996). Nanoparticles of biodegradable polymers may provide an 
alternative solution for oral delivery of anticancer drugs across the gastrointestinal 
barrier due to their extremely small size and their appropriate surface coating to 
escape from the recognition by P450/P-gp (Maincent et al., 1986; Florence et al., 
1995; Wang et al., 1996; McClean et al., 1998; Suh et al., 1998; Delie, 1998; 
Matsumoto et al., 1999; Jung et al., 2000; Feng and Huang, 2001; Mu and Feng, 2002; 
Mu and Feng, 2003). 
It has been found that the size of the nanoparticles plays a key role in their adhesion to 
and interaction with the biological cells. The possible mechanisms for the particles to 
pass through the gastrointestinal (and other physiological) barriers could be (1) 
paracellular passage – particles “kneading” between intestinal epithelial cells due to 
their extremely small size (<50 nm); (2) endocytotic uptake – particles adsorbed by 
intestinal enterocytes through endocytosis (particles size < 500 nm); and (3) 
lymphatic uptake – particles adsorbed by M cells of the Peyer’s patches (particle size 
< 5 microns) (Sanders and Ashworth, 1961; Lefevre et al., 1978; Florence et al., 
1995).  Also, coating the particles by appropriate bioadhesive materials such as 
polyvinyl alcohol (PVA), poly(ethylene glycol) (PEG), vitamin E TPGS, etc can 
greatly improve their adhesion to and adsorption into the intestinal cells as well as the 
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ability to escape from the multi-drug resistance pump proteins (Feng and Huang, 2001; 
Mu and Feng, 2002; Mu and Feng, 2003).    
Vitamin E succinated polyethylene glycol 1000 (Vitamin E TPGS or simply TPGS) is 
a water soluble derivative of vitamin E, which has been found to be an excellent 
emulsifier/solubilizer/absorption enhancer of high emulsification efficiency and 
cellular adhesion (Mu and Feng, 2002; Mu and Feng, 2003). Fischer (2002) reported 
that co-administration of vitamin E TPGS increased the oral bioavailability of 
cyclosporine A in healthy dogs by non-compartmental pharmacokinetic analysis. 
Vitamin E TPGS acts as a reversal agent for P-glycoprotein mediated multidrug 
resistance and inhibits P-gp mediated drug transport (Dintaman and Silverman, 1999; 
Rege et al., 2002). Vitamin E TPGS can also enhance the absorption flux of 
amprenavir, a HIV protease inhibitor, by increasing its solubility and permeability 
(Yu et al., 1999). 
Phospholipid, 1,2-dipalmitoylphosphatidylcholine (DPPC) is used as as an additive in 
our drug delivery formulation as it can improve the performance of the PLGA 
microspheres in blood flow (Garti, 1999), enhance the pulmonary absorption of 
peptides and proteins (Zhen et al., 1995), reduce phagocytic uptake of the 
microparticles (Evora et al., 1998), and impart better emulsifying effects and higher 
encapsulation of drug in the nanoparticles (Feng and Huang, 2001). Phospholipids 
exhibit high potential of application in drug delivery formulations. 
The present study evaluated the cellular uptake of polymeric nanoparticles by using 
Caco-2 cells as an in vitro model with the aim to apply nanoparticles of biodegradable 
polymers for oral chemotherapy with emphasis on possible effects of particles size 
and particle surface coating on the cellular uptake of the drug loaded nanoparticles. 
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Caco-2 cells are an established epithelial cell line derived from a human colon 
adenocarcinoma that undergoes enterocyte differentiation in culture (Pinto et al., 
1983). Confluent Caco-2 cell monolayers form tight junctional complexes, exhibit 
dome formation and electrical properties similar to those of the intestinal epithelium. 
This cell line has been suggested to possess attributes that make it a suitable in vitro 
model system for the investigation of transport across the small intestinal epithelium 
(Hidalgo et al., 1989) and particle uptake into human intestine (Artursson et al., 1990; 
Desai et al., 1997; McClean et al., 1998; Delie, 1998; Boudad et al., 2001). In the 
present study, fluorescent marker coumarin-6 was encapsulated in the poly (lactic-co-
glycolic acid) (PLGA) nanoparticles to visualize the cellular uptake of the 
nanoparticles, which were manufactured by a modified solvent extraction/evaporation 
technique with PVA or vitamin E TPGS or phospholipids DPPC as emulsifier. To 
investigate the quantitative effects of the particle size on the cellular uptake of 
nanoparticles, commercially available fluorescent polystyrene nanoparticles were also 
used. The nanoparticles were characterized by laser light scattering (LLS) for their 
size and size distribution, scanning electron microscopy (SEM) for their surface 
morphology and zeta-potential measurement for their surface charge. The in vitro 
fluorescence release from the nanoparticles was measured by high performance liquid 
chromatography (HPLC). Cell uptake of the coumarin-6 loaded nanoparticles and 
intracellular location of the nanoparticles of various size and surface coating were 
investigated by confocal laser scanning microscopy (CLMS), cryo-SEM and 
transmission electron microscopy (TEM). It was found that vitamin E TPGS coated 
PLGA nanoparticles have advantages in favor of cellular uptake over those of other 
formulations and are thus of great potential for oral chemotherapy. 
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4.2. Experimental methods 
4.2.1. Materials 
Fluorescent polystyrene nanoparticles were purchased from Duke Scientific (CA, 
USA).  Fetal bovine serum (FBS) was received from Gibco (Life Technologies, AG, 
Switzerland). All the remaining materials are the same as in section 3.2.1. Ultrapure 
water (Millipore, Bedford, MA, USA) was used throughout the experiment.  
 
4.2.2. Preparation of nanoparticles  
For the in vitro particle uptake studies, fluorescence labeled nanoparticles were also 
successfully prepared by a modified solvent extraction/evaporation method (single 
emulsion), as mentioned in the section 3.2.2, using PVA, Vitamin E TPGS and 
phospholipids DPPC as emulsifier. Coumarin-6 was encapsulated in the nanoparticles 
as the same manner of drug loading. The polymer solution contained 0.05% (w/v) 
coumarin-6 as fluorescent marker in preparation of fluorescent nanoparticles. 
Formulation optimization was pursued to obtain nanoparticles of desired 
physicochemical properties.  
 
4.2.3. Characterization of nanoparticles 
4.2.3.1. Size and size distribution 
Nanoparticle size and size distribution were determined by laser light scattering with 
particle size analyzer (90 Plus, Brookhaven Inst, Huntsville, NY, USA) at a fixed 
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angle of 90° at 25°C. The data reported in Table 4.1 represent the average of 5 
measurements. 
 
4.2.3.2. Surface morphology  
Morphology of the formulated nanoparticles was observed by scanning electron 
microscopy (SEM, Jeol JSM 5600LV) after preparing the sample with a platinum 
coating by a sputter coater (JFC-1300, Jeol, Tokyo) for 40 seconds in a vacuum at a 
current intensity of 40 mA.  
 
4.2.3.3. Surface charge 
Zeta potential of nanoparticles, an indicator of surface charge and stability of 
dispersion, was determined by a zeta potential analyzer (Zeta Plus, Brookhaven 
Instruments, Huntsville, NY) and the mean value of 10 readings was reported. 
 
4.2.4. In vitro release of fluorescent markers from nanoparticles 
Coumarin-6 loaded nanoparticles were dispersed in transport buffer at pH 7.4, which 
was used to simulate physiological fluid.  The buffer solution was kept in an orbital 
shaker at constant gentle shaking of 110 rpm at 37°C. At pre-determined time 
intervals, the suspensions were centrifuged at 11,000 rpm for 8 min.  The precipitated 
particles were re-suspended in fresh buffer and placed back into the shaker. The 
supernatant containing released fluorescent marker was then analyzed to determine 
the percentage release of the fluorescent markers from the nanoparticles. 
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4.2.5. Cell culture 
In the present study, Caco-2 cells of passages between 24 and 30 were used. Caco-2 
cells were cultured in MEM medium with 1.5 mM L-glutamine, supplemented with 
20% fetal bovine serum (FBS), 1mM sodium pyruvate, 1.5 g/L of sodium bicarbonate 
and 1% penicillin-streptomycin solution.  Cells were seeded at 6.4 x 104 cells/cm2 on 
the 96-well black plates with transparent bottom (Costar, IL, USA) for quantitative 
uptake experiments or on the Lab-Tek® chambered cover glasses (Nalge Nunc, IL, 
USA) for confocal microscopy. Cells were cultured as a monolayer at 37°C in a 
humidified atmosphere containing 5% CO2 and medium was replenished every other 
day. 
 
4.2.6. Nanoparticle uptake by Caco-2 cells 
4.2.6.1. Quantitative studies 
Caco-2 cells were seeded in 96-well black plates (Costar, IL, USA) and incubated 
until they formed a confluent monolayer. Upon reaching confluence, the culture 
medium was replaced by transport buffer (Hank’s balanced salt solution, HBSS, pH 
7.4) and pre-incubated at 37ºC for 30 min. After equilibration, cell uptake of 
nanoparticles was initiated by exchanging the transport medium with 100 µL of 
specified nanoparticle suspension (100 µg/ml to 500 µg/ml in HBSS) and incubating 
the cells at 37°C for 0.5 to 4 h. The experiment was terminated by washing the cell 
monolayer three times with phosphate-buffered saline (PBS, pH 7.4) to eliminate 
excess particles which were not entrapped by the cells. Cell membrane was 
permeabilized with 0.5% Triton X-100 in 0.2 N NaOH solution to expose the 
internalized nanoparticles for the quantitative measurement. Cell-associated 
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nanoparticles were quantified by analyzing the cell lysate in a Genios microplate 
reader (Tecan, Männedorf, Switzerland, λex 430 nm, λem 485 nm). Uptake was 
expressed as the percentage of fluorescence associated with cells versus the amount of 
fluorescence present in the feed solution. 
 
4.2.6.2. Qualitative studies 
4.2.6.2.1. Confocal laser scanning microscopy 
Caco-2 cells were seeded on Lab-Tek® chambered cover glasses (Nalge Nunc 
International, Naperville, IL, USA) and incubated at 37°C in 95 % air and 5 % CO2 
environment until cells were about 70 % confluent. On the day of experiment, the 
growth medium was replaced by HBSS (pH 7.4). After equilibration with HBSS at 
37ºC for 30 min, the buffer was replaced with nanoparticle suspension (250 µg/ml in 
HBSS) and then the monolayers were further incubated for 1 hr or 2 hr. At the end of 
experiment, the monolayers were washed 3 times with fresh pre-warmed transport 
buffer to eliminate excess nanoparticles which were not attached to the cells. Cells 
were then fixed with 70% ethanol and the nuclei were stained by propidium iodide 
(PI). The samples were mounted in the fluorescent mounting medium (Dako, CA) 
until examination was performed by the confocal laser scanning microscope (Zeiss 
LSM 410, Germany) equipped with an imaging software, Fluoview FV300. 
 
4.2.6.2.2. Cryo-scanning electron microscopy (Cryo-SEM) 
The cellular internalization of nanoparticles was confirmed by cryo-SEM. Caco-2 
cells of passage 30 were incubated with nanoparticle suspension (250 µg/ml in HBSS, 
pH 7.4) for 1 hour and then the excess nanoparticles were washed away with pre-
 98
Chapter 4: Effects on Cellular Uptake 
warmed PBS (pH 7.4) for 3 times. Cells were fixed by using 2.5% glutaraldehyde 
solution and were plunged frozen in nitrogen sludge (-194°C). The specimen was 
transferred to the cryo-preparation chamber of a cryo-system attached to a Philips 
XL30 scanning electron microscope. The temperature was raised to -95°C. The 
specimen was then fractured and etched for 15 min. The frozen specimen was sputter-
coated with approximately 5 nm of platinum, introduced onto the specimen stage of 
the SEM at -130°C and examined at 5-10 kV accelerating voltage. 
 
4.2.6.2.3. Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) of Caco-2 cells treated with nanoparticles 
was performed by negative staining. Briefly, at the end of 1 hr incubation with 
nanoparticles (250µg/ml), Caco-2 cells were washed, pre-fixed with 2.5% 
glutaraldehyde and 2% paraformaldehyde solution, post-fixed with 1% osmium 
tetroxide, dehydrated with a series of alcohols and infiltrated with resin. The resin 
sample block was trimmed, thin-sectioned to thickness of 70nm, and collected on 
formvar-coated copper grids. Before examining under the TEM, these grids were 
stained by uranyl acetate and lead citrate, followed by blotting with a filter paper and 
air-drying. Samples were examined in Philips CM10 at 200 kV. 
 
4.3. Results and discussion 
4.3.1. Physicochemical properties of nanoparticles 
4.3.1.1. Size and size distribution  
 The particle size, polydispersity index, and zeta potential of the fluorescent 
nanoparticles are presented in Table 4.1. The nanoparticles formulated in this study 
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were found to be in the size range of 200-500 nm. The light scattering measurement 
of particle size agreed well with the measurement given by the SmileView software 
from SEM micrographs.  
 
Table 4.1.  Characteristics of fluorescent PLGA nanoparticles coated with PVA or 
vitamin E TPGS and standard fluorescent polystyrene nanoparticles 
Sample Group Emulsifier 
(w/v) 
Size ± SD 
(nm) 
Polydispersity Zeta Potential 
(mV) 
PVA 2 % 262 ± 8.8 0.133 -18.4 
TPGS 0.03 % 295 ± 15 0.201 -29.7 
DPPC 0.06 % 263 ± 3.9 0.046 -16.1 
200nm PS - 201 ± 2.3 0.036 -36.8 
500nm PS - 498 ± 8.4 0.136 -29.2 
1000nm PS - 1007 ± 35 0.125 -27.5 
* Polydispersity = the size distribution width 
 
4.3.1.2.Morphology of nanoparticles 
The scanning electron microscopic images of the drug-loaded nanoparticles revealed 
their regular spherical shape (Fig. 4.1). Generally, their surface morphology was 
smooth without any noticeable pinholes or cracks within the conventional SEM 
resolution. The size distribution of all nanoparticles was unimodal with diameters in 
the total range of 150–500 nm and a mean diameter of 200–300 nm as confirmed by 






































Figure 4. 1.  SEM images of coumarin 6-loaded PLGA particles coated with PVA (A); 
vitamin E TPGS (B); and DPPC (C) (bar = 1 μm). 
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4.3.1.3.Surface charge of nanoparticles 
The zeta potential was strongly influenced by the emulsifier used in the fabrication 
process of the nanoparticles. The nanoparticles in the present study were found stable 
in dispersion state, possessing high absolute values of zeta potential and having 
negative surface charges (Table 4.1). 
 
4.3.2. In vitro fluorescent marker release 
The use of fluorescent markers in nanoparticle visualization can lead to 
misinterpretation of nanoparticle uptake data due to the leaching or dissociation of 
fluorescent markers into the released medium (Suh et al., 1998) and hence 
subsequently into the cells. Neither could fluorometric analysis differentiate between 
intracellular and surface located particles, nor determine whether fluorescence 
detected was due to the cell-associated particles or the fluorescence released from the 
particles in the medium which was subsequently taken up by the cells. Thus, in vitro 
release study of fluorescence from the nanoparticle specimen was conducted to 
confirm the results obtained mainly due to the cell-associated nanoparticles but not 
from the released fluorescence in the medium. From Fig. 4.2, it can be found that the 
coumarin-6 was released only 3.75% and 2.55% from the TPGS and PVA 
nanoparticles, respectively, over 24 hr incubation time (Fig. 4.2), which was 
considered negligible in comparison with the nanoparticle uptake outcome of the 
Caco-2 cells. It is thus reasonable to assume that most of the coumarin-6 was 
associated in the nanoparticles and the fluorescence measured from the uptake 
samples mainly reflects the cellular associated fluorescent nanoparticles but not the 
released fluorescence in the medium. 
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Figure 4. 2. In vitro release profiles of fluorescence from standard fluorescent 
polystyrene nanoparticles of 200nm, 500nm, 1,000nm diameter and PLGA nanoparticles 
coated with PVA, vitamin E TPGS, or phospholipids DPPC respectively. Data 
represents average value of triplicates. 
 
4.3.3. Cell uptake of nanoparticles 
In order to study cellular uptake of nanoparticles in vitro or in vivo, the use of 
fluorescently or radioactively labeled nanoparticles is the most common experimental 
approach found in the literature. Fluorescent labeling was chosen for the present study 
to avoid exposure of the samples to radioactive materials. Fluorescent labeling makes 
cellular uptake of nanoparticles readily detectable by fluorescence microscopy or 
CLSM. The extent of particle uptake can then be determined by flow cytometry, 
fluorometry, or quantitative extraction of the markers from the cells. Due to its similar 
structural and functional differentiation to mature enterocytes, the Caco-2 monolayer 
model is an established in vitro tool to evaluate the intestinal permeability and 
metabolism of drugs (Artursson, 1991; Yee, 1997). Reasonable correlations could be 
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established between in vivo data and data obtained in Caco-2 monolayers 
(Schakenraad, 1996). Thus, Caco-2 monolayers were used to study the various effects 
on cellular uptake of nanoparticles. The present study demonstrates that the Caco-2 
cell uptake of nanoparticles is influenced by various parameters such as particle size, 
incubation time, particle concentration, surface properties of the particles, etc. TPGS 
coated nanoparticles are expected to increase their circulation time and internalization 
efficiency, and thus, to effectively improve the bioavailability of the drugs 
encapsulated in the nanoparticles.  
 
4.3.3.1. Effect of particle surface coating, incubation time and temperature 
Development of PLGA nanoparticles as an efficient delivery system would depend on 
their efficient internalization into, and sustained retention inside the cells. Here, 
surface properties of delivery system play an important role. Vitamin E TPGS coated 
PLGA nanoparticles were found to have improved the uptake of the nanoparticles by  
3.9-folds, 4.4-folds and 6.1-folds over that of 200 nm, 500 nm and 1000 nm nude PS 
particles, respectively, and 1.4-folds over that of the PVA coated PLGA nanoparticles 
(Fig. 4.3). Moreover, the cell uptake of the DPPC coated PLGA nanoparticles was 
found to achieve the comparable uptake efficiency to that of TPGS nanoparticles. The 
PVA coated PLGA nanoparticles enhanced the uptake by 2.9-folds over that of the PS 
nanoparticles of about the same particle size, indicating that the polymer material of 
nanoparticles also contributes to the efficiency of cellular uptake. These results can 
thus support the assumption that the nanoparticle surface in contact with biological 
fluids, cells, or cellular components can be modified to provide favorite interactions 
with the cells (Zauner et al., 2001).   
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Figure 4. 3. Cellular uptake efficiency of standard fluorescent polystyrene nanoparticles 
of 200nm, 500nm, 1,000nm diameter and PLGA nanoparticles coated with PVA or 
vitamin E TPGS or DPPC, respectively, which is measured after 2 hours incubation 
with Caco-2 cells at 37°C. The control is the cellular uptake of coumarin-6 released from 
the nanoparticles under in vitro conditions and incubated with Caco-2 cells. Data 
represents mean ± SD, n=4. 
 
Figure 4.4 shows that the uptake of nanoparticles by the Caco-2 cells at 37°C 
increased with the incubation time over 4 hr period. However, uptake of the 
nanoparticles by Caco-2 cells had no significant further increase beyond 2 hr 
incubation period since the curves showed a plateau effect. That could be due to the 
limited saturation level, which supports the claim by Desai (1997). 
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Figure 4. 4. Time courses for the Caco-2 cell uptake profile of fluorescent polystyrene 
nanoparticles of 100 nm cultured with nanoparticle concentration of 250 µg/mL at 37°C. 
The control is the cellular uptake of the coumarin-6 released from the nanoparticles 
under in vitro conditions and incubated with Caco-2 cells at the same conditions. Data 
represents mean ± SD, n = 4. 
 
There was, in another series of experiment, a significant reduction in nanoparticle 
uptake by the Caco-2 cells at 4°C (data not shown), with the uptake being reduced to 
25% to 46% of that at 37°C at equivalent particle concentration and incubation time. 
This suggests that the nanoparticle uptake by the Caco-2 cells could be due to the 
energy-dependent endocytic process. 
 
4.3.3.2.Effect of particle size and concentration  
Nanoparticles for chemotherapy need to be absorbable to cells with a sufficiently high 
rate and extent. It has been proposed that the size of the particles plays a key role in 
their adhesion to and interaction with the biological cells (Foster et al., 2001). It is, in 
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general, assumed that particles up to about 100–200 nm can be internalized by 
receptor-mediate endocytosis, while larger particles have to be taken up by 
phagocytosis (Couvreur and Puisicux, 2003). In the present study, Caco-2 cells were 
found to uptake the nanoparticles to an acceptable extent. Figure 5 demonstrates that 
100 nm particles had 2.3-folds greater uptake compared to that of 50nm particles, 1.3-
folds to that of 500 nm particles, about 1.8 folds that of 1000 nm particles. Thus, it is 
demonstrated that nanoparticles of 100 – 200 nm size acquire the best properties for 
cellular uptake. Not only does this highlight the misconception that the smaller the 
particle size is, the better the cellular uptake can be resulted, but also bring to light of 
the fact that there has an optimum size range.  
The control experiments performed by incubating Caco-2 cells with medium of the 
coumarin-6 released from the nanoparticles did not show any significant uptake, 
which demonstrates that the raw coumarin-6 markers can not be directly internalized 
by the cells (Fig. 4.5). Furthermore, the uptake of nanoparticles by Caco-2 cells was 
found increased with increase in the concentration of nanoparticles in the medium. 
9.4% of nanoparticles were taken up at the particle concentration of 100 μg/ml, 15.6% 



































Figure 4. 5. Effect of particle size on cellular uptake by Caco-2 cells of polystyrene  
nanoparticles after 1 hour incubation at particle concentration of 250 µg/ml at 37°C. 
The control is the cellular uptake of the coumarin-6 released from the nanoparticles 
under in vitro conditions and incubated with Caco-2 cells at the same conditions. Data 












































Figure 4. 6. Effect of particle concentration on cellular uptake by Caco-2 cells of 100 nm 
polystyrene  nanoparticles after 1 hour incubation at 37°C. The control is the cellular 
uptake of the coumarin-6 released from the nanoparticles under in vitro conditions and 
incubated with Caco-2 cells at the same conditions. Data represents mean ± SD, n=3. 
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Our Caco-2 cell uptake studies exhibit its dependency upon the nanoparticle size with 
smaller particles possessing greater uptake in general. This supports the findings 
reported in the literature that the extent of particle uptake is indirectly proportional to 
the particle size (Desai et al., 1997). The only exception is that the smallest size 
particles we studied, 50nm, showed the lowest uptake, indicating there may be a limit 
beyond which the size no longer plays an influencing key role in the extent of uptake. 
However, due to numerous discrepancies in the literature, no set criteria are available 
for the design of an appropriate particulate carrier system. A major source of 
confusion may lie in the large variety of analytical methods and experimental models 
that have been employed to investigate particle uptake (McClean et al., 1998). 
The smaller size particles seem to have efficient interfacial interaction with the cell 
membrane compared to larger size particles. Probably the larger size particles (> 1µm) 
are taken up by mechanism other than endocytosis, such as fluid-phase pericytosis 
(Boudad et al., 2001). Since the small size particles could improve efficacy of the 
particle-based oral drug delivery systems (Kreuter, 1991; Fujikawa and Kuroda, 2000) 
and vitamin E TPGS attributes inhibition of P-gp mediated drug transport in addition 
to increased absorption by enhancing solubility and permeability (Dintaman and 
Silverman, 1999; Yu et al., 1999), the smaller size nanoparticles with TPGS modified 
surface could definitely improve the efficiency of cellular uptake and be highly 
feasible for oral chemotherapy. 
 
4.3.3.3.Confocal microscopy 
Figure 4.7 and Figure 4.8 show confocal microscopic images of Caco-2 cell 
monolayers after nanoparticle uptake experiments, which strongly support the 
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previous quantitative measurements of the cellular uptake of nanoparticles by 
showing strong fluorescence in the cell cytoplasm as well as in the nucleus. Effects of 
particle size, culture time and surface modification on nanoparticle uptake are clearly 
evidenced. The confocal micrographs in Fig. 4.7 represent the optical sections (x-y 
axis) of Caco-2 cells after 1 hr incubation with coumarin-6 loaded, PVA-coated (Fig. 
4.7a), vitamin E TPGS-coated (Fig. 4.7b), and DPPC-coated (Fig. 4.7c) PLGA 
nanoparticles. The cells incubated with vitamin E TPGS-coated nanoparticles at 37°C 
exhibit a thicker layer of stronger fluorescence than those incubated with the PVA-
coated nanoparticles under the same other conditions. The cells treated with DPPC-
coated nanoparticles demonstrate comparable strong fluorescence intensity, even 
though slightly weaker, with those TPGS-coated nanoparticles. In these images, a 
fluorescent layer coinciding with the cell outline can be observed. However, no 
fluorescence can be detected from the image of the control cells (figure not shown), 
which were not exposed to the coumarin-6 loaded nanoparticles and/or placebo 
nanoparticles, implying there is no auto-fluorescence of the cells or polymer material 
of nanoparticles which can lead to misinterpretation of the data. Three-dimensional 
analyses of the confocal images of the cells incubated with the vitamin E TPGS-
coated and DPPC-coated fluorescent PLGA nanoparticles at 37°C were shown in Fig. 
4.8 in which the reconstruction of the z-axis especially clearly demonstrates the 
fluorescent signals inside the cells. This implicates the actual internalization of the 
nanoparticles by the Caco-2 cells. In contrast, uptake of polystyrene nanoparticles into 
Caco-2 cells is very poor (figures not shown). Typically, polystyrene nanoparticles 
are found attached to the apical cell surface only. No particles could be observed 
intracellularly or at the basolateral side.  
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Figure 4. 7. Confocal microscopic images of Caco-2 cells after 1 hour incubation with 
coumarin 6-loaded PLGA nanoparticles coated with (A) PVA; (B) vitamin E TPGS; and 
(C)DPPC at 37°C. The cells were stained by propidium iodide (red) and uptake of green 
fluorescent 6-coumarin-loaded nanoparticles in Caco-2 cells was visualized by 
overlaying images obtained by FITC filter and RITC filter. These figures show a distinct 
extent in cellular uptake of the nanoparticles. 
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Figure 4. 8. Confocal microscopic images of Caco-2 cells after 1 hour incubation at 37°C 
with coumarin 6-loaded PLGA nanoparticles coated with vitamin E TPGS (A) and 
DPPC (B). Optical sections (xy-) with xz- and yz-projections allow to clearly 
differentiate between the extracellular and the internalised nanoparticles. Small blue 




Chapter 4: Effects on Cellular Uptake 
Optical sectioning proved that the nanoparticles were internalized and not simply 
bound to the surface of the cells (Fig. 4.9 and Fig. 4.10).  
 
 
Figure 4. 9. Intracellular distribution of DPPC-coated PLGA nanoparticles in Caco-2 
cells after incubated for 1 hr at 37°C as examined by optical sectioning using confocal 
laser microscope. The focus plane was moved from bottom to top in the vertical axis at 
an interval of 1.0 μm. 
5.0 μm3.0 μm 4.0 μm
0.0 μm 1.0 μm 2.0 μm
6.0 μm 7.0 μm 8.0 μm
9.0 μm 10.0 μm 11.0 μm 
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Figure 4. 10. Intracellular distribution of TPGS-coated PLGA nanoparticles in Caco-2 
cells after incubated for 1 hr at 37°C as examined by optical sectioning using confocal 
laser microscope. The focus plane was moved from bottom to top in the vertical axis at 
an interval of 1.0 μm. 
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9.0 μm 10.0 μm 11.0 μm 
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4.3.3.4.Cryo-SEM and TEM  
Cryo-SEM enables the observation of bulk biological materials in hydrated conditions 
by conversion of liquid water to solid by cryo-fixation, which has been widely used 
for ultrastructural study of biological materials and water distribution within tissues as 
well as for observation of ice crystal distributions following the freezing of biological 
materials, especially plant tissues (Fujikawa and Kuroda, 2000). Cryo-SEM can 
provide direct observation of the cells which are arrested at the existing state with less 
risk of damaging the cell due to preparation process. Moreover, the preparation of 
Cryo-SEM samples is much simpler comparing to that of TEM.   
Despite the advantages and wide applicable options, there has been no report in the 
literature on cryo-SEM analysis of cellular uptake of particles to our best knowledge. 
Figure 4.11 shows the cryo-SEM image of a cross-section of a single Caco-2 cell after 
treated with vitamin E TPGS-coated PLGA nanoparticles for 1 hr at 37°C, which 
indeed confirms the efficient uptake and internalization of nanoparticles. The arrows 
indicate some of the nanoparticles found throughout the endoplasm of the cell and 
around the nucleus. Some nanoparticles can be found adsorbed on the cell membrane. 
Some free nanoparticles scattered near the cell can also be observed. 
 






















Figure 4. 11. Cryo-SEM image of a cross-section of a typical Caco-2 cell after 1 hour 
incubation at 37°C with coumarin 6-loaded PLGA nanoparticles coated with vitamin E 
TPGS. The arrows indicate some nanoparticles found throughout the endoplasm and 




Figure 4.12 shows the TEM micrograph of a single Caco-2 cell with uptaken TPGS-
coated PLGA nanoparticles of ~200 nm size throughout the cytoplasm and some in 
the nucleus. The arrows indicate some of the nanoparticles distributed in the cell. The 































Figure 4. 12. TEM image of a typical Caco-2 cell after 1 hour incubation at 37°C with 
coumarin 6-loaded PLGA nanoparticles coated with vitamin E TPGS. The arrows 




Caco-2 cells were used in the present study as an in vitro model to evaluate the 
cellular uptake of fluorescent polystyrene nanoparticles of standard size and 
coumarin-6 loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with 
polyvinyl alcohol (PVA) or vitamin E TPGS or DPPC with the aim  to promote oral 
delivery of anticancer drugs by nanoparticles of biodegradable polymers. The 
emphasis was given to the possible effects of particle size and particle surface coating 
on the cellular uptake of the nanoparticles.  Our results illustrated that PLGA 
nanoparticles have significantly higher level of the cellular uptake compared with 
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polystyrene nanoparticles and the vitamin E TPGS coated PLGA nanoparticles have 
advantages in favor of the cellular uptake over the PVA coated or DPPC coated 
PLGA nanoparticles. Thus, TPGS coated PLGA nanoparticle formulation was 
selected for further detailed studies. An observed plateau effect of the cellular uptake 
efficiency against the nanoparticle concentration or the cell incubation time suggested 
that the cellular uptake of polymeric nanoparticle is saturable. The internalized 
nanoparticles were mostly seen throughout the cytoplasm surrounding the nucleus and 
minority of them were found in the nucleus, especially in the case of vitamin E TPGS 
coated PLGA nanoparticles, in the images of confocal laser scanning microscopy 
(CLSM), cryo-SEM and transmission electron microscopy (TEM). Our results 
demonstrated that nanoparticles of biodegradable polymers of small enough size and 
with appropriate surface coating may have great potential to be applied for oral 
delivery of anticancer drugs as well as other therapeutic agents. “Chemotherapy at 
home” may be a dream which is coming true.  
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CHAPTER 5 
IN VITRO AND IN VIVO EVALUATIONS ON PLGA 




Cancer and cardiovascular diseases are the leading causes of human deaths and cancer 
is becoming the number 1 killer in many countries including Singapore. However, no 
substantial progress can be observed in the past 50 years in fighting against cancer. 
The cancer death rate in US was 1.939% of the total population in 1950 and still 
1.940% in 2001. Cancer nanotechnology will change the very foundations of cancer 
diagnosis, treatment and prevention. The traditional treatment of cancer has been 
surgery followed by radiotherapy. If the treatment fails, the patients have only 10% 
chance to be cured by other therapies. Chemotherapy can play more important role 
and will become one of the most effective treatments available for cancer and other 
diseases such as cardiovascular diseases and AIDS. Chemotherapy, however, carries a 
high risk due to the drug toxicity, and the more effective drugs tend to be more toxic. 
Problems still exist even for successful chemotherapy. The current regimen of 
chemotherapy is far from being satisfactory. Its efficacy is limited and patients have 
to suffer from severe side effects. Nanoparticles of biodegradable polymers may 
provide an ideal solution and promote a new concept of chemotherapy, which may 
include sustained, controlled and targeted chemotherapy; personalized chemotherapy; 
chemotherapy across various physiological drug barriers; and eventually, 
chemotherapy at home (Feng and Chien, 2004; Feng, 2004). 
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Paclitaxel, a naturally occurring diterpenoid originally extracted from the Pacific Yew 
tree in the early 1960’s, has been considered by the National Cancer Institute (NCI) as 
the most significant advance in drug discovery for chemotherapy and has become 
commercially most successful antineoplastic agent. The drug has been known to 
exhibit a significant activity against a wide spectrum of cancers, including breast 
cancer, ovarian cancer, colon cancer, bladder cancer, lung cancer, head and neck 
carcinomas, and acute leukemia (Wani et al., 1971; Spencer and Faulds, 1994; 
Thigpen, 2000; Ishitobi et al., 2001; Chang et al., 2001; Davidson, 2002). The 
mechanism of antitumor activity of paclitaxel is unique. It inhibits cellular growth by 
promoting and stabilizing microtubule assembly by non-covalent interaction with 
tubulin, thereby blocking cell replication in the late G2 mitotic phase of the cell cycle 
(Kumar, 1981; Manfredi and Horwitz, 1984; Horwitz, 1994; Huizing et al., 1995). 
Paclitaxel has several drawbacks including its marked nephrotoxicity and little oral 
bioavailability. However, the main limitation for its clinical application is its low 
solubility in water and most of the pharmaceutical solvents (Panchagnula, 1998). Its 
dosage form Taxol® is formulated in Cremophor EL and dehydrated alcohol at a 
50:50 (v/v) ratio, which has been found associated with severe side effects including 
hypersensitivity reactions, nephrotoxicity, neurotoxicity and cardiotoxicity (Weiss et 
al., 1990; Waugh et al., 1991; Dorr, 1994; Szebeni et al., 1998; Gelderblom et al., 
2001; Singla et al., 2002). Alternative paclitaxel formulation strategies have been 
suggested to eliminate such an adjuvant and to improve its therapeutic efficacy, which 
include parenteral emulsions (Tarr et al., 1987; Ludenberg, 1997; Kan  et al., 1999), 
liposomes (Sharma and Straubinger, 1994; AI-Angary et al., 1995; Crosasso et al., 
2000), micelles (Liggins and Burt, 2002), nanoparticles (Sharma  et al., 1996; Feng et 
al., 2000; Feng and Huang, 2001; Chen et al., 2001; Kim and Lee, 2001; Feng et al., 
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2004) and microspheres (Wang et al., 1996; Sato et al., 1996; Mu and Feng, 2001; 
Liggins and Burt, 2001; Ruan and Feng, 2003). Among them, nanoparticles of 
biodegradable polymers could provide an ideal solution as well as realize a sustained, 
controlled and targeted delivery of the drug and promote oral chemotherapy.  
There has been intensive investigation directed to oral delivery of paclitaxel, which is 
expected to provide a long-time exposure at an appropriate therapeutic level of drug 
and to greatly improve the quality of life of the patients. The obstacle to the successful 
formulation of oral dosage form is its low oral bioavailability (less than 1%) due to 
the elimination by the multi-drug efflux pump transporter P-glycoprotein (P-gp) 
(Sparreboom et al., 1997) and the first pass of cytochrome P450 enzymes (Cresteil et 
al., 1994; Harris et al., 1994). Medical solution to overcome this problem is to apply 
P450/P-gp inhibitors such as cyclosporin A (Scambia et al., 1995; Bardelmeijer et al., 
2000; Choi et al., 2004). However, the inhibitors would also fail the immune system 
of the patients and thus lead to medical complications. Moreover, most of the P450/P-
gp inhibitors have their own side effects and difficulties in formulation (Bonduelle et 
al., 1996). Nanoparticles of biodegradable polymers represent a chemotherapeutic 
engineering solution or cancer nanotechnology solution. 
Nanoparticles of biodegradable polymers for drug formulation and for oral 
chemotherapy have shown advantages in improving the pharmacokinetics and tissue 
distribution and thus the therapeutic effects of the formulated drug (Couvreur et al., 
1980; Rolland, 1989). Preliminary results have demonstrated that nanoparticles can 
escape from the vasculature through the leaky endothelial tissue that surrounds the 
tumor and thus accumulate in solid tumors (Leroux et al., 1996; Monsky et al., 1999). 
It was demonstrated that nanoparticle formulation can overcome the multi-drug 
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resistance phenotype mediated by P-glycoprotein and thus lead to an increase in drug 
content inside the neoplastic cells (Seelig, 1998; Rowinsky and Donehower, 1995; 
Bennis et al., 1994). 
The key factors which determine the performance of the drug-loaded nanoparticles 
include the particle size and surface coating (Win and Feng, 2005). Modification of 
nanoparticle surface could be an important strategy to improve the half life of the 
nanoparticles in plasma and the cellular uptake of the nanoparticles. We have 
successfully developed a nanoparticle technique to coat nanoparticles of 
biodegradable polymers by phospholipids, cholesterol and vitamin E TPGS, which 
showed great advantages over the traditional coating techniques by polyvinyl alcohol 
(PVA) and poly(ethylene glycol) (PEG) (Feng and Huang, 2001; Win and Feng, 
2005). Vitamin E succinated polyethylene glycol 1000 (TPGS) is a water soluble 
derivative of vitamin E, which has been found to be an excellent 
emulsifier/solubilizer/absorption enhancer of high emulsification efficiency and 
cellular adhesion (Mu and Feng, 2002; Mu and Feng, 2003a and 2003b) as well as a 
Pg-p inhibitor (Bennis et al., 1994; Rowinsky and Donehower, 1995; Seelig, 1998). 
Co-administration of vitamin E TPGS has been found to increase the oral 
bioavailability of cyclosporine A in healthy dogs by non-compartmental 
pharmacokinetic analysis (Fischer et al., 2002). Dintaman and Silverman (1999) 
reported vitamin E TPGS inhibits P-glycoprotein mediated multidrug resistance. 
Vitamin E TPGS can also enhance the absorption flux of amprenavir, a HIV protease 
inhibitor, by increasing its solubility and permeability (Yu et al., 1999). 
The objective of this study was to develop a polymeric drug delivery system for an 
alternative formulation as well as for oral delivery of paclitaxel, which is used in our 
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research as a prototype anticancer drug due to its excellent efficiency against a wide 
spectrum of cancers and its great commercial success as the best seller among 
antineoplastic agents, In our nanoparticle technique, vitamin E TPGS is used as a 
necessary auxiliary in nanoparticle formulation as well as a “ mask ＂  for the 
nanoparticles to cross the GI barrier for oral chemotherapy. Paclitaxel-loaded, TPGS-
emulsified PLGA nanoparticles were prepared by a modified solvent 
extraction/evaporation single emulsion technique. Nanoparticles of various recipes 
were characterized by various state-of-the-art techniques such as laser light scattering 
for particle size and size distribution, scanning electron microscopy (SEM) for surface 
morphology, X-ray photoelectron spectroscopy (XPS) for surface chemistry, and high 
performance liquid chromatography (HPLC) for in vitro drug release kinetics. Caco-2 
cells were employed as an established in vitro model of the GI barrier (Artusson, 1990; 
Desai et al., 1997; Delie, 1998). Human colon adenocarcinoma cells (HT-29 cells) 
were used to evaluate the cytotoxicity of the drug formulated in the nanoparticles. In 
vitro and in vivo pharmacokinetics of the drug in nanoparticle dosage form were 
measured and analyzed in a close comparison with its current clinical dosage form, 
Taxol®. 
 
5.2.  Materials and methods 
5.2.1. Materials  
Paclitaxel of purity 99.8% was purchased from Dabur India Ltd. (India). The details 
of the materials were the same as reported in section 3.2.1 and 4.2.1. All chemicals 
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5.2.2. Nanoparticle preparation 
Nanoparticles with drug or coumarin-6 were prepared by a modified solvent 
extraction/evaporation single emulsion technique as mentioned in section 3.2.2. In 
brief, an oil phase solution of DCM containing PLGA (50:50) and paclitaxel was 
slowly poured into an aqueous solution containing PVA or vitamin E TPGS and 
emulsified using a microtip probe sonicator at an energy output of 20Watts in pulse 
mode. For fluorescent nanoparticles, the drug was replaced by 0.05% (w/v) coumarin-
6 as a fluorescent marker. The resultant oil-in-water emulsion was then stirred at room 
temperature by a magnetic stirrer to evaporate DCM. The produced nanoparticles 
were collected by centrifugation and washed with Millipore water for three times to 
remove excessive emulsifier and drug or fluorophore. The nanoparticle suspension 
was then freeze-dried to obtain fine powder of nanoparticles, which was kept in a 
vacuum desiccator. The theoretical loading ratio of paclitaxel in the nanoparticles was 
set to be 5%. Formulation optimization was pursued to meet various therapeutic needs.  
 
5.2.3. Characterization of nanoparticles 
5.2.3.1. Size and size distribution 
The size and size distribution of the formulated nanoparticles were determined by 
laser light scattering with particle size analyzer (90 Plus, Brookhaven Inst, Huntsville, 
NY) at a fixed angle of 90° and 25°C. The data reported were obtained from the 
average of 5 measurements. 
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5.2.3.2. Morphology of nanoparticles 
The morphology of nanoparticles was observed by scanning electron microscopy 
(SEM). SEM (JSM 5600LV, Jeol, Tokyo) requires an ion coating with platinum by a 
sputter coater (JFC-1300, Jeol, Tokyo) for 40 seconds in a vacuum at a current 
intensity of 40 mA after preparing the sample on metal studs with double-sided 
conductive tape. The accelerating voltage ranged from 10-15 kV during scanning. The 
size of the formulated nanoparticles was confirmed by measuring the diameters in the 
SEM images by using the SmileView software. 
 
5.2.3.3. Surface properties of nanoparticles 
Zeta potential is an indicator of surface charge, which determines particle stability in 
dispersion. The zeta potential of the formulated nanoparticles was determined by a 
zeta potential analyzer (Zeta Plus, Brookhaven Instruments, Huntsville, NY) by 
dipping the palladium electrode in the sonicated particle suspension of interest and the 
means of 10 readings were reported. 
Surface chemistry of nanoparticles was analyzed by X-ray photoelectron spectroscopy 
(XPS, AXIS His-165, Kratos Analytical, Shimadzu). For all samples, the angle of X-
ray used was 90°C and the survey spectrum recorded covered a binding energy range 
from 0 to 1200 eV with pass energy of 80 eV. Curve fitting was performed using the 
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5.2.3.4. Drug encapsulation efficiency 
The amount of drug encapsulated in the nanoparticles was determined in triplicates by 
high performance liquid chromatograph (HPLC, Agilent LC 1100 series). 3 mg of 
nanoparticles was dissolved in 1 ml of DCM and 3 ml of acetonitrile-water (50:50) 
was then added. A nitrogen stream was introduced to evaporate the DCM until a clear 
solution was obtained. The solution was put into vials to detect the paclitaxel 
concentration by HPLC analysis using a reverse phase Inertsil® ODS-3 column. 50 μl 
of sample was injected by an auto-sampler and the column effluent was detected at 
227 nm with a variable wavelength detector. The calibration curve was prepared for 
the quantification of drug in the nanoparticles and it was linear over the range of 50-
10,000ng/ml with a correlation factor of r2 = 0.9999. 
To correct the error arising from possible inefficient extraction, the recovery 
efficiency factor of the extraction procedure was determined. The resulted recovery 
was 91.99 %, which implies that 91.99 % of the original amount of paclitaxel could 
be extracted in the process and thus all the data obtained should be corrected 
accordingly to determine the drug encapsulation efficiency in the formulated 
nanoparticles. The encapsulation efficiency of paclitaxel was obtained as the mass 
ratio between entrapped amount of paclitaxel from the formulated nanoparticles and 
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5.2.4. In vitro drug release 
The drug-loaded nanoparticles were dispersed in a simulated physiological fluid, PBS, 
at pH 7.4.  The nanoparticle suspension was kept in an orbital shaker at constant 
gentle shaking of 110 rpm at 37°C. At pre-determined time intervals, the suspensions 
were centrifuged at 10,000 rpm at 37°C for 15 min.  The precipitated particles were 
re-suspended in fresh buffer and placed back into the shaker. The released paclitaxel 
in the supernatant was first extracted with 1 ml of DCM, followed by 3 ml of the 
mixture of acetonitrile and water (50:50, v/v), then evaporated under a stream of 
nitrogen until a clear solution was obtained. HPLC analysis was then conducted as 
previously described.  
Due to possible inefficient extraction process of the highly hydrophobic paclitaxel, the 
extraction factor had to be determined by measuring the extracted amount of drug for 
a known amount of paclitaxel which underwent the same extraction procedure. It was 
found that only 68 % of the original paclitaxel could be extracted by the procedure. 
Therefore, all the data obtained from in vitro release studies were corrected 
accordingly. 
 
5.2.5. Cell Culture 
In this study, Caco-2 cells (ATCC, VA) of passages between 26 and 31 were 
maintained in MEM medium supplemented with 20% FBS, 100mM sodium pyruvate, 
1.5g/L of sodium bicarbonate and 1% penicillin-streptomycin solution. Human colon 
adenocarcinoma cells (Caco-2), HT-29 cells (ATCC, VA) of passages between 20 and 
24 were cultured in McCoy’s 5A medium with 1.5mM L-glutamine, supplemented 
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with 10% FBS, 2.2g/L of sodium bicarbonate and 1% penicillin-streptomycin solution. 
Cells were seeded at 4.3 × 104 cells/cm2 in the 96-well black plates with transparent 
bottom (Costar, IL, USA) for quantitative uptake experiments or on coverglass in 
chamber system for confocal microscopy, and in the 96-well transparent plates 
(Costar, IL, USA) for cytotoxicity experiments. Cells were cultured as a monolayer at 
37°C in a humidified atmosphere containing 5% CO2. Medium was replenished every 
other day. 
 
5.2.6. In Vitro Cellular Uptake of Nanoparticles 
To measure the cellular uptake of nanoparticles, Caco-2 cells were seeded in 96-well 
black plates (Costar, IL, USA) and incubated until they formed a confluent monolayer. 
Upon reaching confluence, the culture medium was replaced by transport buffer 
(HBSS, pH 7.4) and pre-incubated at 37ºC for 30 min. After equilibration, cellular 
uptake of nanoparticles was initiated by exchanging the transport medium with 100 
µL of the specified nanoparticle suspension (250µg/ml in HBSS). The cells were 
further incubated for 2 hrs. The experiment was terminated by washing the cell 
monolayer three times with PBS (pH 7.4) to eliminate the excess nanoparticles, which 
were not associated to the cells. The cell membrane was permeabilized with 0.5% 
Triton X-100 in 0.2M NaOH solution to expose the internalized nanoparticles for the 
measurement. Cell-associated nanoparticle was quantified by analyzing the cell lysate 
in a fluorescence plate reader (Genios, Tecan, Männedorf, Switzerland, λex = 430 nm, 
λem = 485 nm). Cellular uptake of the nanoparticles was expressed as the percentage 
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5.2.7. Confocal laser scanning microscopy (CLSM) 
Caco-2 cells were seeded on Lab-Tek® chambered cover glasses (Nalge, Nunc 
International, Naperville, IL, USA) and incubated at 37°C in 95% air/5% CO2 
environment until cells were about 70% confluent. On the day of experiment, the 
growth medium was replaced by transport buffer (HBSS, pH 7.4). After equilibration 
with HBSS at 37ºC for 30 min, the buffer was replaced with the nanoparticle 
suspension (250µg/ml in HBSS). The monolayers were further incubated for 1 hr. At 
the end of experiment, the monolayers were washed 3 times with fresh pre-warmed 
transport buffer to eliminate the excess nanoparticles not taken up by the cells.  The 
cells were then fixed and the cell nuclei were stained by propidium iodide (PI). The 
samples were mounted in the fluorescent mounting medium (Dako, CA) until 
examination was performed by the confocal laser scanning microscope (Zeiss LSM 
410, Germany) equipped with an imaging software, Fluoview FV300. 
 
5.2.8. In vitro cytotoxicity 
HT-29 cells were used for cytotoxicity evaluation of the drug formulated in the 
nanoparticles against that formulated in Cremophor EL (Taxol®) with the drug 
concentration ranging from 0.25 to 25µg/ml for 24, 48, 72 and 96 hour incubation. 
Cytotoxicity was determined by MTT assay, in which the optical density at 570 nm 
was determined by a microplate reader (Genios, Tecan, Männedorf, Switzerland). The 
amount of the formazan product which is determined by absorbance measurement is 
directly proportional to the number of viable cells. This is because only the viable 
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5.2.9. Detection of internucleosomal fragmentation 
HT-29 cells were seeded at a density of 1x105 cells/chamber on Lab-Tek® chambered 
cover glass system and incubated at 37°C. Upon reaching about 70% confluency, cells 
were incubated with the paclitaxel loaded nanoparticles of interest and Taxol® which 
were adjusted with the culture medium to have the same paclitaxel concentration of 
2.5μg/ml. for a predetermined time. Cells incubated with the culture medium served 
as the control. Experiment was terminated by removing the paclitaxel formulations 
and washing with PBS for 3 times and fixing the cells with 70% ethanol solution for 
20min. The cells were washed with PBS for 2 times and stained with PI (20μg/ml) for 
20min. Excess PI was removed by washing with PBS for 3 times and cells were 
mounted in Dako fluorescent mounting medium until confocal microscopy. 
 
5.2.10. In vivo pharmacokinetics  
Care and handling of animals, and animal experiment protocols were approved by the 
Institutional Animal Care and Use Committees (IACUC), Office of Life Science, 
National University of Singapore. The in vivo pharmacokinetics was measured with 
male Sprague-Dawley rats of 180-200gm and 6-8 week old, which were supplied by 
the Laboratory Animals Centre of Singapore and were maintained at the Animal 
Holding Unit of National University of Singapore. The animals were housed in air-
conditioned facility and provided with standard food and filtered water. Animals were 
randomly assigned to three groups of three rats. Group 1 received an i.v. injection and 
Group 2 received an i.v. infusion of paclitaxel-loaded TPGS-emulsified PLGA 
nanoparticles. Group 3 received an i.v. injection of Taxol®. The nanoparticles were 
dispersed with saline for dosing at a concentration of 10mg/ml. Taxol® was diluted 
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with saline for dosing at a paclitaxel concentration of 1mg/ml. The formulations were 
administrated through the tail vein at the paclitaxel concentration of 10mg/kg of the 
rat body weight. All animals were observed for mortality, general condition and 
potential clinical signs. 
For Groups 1 and 2, blood samples were collected at 0 (pre-dose), 0.5, 1, 3, 5, 10, 24, 
48 hrs post-treatment. For Group 3, blood samples were collected at 0 (pre-dose), 0.5, 
1, 2, 3, 5, 8, 12 and 24 hrs after administration of the drug. Plasma samples were 
harvested by centrifugation at 1500 × g for 10 min and stored at -20°C until analysis. 
Liquid-liquid extraction was performed prior to analysis by LC/MS/MS. Briefly, 5µl 
of internal standard (2µl/ml, in methanol) was added to 50µl of rat plasma and the 
mixture was extracted with 1ml of tert-butyl methyl ether on a vortex-mixer for 30 s. 
Upon centrifugation at 2000 × g for 15 minutes, the organic layer was transferred to a 
clean tube and evaporated under nitrogen at room temperature. The residue was 
reconstituted with 100μL of mobile phase (acetonitrile:H2O = 60:40 v/v) and 
transferred to autosampler vials containing limited-volume inserts (100μL) before 
analyzed by LC/MS/MS (Wang et al., 2003). Pharmacokinetic parameters were 
expressed as area under the curve (AUC) and sustainable therapy index which is 
determined by the ratio of the time the plasma paclitaxel concentration of Taxol 
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5.3. Results and discussions 
5.3.1. Size, surface morphology and zeta-potential of nanoparticles 
The physicochemical characteristics of the formulated nanoparticles such as particle 
size and size distribution, zeta potential and drug encapsulation efficiency were 
summarized in Table 5.1. It can be seen that TPGS has great advantages over PVA in 
the emulsification process. The emulsification efficiency of TPGS is 66.7 times 
higher that that of PVA, which means that the amount of TPGS needed to formulate 
the drug-loaded nanoparticles is only 1/66.7 of that of PVA to formulate the same 
amount of the nanoparticles. TPGS emulsified NPs (polydispersity = 0.012) are much 
more uniform in size than the PVA-emulsified NPs (polydispersity = 0.110). The 
nanoparticles were obtained in the size range of 200-400 nm. The size and size 
distribution of the drug-loaded nanoparticles are crucial parameters in the design of a 
particulate drug delivery system since they are main factors in determining the drug 
release kinetics and cellular uptake efficiency of the nanoparticles (Rome et al., 1994). 
Moreover, the particle size is associated with the biological response of the tissue to 
foreign biomaterials (Anderson, 1997; Labhasetwar et al., 1998). Nanoparticles of 
FDA approved biodegradable polymers usually cause little or no focal inflammation. 
The inflammatory reactions ensuing fibrosis is a typical response of vascular tissue to 
microparticles ranging in size between 5 and 10µm (Gradus-Pizlo et al., 1995; Dev et 
al., 1997). Thus, nanoparticle formulation was effectively attuned to achieve the 
desired size which falls within a suitable size range (200-500nm) for drug delivery as 
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Drug encapsulation efficiency plays a key role in formulation of a drug delivery 
system especially for expensive drugs and directly related to the therapeutic effects of 
the system. The encapsulation efficiency of paclitaxel in our nanoparticles 
formulation was 65 – 90% which is quite satisfactory in comparison with other work 
in the literature.  
 
Table 5. 1. Physicochemical characteristics of paclitaxel-loaded PLGA nanoparticles, 
fluorescent PLGA nanoparticles and standard PS nanoparticles 
Sample Emulsifier 
(w/v) 




ζ (mV) EE (%) 
PVA NPs 2 % PVA 294 ± 4.8 0.110 -26.0 89 
TPGS NPs 0.03 % TPGS 236 ± 15 0.012 -35.6 66 
PVA FL NPs# 2 % PVA 243 ± 8.7 0.173 -29.4 - 
TPGS FL NPs# 0.03 % TPGS 283 ± 4.0 0.140 -31.2 - 
200nm FL NPs* - 201 ± 2.3 0.036 -36.8 - 
500nm FL NPs* - 498 ± 8.4 0.136 -29.2 - 
1000nm FL NPs* - 1007 ± 35 0.125 -27.5 - 
# Fluorescent PLGA nanoparticles 
* Standard fluorescent Polystyrene nanoparticles 
 
Surface morphology of the formulated PLGA nanoparticles and fluorescent 
polystyrene nanoparticles can be observed by scanning electron microscopy (SEM, 
Fig. 5.1). The images revealed that formulated nanoparticles have regular spherical 
shape with narrow size distribution and smooth surface without any noticeable 
pinholes, tiny pores or cracks at the SEM resolution level. No apparent aggregation 





















Figure 5. 1. SEM images of paclitaxel-loaded PLGA nanoparticles emulsified by PVA 
(A) and vitamin E TPGS (B); coumarin-6-loaded  PLGA nanoparticles emulsified with 
TPGS (C); and 200nm fluorescent polystyrene nanoparticles (D) (bar = 1 μm). 
 
Zeta potential of the formulated nanoparticles was found to be strongly influenced by 
the emulsifier applied in fabrication of the nanoparticles. Although both formulations 
of the PVA and the TPGS emulsified nanoparticles exhibited negative surface charge 
(Table 5.1), the latter possessed higher absolute value of zeta potential (-35.60 mV) 
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5.3.2. Surface chemistry of nanoparticles 
It is of interest to analyze the surface chemistry of the formulated nanoparticles, 
which was carried out by the X-ray photoelectron spectroscopy (XPS). The results are 
shown in Table 5.2. From the chemical structures of PLGA, PVA, vitamin E TPGS 
and paclitaxel, it is apparent that paclitaxel is the only substance which contains 
nitrogen. Thus, nitrogen can be the characteristic element of paclitaxel on the surface 
of the formulated nanoparticles. Since the scan of nitrogen failed to detect the 
existence of N1s (atomic orbital 1s of nitrogen) core-level signal on the exterior of the 
nanoparticles, it is clear that there was no or little (if any) paclitaxel on the surface of 
the drug-loaded PLGA nanoparticles. This fact implicated that the drug tends to stay 
inside the polymeric nanoparticles but not on the particle surface as it is highly 
hydrophobic. The XPS C1s (atomic orbital 1s of carbon) regions were then studied for 
the pure PLGA, PVA and TPGS as well as the paclitaxel-loaded PLGA nanoparticles 
emulsified with PVA and TPGS, respectively. The existence of different carbons 
varies according to the corresponding chemical structures and the amount of the 
emulsifier on the surface since the depth XPS can detect is limited to 50Å. Table 5.2 
shows the quantification of each carbon environment of the polymer, the pure 
emulsifiers and the formulated nanoparticles in summary. PLGA expresses carbon in 
C-C or C-H, carbon of ether and carbon of carboxylate and percentage of these 3 
carbons vary little from one to another since the contribution of these 3 carbons is 
close in the molecular chain of PLGA but does not acquire carbon of ether while pure 
PVA and TPGS attain carbon of ether but lack carbon of ester. In comparison of the 
XPS peaks of the paclitaxel-loaded, PVA- or TPGS-emulsified PLGA nanoparticles 
with those of pure PVA, TPGS, and PLGA respectively, it was evident that 
incorporation of PVA or TPGS provides surface coating or co-existence on the 
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surface of the nanoparticles. The presence of all four carbons including C-O-C ether 
peak in the C1s spectrum of PVA or TPGS incorporated PLGA nanoparticles 
confirms the presence of PVA or TPGS on the surface of nanoparticles since there is 
no such peak in pure PLGA. Furthermore, the atomic composition of these carbons 
falls around the values determined for pure PLGA and PVA and/or TPGS which 
strongly suggests a co-existence of both PLGA and PVA and/or TPGS on the surface. 
 
Table 5. 2. Surface chemistry of the formulation materials and the paclitaxel-loaded 
PLGA nanoparticles 
XPS C1s envelope ratios (%) 
Sample 
C-C C-O-C C-O-C=O O-C=O 
PLGA 33.81 - 33.29 32.90 
PVA 48.72 46.67 - 4.81 
TPGS 53.40 33.81 - 12.79 
PLGA/PVA NPs 57.33 24.88 2.26 15.53 
PLGA/TPGS NPs 53.95 25.87 2.39 17.79 
 
5.3.3. In Vitro drug release 
The in vitro release profiles of paclitaxel from the PLGA nanoparticles with drug 
loading 5% (w/w) are shown in Fig. 5.2, from which the effect of surface coating of 
the nanoparticles on the in vitro drug release behavior can be observed. The drug 
release kinetics exhibited a biphasic pattern characterized by a fast initial burst during 
the first 24 h, followed by a slow, sustained release. After 30 days, the accumulated 
drug release was found to be 33% and 28% of the entrapped amount in the vitamin E 
TPGS-emulsified and the PVA-emulsified PLGA nanoparticles, respectively. Vitamin 
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E TPGS coating obviously enhanced the drug release rate compared with the 
conventional PVA-coated nanoparticles. The reason could be that TPGS acts to 














































Figure 5. 2. In vitro drug release profiles of paclitaxel-loaded PLGA nanoparticles 
emulsified by PVA and vitamin E TPGS, respectively. Each point represents the mean 
with ± standard deviation obtained from triplicates of the samples. 
 
The drug release profile plays important role in determining the therapeutic effects of 
the drug delivery system. It is believed that the therapeutic effect of a dosage form is 
determined by the area-under-the-curve (AUC) of the time course of the in vivo 
concentration of the drug released from the nanoparticles. The drug release kinetics 
can be controlled by varying the composition and process parameters such as the 
polymer type, its molecular weight and copolymer blend ratio, the type and amount of 
emulsifier, the drug loading ratio, the mechanical strength of mixing, the pH and 
temperature (Mu and Feng, 2003b). One of the advantages of nanoparticle 
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formulation is that any desired pharmacokinetics can always be achieved by a specific 
design to meet the needs of individual patients.   
 
5.3.4. In vitro cellular uptake of nanoparticles 
Nanoparticles for oral chemotherapy need to be able to cross the gastrointestinal (GI) 
barrier. The GI barrier is believed to be caused by the tight junctions of intestinal 
endothelial cells, which are also rich in the multi-drug pump p-glycoproteins 
(Malingre et al., 2001; Malingre et al., 2000a; Malingre et al., 2000b). The colon 
adenocarcinoma (Caco-2) cell line was used in this study to simulate the GI barrier 
since confluent Caco-2 monolayers form tight junctional complex, exhibit dome 
formation, and possess electrical properties similar to those of the intestinal 









Figure 5. 3. Confocal microscopic images of Caco-2 cells after 1 hour incubation with 
coumarin 6-loaded PLGA nanoparticles emulsified by (A) PVA or (B) vitamin E TPGS 
at 37°C. The cells were stained by propidium iodide (red). The uptake of green 
fluorescent Coumarin 6-loaded nanoparticles in Caco-2 cells was visualized by 
overlaying images obtained by green filter and red filter. The two figures show a distinct 
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Cellular uptake of nanoparticle was evidenced by the confocal microscopy of the cell 
monolayers. Figure 5.3 represents the optical sections (x-y axis) of Caco-2 cells after 
1 hr incubation with coumarin-loaded, PVA- or vitamin E TPGS-coated nanoparticles. 
Cells incubated with the vitamin E TPGS-coated nanoparticles at 37°C (Fig. 5.3b) 
exhibited a thicker layer of stronger fluorescence intensity than those incubated with 
the PVA-coated nanoparticles under the same conditions (Fig. 5.3a). In both images, a 
fluorescent layer coincident with the cell outline was observed. However, there was 
no fluorescence detected in the control cells (figure not shown) that were not exposed 
to the coumarin 6-loaded nanoparticles, implying there was no auto-fluorescence of 
the cells which can lead to misinterpretation of the data. We hypothesized that TPGS 
could be absorbed intact readily in the GI tract and could inhibit P-gp recognition to 
enhance nanoparticle absorption to the cells (Dintaman JM, Silverman JA. 1999; Mu 
and Feng, 2002).  
To investigate the particle size effect, commercially available fluorescent polystyrene 
(PS) nanoparticles of uniform size were employed in the present study. The uptake 
amount of the PS nanoparticles was found 2.7-folds higher when size was reduced 
from 1,000nm to 200nm (Fig. 5.4).  However, size effect was found not pronounced 
between the 200 nm and 500 nm standard fluorescent PS nanoparticle. Thus, 200 – 
500 nm can be regarded as the ideal size range of nanoparticles for oral drug delivery 
system.  
Surface coating is another important factor to determine the cellular uptake of the 
nanoparticles. Figure 5.4 shows that the uptake of the drug-loaded PLGA 
nanoparticles by Caco-2 cells is significantly higher for the TPGS-emulsified 
nanoparticles than that for the PVA-emulsified nanoparticles. Also, vitamin E TPGS 
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coating on the drug-loaded PLGA nanoparticles improved the cellular uptake by 1.6-
folds over that of the PVA-coated PLGA nanoparticles, 5.5-folds over 200nm PS 
nanoparticles (with no coating) though they possessed about the same particle size, 
6.5-folds over the 500nm PS particles, and 14.6-folds over the 1,000nm PS particles. 
PVA-coated PLGA nanoparticles enhanced the cellular uptake by 3.5-folds over that 
of the 200nm PS nanoparticles. Our investigation clearly demonstrates that the 
particle size and the particle surface coating are the two most important factors that 
determine the Caco-2 cell uptake of the nanoparticles and therefore, the feasibility of 



































Figure 5. 4. Cellular uptake of standard fluorescent polystyrene nanoparticles with 
diameter of 200nm, 500nm, 1000nm and PLGA nanoparticles coated with PVA or 
vitamin E TPGS, which is measured after 2 hours incubation with Caco-2 cells at 37°C. 
Data represent mean ± SD, n=5. 
 
5.3.5. Cytotoxicity of Nanoparticle Formulation of Paclitaxel  
In this study, a human colon cancer cell line (HT-29) was used to determine the anti-
tumoral activity of paclitaxel formulated either in the PVA-emulsified or the TPGS-
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emulsified PLGA nanoparticles in comparison with its Cremophor EL formulation 
(Taxol®). Cytotoxic activity of paclitaxel was evaluated by assessing HT-29 cell 
viability by the MTT assay. The results obtained clearly demonstrate that surface 
coating of the nanoparticles, the incubation time and the drug concentration play a 

























































































Figure 5. 5. Viability of HT-29 cells indicating effect of the treatment time when 
incubated with (A) 0.25µg/ml; (B) 2.5µg/ml; and (C) 25µg/ml of paclitaxel in different 
formulations: Taxol® and vitamin E TPGS-coated PLGA nanoparticles, for 24, 48, 72, 
and 96 hrs at 37°C. Yellow bars (Blank) represent the viability of control cells and 
dotted cyan bars (TPGS (Corrected)) for the viability of cells after taking into account 
of the paclitaxel release from TPGS nanoparticles.  Cell viability was determined by the 
MTT assay and expressed as a percentage of the control wells (cells without treatment). 
Results shown in this figure represent the mean ± standard deviation obtained for two 
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Figure 5.5 shows the viability of HT-29 cells incubated with the same amount of the 
drug formulated in vitamin E TPGS PLGA nanoparticles or Cremophor EL (Taxol®, 
0.25, 2.5 and 25µg/ml of paclitaxel) for 24, 48, 72, and 96 hrs respectively at 37°C, 
from which a significant reduction in HT-29 cell viability can be observed when the 
cells were exposed to the TPGS-emulsified nanoparticles in comparison with the 
Taxol® formulation, especially for the lower paclitaxel concentration. For 0.25μg/ml, 
the measured value of HT-29 cell viability after 24 hour incubation with the same 
amount of drug in the Taxol® and in the TPGS-emulsified nanoparticle formulation is 
96.81 and 82.01, respectively. Accordingly, the cell mortality is thus 3.19 and 17.99, 
respectively. Considered that the cumulative release of paclitaxel from the TPGS-
emulsified PLGA nanoparticles increased from 0% to 24.42% in these 24 hours, the 
cell mortality for the TPGS-emulsified nanoparticle formulation should be corrected 
to be 17.99/(0.2442×0.5) = 147.34 (assuming perfectly linear increase of the drug 
release). Theoretically, the TPGS-emulsified nanoparticle formulation should thus be 
46.18 times (= 147.34/3.19) more effective than the Taxol® formulation. Similar 
interpretation of the measured data shows that the drug formulated in the TPGS-
emulsified PLGA nanoparticle formulation could be 41.64, 19.65, and 10.47 times 
more effective than that formulated in Cremophor EL (Taxol®) after 48, 72, and 96 
hours treatment, respectively. The enhancement of cytotoxic activity of paclitaxel 
formulated in the nanoparticles can be justified by that the tumor cells can internalize 
the drug-loaded nanoparticles, allowing the drug to be released inside the cells and 
therefore, contributing to an increase of the drug concentration near its site of action 
(Leroux et al., 1996).  
For the middle paclitaxel concentration of 2.5μg/ml, the measured cell viability for 
TPGS-emulsified nanoparticle was comparable to that of Taxol® after 48hrs of 
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treatment although not 100% of the drug encapsulated was released from the 
nanoparticles after 48hrs. For the higher paclitaxel concentration of 25μg/ml, Taxol® 
expressed the lower viability of HT-29 cells. Its higher toxicity was probably 
attributed by the presence of relatively higher amount of toxic adjuvant, CrEL. 
However, if the drug release effect was taken into consideration when interpreting the 
cell viability or mortality of either the middle or the higher drug concentration, the 
TPGS-emulsified nanoparticles have much higher efficacy comparing to the clinical 
formulation, Taxol®.  
Figure 5.5 also shows the effects of incubation time duration of HT-29 cell viability. 
As expected, the cell viability was lower for longer periods of incubation with drug or 
with the drug-loaded nanoparticles, which is consistent with previous reports on the in 
vitro cytotoxicity of paclitaxel against tumor cell lines and in agreement with the 
mechanism of action of paclitaxel (Raymond et al., 1997; Liebmann et al., 1993; 
Lopes et al., 1993). 
Figure 5.6 shows the effects of the drug concentration on viability of HT-29 cells, 
which were treated by the drug formulated either in Taxol® or in the TPGS-emulsified 
PLGA nanoparticles for 24 hrs at 37°C. The drug concentration was chosen to be 0.25, 
2.5 and 25µg/ml because this level corresponds to the effective drug concentration in 
the plasma in chemotherapy (Raymond et al., 1997). It can be seen from Figure 5.6 
that there is no noticeable cytotoxicity for the Taxol® formulation at 0.25µg/ml 
paclitaxel after 24 hrs culture. However, the HT-29 cell viability decreased by 20% at 
the same drug concentration of 0.25µg/ml but formulated in the TPGS-emulsified 
PLGA nanoparticles.  Significant decreases in the cell viability could be observed as 
the drug concentration increased from 0.25 to 2.5µg/ml, but further increase in drug 
concentration did not cause further decrease in HT-29 cell viability for both of the two 
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formulations. There seems to be a saturate effect as the drug concentration continues 
to increase. In any case, however, the nanoparticle formulation showed advantages 
versus Taxol® formulation in in vitro cytotoxicity. For 48, 72 and 96 hour incubation, 
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Figure 5. 6. Viability of HT-29 cells indicating effect of paclitaxel concentration 
formulated in Taxol® (dotted bars) and the vitamin E TPGS-coated PLGA nanoparticles 
(lined bars), which were treated for 24 hrs at 37°C. Open bars stand for cell viability 
after corrected with the release of paclitaxel from nanoparticles. Results shown in this 
figure represent the mean ± standard deviation obtained from two independent 
experiments performed with n = 5. 
 
5.3.6. Detection of apoptosis sign: intranucleosomal fragmentation 
PI staining assay was employed to detect the evidence of paclitaxel-induced apoptotic 
cell death due to nanoparticle formulation. Nuclear apoptosis can be determined from 
a series of morphological modifications associated with the execution phase of  
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Figure 5. 7. Confocal images of HT-29 cells after incubation with paclitaxel formulations: 
(A) control; (B) Taxol for 2hr; (C) TPGS-coated nanoparticles for 15min; (D) 30min; (E) 
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apoptosis (Arends and Wyllie, 1991) which begins with an early perinuclear 
chromatin condensation leading to massive nuclear destruction. Nuclear apoptosis is 
accompanied by karyohexis – the segmentation of nucleus into dense nuclear parts 
which further distributed into apoptotic bodies. This process is a feature of apoptosis 
and can be detected by analyses such as PI nuclear stain assay and semi-quantitative 
assay of pulsed-field gel electrophoresis (Walker et al., 1999). 
From Fig. 5.7a, the cell nuclei of the control HT-29 cells were seen as homogeneous 
fluorescence with no evidence of segregation after PI staining. The clinical 
formulation Taxol® did not produce significant morphological changes in the cell 
nuclei after treatment of 2hrs (Fig. 5.7b). However, the TPGS-coated nanoparticle 
formulation lead to fragmentation of the cell nuclei, indicating possible DNA 
condensation, starting from 15min of treatment time and segregation became apparent 
after 2hrs of treatment (Fig. 5.7c-f). The nuclear integrity was relatively intact in the 
cells treated with Taxol® and TPGS-nanoparticles (up to 1hr treatment). Then the 
severely segregated nuclei was evidenced by the segments of dense fluorescence 
which suggested a major breakdown in the chromatin followed by DNA condensation 
in the nuclei. 
 
5.3.7. In vivo pharmacokinetics  
 
Figure 5.8 shows the curves of the paclitaxel concentration in plasma versus the time 
after administration for both of the two formulations. From this figure two key 
indexes can be obtained. One the so-called area under the curve (AUC), i.e. the 
graphic area enveloped by the two coordinate axes and the curve of the drug 
concentration in the plasma versus the time, which is supposed to determine the 
therapeutic effects of the drug of the given dose in the given formulation.  
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Figure 5. 8. Plasma concentration-time profiles of paclitaxel after i.v. administration to 
SD rats at 10mg/kg dose formulated in the TPGS-emulsified PLGA nanoparticles and in 
Taxol®, respectively. The severe side effect level (8,500 ng/ml) and the minimum 
effective level (43 ng/ml) show the therapeutic window of the drug. 
 
The AUC0-48hr of paclitaxel in the Taxol® formulation after i.v. injection was 
7,018.21ng-hr/ml. The AUC for the nanoparticle formulation was 20,934.56ng-hr/ml 
after i.v. infusion, which is 3.0 times larger, and 34,291.76ng-hr/ml after i.v. injection, 
which is 4.9 times larger, respectively. Another important index which can be 
obtained from Fig. 5.8 is the time at which the drug concentration dropped below the 
minimum effective value, which for paclitaxel is 50nM or 43ng/ml (molecular weight 
of paclitaxel is 853.9) (Liebmann et al., 1993). It can be seen from Fig. 5.8 that such a 
characteristic time is 21 hours for 10 mg/kg dose in the Taxol® formulation, and 35 
hours and 50.2 hours for i.v. infusion and i.v. injection, respectively for the same dose 
in the nanoparticle formulation. This means that the sustainable therapy index for the 
nanoparticle formulation is 0.59 for i.v. infusion and 0.41 for i.v. injection.  Both of 
the two in vivo indexes show that the drug formulated in the TPGS-emulsified PLGA 
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nanoparticles can have much higher therapeutic effects that that in the Taxol® 




Vitamin E TPGS-emulsified PLGA nanoparticles were proposed in this study for no-
adjuvant formulation as well as for oral delivery of anticancer drugs. Paclitaxel is 
chosen as a prototype drug due to its high therapeutic effects against a wide spectrum 
of cancers and its great commercial success as the best seller. The nanoparticle 
formulation of paclitaxel has great advantages versus the Taxol® formulation. The 
side effects associated with Cremophor EL contained in the Taxol® formulation can 
be avoided. In vitro cell viability experiment for HT-29 cells showed much higher 
cytotoxicity of paclitaxel in the nanoparticle formulation than the Taxol® formulation. 
The side effects associated with Cremophor EL contained in the Taxol® formulation. 
The cytotoxicity of the proposed nanoparticle formulation resulted from paclitaxel-
induced apoptosis. The nanoparticle formulation can result much higher AUC and 
thus therapeutic effects of the drug in the nanoparticle formulation than that in the 
Taxol® formulation. Sustained chemotherapy by nanoparticle formulation can also be 
realized.  Our experiment for cellular uptake of nanoparticles by Caco-2 cells implies 
that oral chemotherapy by TPGS-emulsified PLGA nanoparticles seems feasible. Our 
preliminary research shows the power of cancer nanotechnology, which will radically 
change the way we detect, treat and prevent cancer (NIH and NCI, 2004). 
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK RECOMMENDATIONS 
 
6.1. Conclusions 
The notion of cancer as a serious, life-threatening disease is very ancient. Cancer is a 
multifactorial disease which can be caused by genetics, lifestyle choices, and 
exposure to certain environmental hazards. There are about 200 different types of 
cancer affecting all the different body tissues and each has their own treatment regime. 
Cancer, in fact, can be cured if diagnosed and treated early; and even if it is at an 
advanced stage, it can be controlled for months or even years. According to the World 
Health Organization, more than 10 million people are diagnosed with cancer every 
year, and it is estimated that this will rise to 15 million new cases every year by 2020. 
Cancer causes 6 million deaths every year or 12% of deaths worldwide. Nevertheless, 
no substantial progress can be observed in the past fifty years in fighting against 
cancer although great effort has been made in cancer research. The death rate by 
cancer in the United States was 1.939% in 1950 and still 1.940% in 2001.  
Chemotherapy is an effective treatment for cancer and other diseases such as 
cardiovascular restenosis and AIDS, however, it carries a high risk due to the drug 
toxicity. Problems still exist even for successful chemotherapy as the more effective 
drugs tend to be more toxic. Thus, patients have to tolerate severe side effects and 
sacrifice their quality of life. It prompted an intensive research in the past decade in 
the development of nanoparticles of biodegradable polymers as an effective drug 
delivery system for improved chemotherapy. In the particulate delivery system, the 
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drug can be either dispersed in the polymeric matrix, or conjugated/attached to the 
polymer molecules. After administration, the drug encapsulated in the nanoparticles 
will be gradually released from the polymer matrix which will eventually degrade into 
harmless molecules. Nanoparticles of biodegradable polymers can be made of small 
enough size to allow intracapillary or transcapillary passage and of appropriate 
coating to allow the particles escape from elimination by the reticuloendothelial 
system as well as to promote adhesion to, and uptake by, cancer cells. 
Paclitaxel is chosen as a prototype drug due to its high therapeutic effects against a 
wide spectrum of cancers and its great commercial success as the best seller 
anticancer drug. In fact, paclitaxel is claimed as one of the best anti-cancer drug in the 
past few decades. However, the limitation of paclitaxel has restricted the dosage and 
infusion period of the drug for clinical administration purposes. Since best medical 
effects are yet to be achieved, it becomes necessary to come up with improved 
formulations of paclitaxel for a more effective clinical administration that eliminates 
premedication and the toxicity of the adjuvant and also improve efficacy. The desired 
formulation should be one that does not consume toxic adjuvant, is capable of 
releasing paclitaxel over an extended period of time with optimum efficacy and 
stabilizing the compound during long term storage of the formulation but yet 
economically feasible to be produced on a large scale. Oral paclitaxel is not inherently 
bioavailable because of the overexpression of P-glycoprotein by intestinal cells and 
the significant first-pass extraction by cytochrome P450-dependent processes. 
However, applying nanotechnology and surface modification of the nanoparticles, 
oral paclitaxel becomes feasible. 
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In this study, biodegradable polymeric nanoparticles were successfully prepared by 
oil-in-water emulsification/solvent evaporation process using both chemical and 
natural emulsifiers. After a process of optimization of fabrication parameters, 
nanoparticle formulations of a reproducible desirable size with narrow size 
distribution and high encapsulation efficiency were achieved.  
Comparing to chemical emulsifiers, natural surfactants are preferred since they 
present better performance in preparation and application of polymeric nanoparticles 
for clinical administration. Among the emulsifiers tested, the natural emulsifiers 
DPPC and TPGS provide much higher emulsifying efficiency comparing to the 
chemical emulsifier PVA. This implies that much lower amount of DPPC (about 1/33 
of PVA) or TPGS (about 1/67 of PVA) is needed for the same formulation procedures. 
The fact that TPGS and DPPC have greater tendency to migrate to the surface of 
nanoparticles has been supported by the XPS analysis of the surface chemistry. XRD 
analyses revealed that the drug was present in these nanoparticles in an amorphous 
state. The nanoparticle degradation profile suggested the drug release was mainly due 
to the drug diffusion followed by polymer matrix degradation. The drug release 
profile and the degradation pattern are comparable for these TPGS and DPPC-
incorporated nanoparticle formulations. Therefore, nanoparticle formulations 
incorporating TPGS and DPPC were selected as the most suitable formulations for 
further evaluations. 
Pharmaceutical scientists are increasingly turning to the use of cell culture models as 
an essential tool in high throughput screening assays for absorption and tissue 
distribution of potential new drug as well as mechanistically to identify specific routes 
of drug absorption. In this study, Caco-2 cells were used as an in vitro model to 
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evaluate the cellular uptake of nanoparticles coated with vitamin E TPGS or DPPC 
which aim to promote oral delivery of anticancer drugs. The emphasis was given to 
the possible effects of particle size and particle surface coating on the cellular uptake 
of the nanoparticles. Our results illustrated that PLGA nanoparticles have 
significantly higher level of the cellular uptake compared with polystyrene 
nanoparticles and the vitamin E TPGS coated PLGA nanoparticles have advantages in 
favor of the cellular uptake over the PVA coated or DPPC coated PLGA nanoparticles. 
Thus, TPGS coated PLGA nanoparticle formulation was selected for further detailed 
studies. An observed plateau effect of the cellular uptake efficiency against the 
nanoparticle concentration or the cell incubation time suggested that the cellular 
uptake of polymeric nanoparticle is saturable. In the images of confocal laser 
scanning microscopy (CLSM), cryo-SEM and transmission electron microscopy 
(TEM), the internalized nanoparticles were mostly seen throughout the cytoplasm 
surrounding the nucleus and minority of them in the nucleus, especially in the case of 
vitamin E TPGS coated PLGA nanoparticles. Our results demonstrated that 
nanoparticles of biodegradable polymers of small enough size and appropriate surface 
coating may have great potential to be applied for oral delivery of anticancer drugs as 
well as other therapeutic agents.  
The nanoparticle formulation of paclitaxel has great advantages versus the Taxol® 
formulation as the side effects associated with Cremophor EL contained in the Taxol® 
formulation can be avoided. In vitro cell viability experiment for HT-29 
adenocarcinoma cells showed much higher cytotoxicity of paclitaxel in the 
nanoparticle formulation than the Taxol® formulation. The cytotoxicity of the 
proposed nanoparticle formulation resulted from paclitaxel-induced apoptosis. The 
nanoparticle formulation can exert much higher AUC and thus therapeutic effects of 
 153
Chapter 6: Conclusion 
the drug in the nanoparticle formulation than that in Taxol® formulation. Sustained 
chemotherapy by nanoparticle formulation can also be realized. The experimental 
result of cellular uptake of nanoparticles by Caco-2 cells implies that oral 
chemotherapy by TPGS-emulsified PLGA nanoparticles seems feasible. Our 
preliminary research shows the power of cancer nanotechnology, which will radically 
change the way we detect, treat and prevent cancer. 
 
6.2. Recommendations for future studies 
 
This study is mainly on the formulation optimizations and investigations on their in 
vitro (thoroughly) and in vivo (a few) efficacy of biodegradable polymeric 
nanoparticles for clinical administration of paclitaxel. From the results obtained so far, 
the proposed TPGS coated PLGA nanoparticles strongly demonstrated the feasibility 
as an efficient drug delivery system. However, it would be more convincing for the 
clinical application of this proposed formulation if more in vivo experiments could be 
done to support the existing evidences of feasibility. 
 
6.2.1. In vivo pharmacokinetics studies for oral administration of paclitaxel 
loaded TPGS coated PLGA nanoparticles 
To investigate the drug plasma concentration after oral administration of the proposed 
formulation of paclitaxel, SD rats are orally administered by gavage at a determined 
dosage of paclitaxel. A group of animals is to be kept as control group. The blood 
samples are to be taken from the tail vein at predetermined intervals and processed for 
the LC/MS analysis. The oral bioavailability of paclitaxel can be obtained as the ratio 
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of the AUC of paclitaxel via oral administration to that of paclitaxel via intravenous 
injection. All animals were observed for mortality, general condition and potential 
clinical signs. 
 
6.2.2. Biodistribution of drug studies 
The biodistribution study can identify how the drug administered is distributed in the 
body after administration. Thus, the efficacy of drug delivery system can be further 
evaluated. In brief, a group of SD rats are administered with paclitaxel formulation 
and sacrificed at the predetermined intervals. Animals are dissected and organs are 
removed and processed to determine the drug concentration in individual organs using 
LC/MS. 
 
6.2.3. In vivo evaluation of antitumor efficacy 
To decide the efficacy of anticancer drug formulation, antitumor effect of the drug is 
carried out in mice with weak or no immune response to tumor engraftment. 
Generally, severely combined immuno-deficient (SCID) mice or athymic nude mice 
(nu/nu) are used. To develop the tumor model, HT-29 cells are subcutaneously 
injected into the mice. Tumor nodules are allowed to grow to a volume > 150mm3 
prior to the experiment. Tumor-bearing mice are grouped for each type of treatment 
and drug formulations are administered. Using a digital caliper, the length and width 
of tumor are measured in millimeters and tumor size can be calculated using 
[length×(width×width)/2] and expressed in milligrams. The body weights and tumor 
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